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Abstract 
The mechanism of body and organ size control is an unsolved puzzle. Initially 
characterized in Drosophila melanogaster, the Salvador/Warts/Hippo (Hippo) 
signalling pathway, highly conserved throughout evolution, defines a novel signalling 
cascade regulating cell contact inhibition, organ size control, cell growth, proliferation, 
apoptosis, and cancer development in mammals. The upstream regulation of this 
pathway has been less well defined than the core kinase cassette. Previously 
Willin/FRMD6 has been proposed as the human orthologue of Expanded and, to date, 
little is known about the functional role of Willin in mammalian cells. My study 
elucidated the mechanism by which Willin antagonizes the transcriptional co-activator 
YAP. In MCF10A cells, Willin ectopic expression antagonizes YAP-induced epithelial-
mesenchymal phenotypes via YAP Ser127 phosphorylation site. Loss of Willin 
expression attenuates MST1/2, LATS1 and YAP phosphorylation promoting YAP’s 
oncogenic transformation activity in vitro, as analysed by its ability to display 
epithelial-to-mesenchymal transition (EMT) features. These biological outputs are YAP 
dependent. These data support the involvement of Willin in the regulation of the 
mammalian Hippo signalling activity by activating the core Hippo pathway kinase 
cassette. 
KIBRA has been shown to function as an upstream member of the Hippo pathway by 
influencing the phosphorylation of LATS and YAP, but the functional consequences of 
these biochemical changes have not been previously addressed. I showed that in 
MCF10A cells, loss of KIBRA expression displays EMT features, which are 
concomitant with decreased LATS and YAP phosphorylation, but not MST1/2. In 
addition, ectopic KIBRA expression antagonizes YAP via the Ser 127 phosphorylation 
site and I showed that KIBRA, Willin and Merlin differentially regulate genes 
	  	   iv 
controlled by YAP. 
Willin/FRMD6 was first identified in rat sciatic nerve, which is composed of Schwann 
cells and fibroblasts. To elucidate the function of Willin in the mammalian sciatic nerve, 
I showed that Willin is predominantly expressed in fibroblasts and that its expression 
activates the Hippo signalling cascade and induces YAP translocation from the nucleus 
to the cytoplasm. In addition within these cells, although it inhibits cellular proliferation, 
Willin expression induces a quicker directional migration towards scratch closure and an 
increased expression of factors linked to nerve regeneration. These evidence show that 
Willin modulates sciatic nerve fibroblast activity, indicating that Willin may have a 
potential role in the regeneration of the peripheral nervous system. 
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1.1. The expanding FERM family 
The identification and naming of a protein from a coomassie blue stained protein gel 
was the starting point for the discovery of an expanding number of proteins that are part 
of what is now called the Band 4.1 superfamily (Amieva et al., 1994, Sun et al., 2002, 
Diakowski et al., 2006). It is a group of proteins characterised by a conserved domain 
known as the Four point one Ezrin Radixin Moesin (FERM) domain. Band 4.1, the 
prototype of the superfamily, is an erythrocyte membrane protein and a major 
component of the cortical cytoskeleton. Its N-terminal domain is highly conserved 
across a variety of proteins, most of which interact with both the plasma membrane and 
the cytoskeleton. Over time the number of known FERM containing proteins has 
rapidly expanded such that at present approximately 50 different family members exist 
which have been recently categorised into three general groups comprising: 1) Talins 
and kindlins, 2) ERMs, GEFs, kinases and phosphatases, and 3) Myosins and KRITS 
(Krev interaction trapped proteins) (Frame et al., 2010) (Figure 1.1). 
Within the second category are Ezrin, Radixin, Moesin, and Merlin whose functions 
have been reported and summarised in many excellent reviews (McClatchey, 2003, 
McClatchey and Fehon, 2009, Fehon et al., 2010, Stamenkovic and Yu, 2010, Arpin et 
al., 2011). In general, the ERM family together with Merlin have pivotal roles in cell 
signalling events, including those involved in both organization of the cytoskeleton and 
cell proliferation. The maintenance of the sub-membrane cytoskeleton is achieved by 
linking actin filaments, expressed in the cell cortex, with the plasma membrane and with 
plasma membrane associated proteins. These proteins control the organization of 
complex membrane domains by a strict regulation of their structure and function 
(Bretscher et al., 2002). Despite sharing similar regulatory patterns, interplay with 
common partners and similar subcellular localization, ERM proteins do display 
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different tissue specific expression patterns: Ezrin is mainly expressed in polarized 
epithelial and mesothelial cells (Berryman et al., 1993, Saotome et al., 2004), Moesin in 
endothelial and lymphoid cells (Schwartz-Albiez et al., 1995), and Radixin in 
hepatocytes (Amieva et al., 1994, Wang et al., 2006). This suggests incomplete 
functional redundancy and highlights important tissue and context dependent functions 
(Fehon et al., 2010). 
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Figure 1.1 – FERM superfamily of proteins. The upper part of the figure shows a domain map 
of FERM superfamily proteins. (A/FBD, ERM actin and FERM-binding domain; ANK, ankyrin 
repeat region; CC, coiled-coil; DH–PH, Dbl homology–pleckstrin homology (RhoGEF) 
domain; FBD, FERM-binding domain; I/LWEQ, talin actin binding domain (in which E denotes 
glutamic acid; I, isoleucine; L, leucine; Q, glutamine; W, tryptophan); L, extended loop situated 
in the indicated FERM subdomain; MD, myosin motor domain; P, proline-rich region; PDZ, 
PSD95/Dlg/ZO1- homologous peptide binding domain; PH, pleckstrin-homology domain; PTP, 
protein tyrosine phosphatase domain; RF, RING finger; SAB, 4.1 spectrin-actin binding 
domain; WW, WW domain.) Some known FERM-domain binding proteins are indicated on the 
left. The lower figure is a schematic of the moesin crystal structure. F1, F2 and F3 indicate 
FERM subdomains; other proteins/domains that share each subdomain's fold are listed. Figure 
adopted from Bretscher et al., (2002). 
With regard to the ERM-related protein Merlin, it is encoded by the neurofibromatosis-
2 (NF2) gene, located on chromosome 22 (Rouleau et al., 1993, Trofatter et al., 1993), 
and has been demonstrated to function as a tumour suppressor gene in mice and 
humans. Mutations in the NF2 gene have been well characterized in neurofibromatosis 
type 2 (NF2) disease, which also confers a predisposition to the appearance of 
schwannomas and meningiomas (McClatchey et al., 1998, Giovannini et al., 2000). 
Merlin structure is characterized by a considerable homology with the ERM family (~ 
49% identity overall), particularly in the N-terminal FERM domain (~ 65%) as well as 
in the central α helical domain. However, the C-terminal actin-binding domain is not 
present (Rouleau et al., 1993, Trofatter et al., 1993). Alternatively, Merlin has several 
actin binding sites localized within its FERM domain (Xu and Gutmann, 1998, 
Baumgartner et al., 2010). Yet, this direct interaction with the actin cytoskeleton is 
weak and an indirect association with the skeleton mediated by the βII spectrin, an F-
actin binding protein, also known as fodrin (Scoles et al., 1998), has been postulated. 
Merlin and ERM proteins similarly localize in the subcellular domain (Gusella et al., 
1999) and share similar biochemical interactions with both membrane-associated 
proteins (via the amino-(N)-terminal domain) and cytoskeleton components (via the 
carboxyl-(C)-terminal domain) (Bretscher et al., 2002). Merlin is phosphorylated by the 
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p21-activated kinase PAK (Kissil et al., 2002, Xiao et al., 2002), is Rac1 dependent and 
has been shown to occur in its C-terminal half, specifically at the serine residue S518 
(Shaw et al., 2001). Due to the structural homology between Merlin and the ERM 
family, Stemmer-Rachamimov and colleagues (1997) analyzed if abrogation of ERM 
expression in 22 schwannomas samples was observed. It was found that ERM 
expression is conserved despite Merlin expression loss, indicating Merlin´s unique role 
as a tumour suppressor in Schwann cells (Stemmer-Rachamimov et al., 1997). 
Furthermore, Merlin was found to regulate contact inhibition of growth in a cell density 
dependent manner (Morrison et al., 2001). In normal rat Schwann cells, at a high cell 
density, Merlin is dephosphorylated in the closed conformation, and interacts with a 
cytoplasmic tail domain of CD44 (Morrison et al., 2001). Although both Ezrin and 
Moesin are known to bind to the same CD44 binding motif, at a high cell density this 
interaction was abolished. Interestingly, at a low cell density, Ezrin, Moesin, and 
phosphorylated Merlin were found to complex with CD44. The CD44-Merlin 
interaction is indirect and mediated by the ERM family suggesting that Merlin´s ability 
to inhibit cellular proliferation depends on its dephosphorylated, closed state as well as 
of the Merlin-CD44 interaction (Morrison et al., 2001). 
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Figure 1.2 – Merlin structure and interactions. (A) Merlin contains three conserved protein-
protein interaction domains: a FERM domain in its N- terminus and a C-terminal domain (CTD) 
separated by a coiled-coil (α-helical) region. Crystallography shows that the merlin FERM 
domain contains three subdomains, which exhibits a cloverleaf architecture. Merlin FERM has a 
unique ‘Blue Box’ (BB, residues 177-183) compared with other ERM proteins. (B) Merlin can 
adopt two conformations: a ‘closed’ active and ‘open’ inactive form. Merlin can switch from 
these two conformations as a result of phosphorylation, lipid binding, protein interactions, or 
NF2 mutations. (C) Merlin interacts with several molecules, including NHE-RF, βII-
spectrin, CD44, other ERM proteins, SCHIP-1, HRS, actin, and syntenin, which may affect 
merlin function as a growth suppressor. The proposed domains in merlin that mediate these 
interactions are depicted. Figure adopted from Sun et al., (2002). 
More recently, the other ERM proteins have now been associated with cancer. For 
example, Ezrin was found to be upregulated and mislocalized to the cytoplasm and 
away from the apical membrane, while its expression in these scenarios correlated with 
invasiveness, cell migration, and metastasis in breast cancer cell lines as well as primary 
breast carcinomas (Elliott et al., 2005, Sarrio et al., 2006, Li et al., 2008, Li et al., 2010, 
Mak et al., 2012). Finally, strong cytoplasmic Ezrin was found to be independently 
3994
Two major isoforms of merlin result from alternative
splicing of exon 16. Isoform 1 is a 595-residue protein encoded
by exons 1-15 and 17. Isoform 2 contains exon 16, which
inserts 11 unique C-te inal residues followed by a stop codon
that prevents translation of exon 17, generating a 590-residue
protein in which the first 579 residues are identical to isoform
1 (Bianchi et al., 1994). Other splicing variants have also been
identified on the RNA level, but have not been detected by
western blotting. It is not known whether these other isoforms
are expressed under normal physiological conditions or
whether they contribute to merlin function.
In order to function as a tumor suppressor, merlin must form
two intramolecular associations. The first requires the binding
of the N-terminus to the C-terminus, whereas the second
involves folding within the N-terminal domain itself (Fig. 2B).
The association of the N- and C-termini of merlin involves
residues 302-308 within the C subdomain and exon 17
sequences, whereas residues within subdomains A and C
participate in the intra-N-terminus interactio  (Gutmann t al.,
1999a; Sherman et al., 1997). Merlin isoform 2 is not capable
of head-to-tail self-association (Sherman et al., 1997;
Gonzalez-Agosti et al., 1999). Folding of the merlin N-
terminus is required for the proper localization of the protein
beneath the plasma membrane and influences the interaction
between merlin and actin (Brault et al., 2001). However, the
merlin N-/C-terminal domain self-association is relatively
weak and dynamic, such that the C-terminus has a relatively
higher affinity for the N-terminus of ezrin than for its own N-
terminus (Nguyen et al., 2001). The heteromeric interactions
between merlin and ezrin might regulate merlin function
(Meng et al., 2000), perhaps by forming complexes that
differentially modulate the ability of merlin to bind to critical
effector or regulatory molecules. 
Merlin in tumorigenesis and development
Unlike most Protein 4.1 family members, merlin functions as
a tumor suppressor. NF2 inactivation and loss of merlin
expression are associated with the development of
schwannoma a d meningioma tumors (reviewed by Reed and
Gutmann, 2001). Moreover, the NF2 gene has also been
implicated in the development of non-NF2-associated
Journal of Cell Science 115 (21)
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Fig. 2. Merlin structure and interactions. (A) Merlin contains three conserved protein-protein interaction domains: a FERM domain in its N-
terminus and a C-terminal domain (CTD) separated by a coiled-coil (α-helical) region. Crystallography showed that the merlin FERM domain
contains three subdomains, which exhibits a cloverleaf architecture. Merlin FERM has a unique ‘Blue Box’ (BB, residues 177-183) compared
with other ERM proteins. (B) Merlin can adopt two conformations: a ‘closed’ active and ‘open’ inactive form. Merlin can switch from these
two conformations as a result of phosphorylation, lipid binding, protein interactions or NF2 mutations. (C) Merlin interacts with several
molecules, including NHE-RF, βII-spectrin, CD44, other ERM proteins, SCHIP-1, HRS, actin and syntenin, which may affect merlin function
as a growth suppressor. The proposed domains in merlin that mediate these interactions are depicted.
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associated with poorer patient survival in squamous cell carcinomas (Madan et al., 
2006). In a follow-up study, one hundred and thirty-one histologically confirmed 
primary head and neck squamous cell carcinomas (HNSSC) were prospectively 
analysed for cancer progression and survival. Immunohistochemical analysis of Ezrin, 
Moesin, and Merlin expression in tissue microarray samples of HNSCC revealed a 
significant association of increased cytoplasmic Ezrin with poor cancer survival 
(Schlecht et al., 2012), suggesting Ezrin is an important biomarker for HNSCC. 
1.1.1. The FRMD family 
Initially due to the sequencing of the human genome, but now from both from Genome 
Wide Analysis Studies (GWAS) and proteomic studies, a crop of new FERM domain 
containing proteins have been identified in the ERMs, GEFS, kinases, and phosphatases 
subset of the FERM family (Frame et al., 2010). These have been labelled as either 
FRMD (FERM domain) and/or FRMPD (FERM and PDZ domain)-containing proteins. 
For some of these proteins (FRMD1, FRMD8), they remain as hypothetical proteins 
with no experimental investigation; however, recently for the following proteins there 
have been a flurry of publications that have highlighted their importance, either 
associating them with a range of different diseases or uncovering previously 
unrecognised associations between signal transduction pathways. These new FERM 
proteins include: FRMD2/FRMPD1, FRMPD2, FRMD3, FRMD4A, FRMD4B, 
FRMD5, FRMD6, and FRMD7 (Figure 1.3) (Moleirinho et al., 2013c). Both 
biochemical and genetic studies have shown FRMD/ FRMPD genes to be involved both 
in normal cellular processes and with a variety of human diseases. Interestingly, where a 
functional role is known, the proteins are thought to act as scaffolding proteins. 
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Figure 1.3 – Schematic representation of FRMD/FRMPD proteins. Protein names and gene 
identifiers (gi) are listed. Protein domains are annotated according to the corresponding amino 
acids. This representation was based on information obtained from the Conserved Domain 
Architecture Retrieval Tool (CDART). A colour key of the domains is provided: PDZ, 
PSD95/Dlg/ZO1- homologous peptide binding domain; Kind, Kinase non-catalytic C-lobe 
domain; FERM N, FERM N-terminus domain; FERM M, FERM Middle domain; FERM C, 
FERM C-terminus domain; FA, FERM adjacent domain. Figure adopted from Moleirinho et al., 
(2013c). 
 
1578 aa
1309 aa
553 aa
1039 aa
1034 aa
570 aa
614 aa
714 aa
FRMPD1 gi 109731936
FRMPD2 gi 281604114
FRMD3 gi 350276216
FRMD4A gi 116063562
FRMD4B gi 150010540
FRMD5 gi 74738821
FRMD6 gi 109715866
FRMD7 gi 34916000
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1.1.2. Biochemical Structure 
Figure 1.3 shows the broad predicted structures of these proteins indicating that all of 
these proteins have predicted FERM domains. The FERM domain is a cysteine rich 
hydrophobic protein module of around 300 amino acids in length. Producing crystal 
structures of FERM proteins has proven to be problematic and as such only partial 
structures of FERM containing proteins have been developed for Ezrin (Smith et al., 
2003), Moesin (Pearson et al., 2000, Edwards and Keep, 2001), and Radixin (Mori et 
al., 2007, Takai et al., 2007). However, despite these limitations, structural studies of 
the FERM domain have revealed three distinct subdomains termed F1, F2, and F3 
(Edwards and Keep, 2001), which interact together to form a globular clover-leaf-
shaped structure (Hamada et al., 2000, Pearson et al., 2000). F1 has an ubiquitin-like 
structure containing a Ras-binding domain; F2 has an acyl-CoA binding protein-like 
structure; and F3 contains a phosphotyrosine binding (PTB), a pleckstrin homology 
(PH) and an Enabled/VASP Homology 1 (EVH1) domain (Hamada et al., 2000, 
Pearson et al., 2000). 
With regard to the FRMD family, their sequences indicate that they all have a predicted 
N-terminal FERM domain (Figure 1.3), but as yet there is no physical structure for any 
of these proteins. However, an unbiased fold recognition server 3D-PSSM reveals that a 
3D model of the FERM domain of FRMD6/Willin (14 to 322 amino acids) is 
structurally very similar to the known 3D crystal structure of the Moesin FERM domain 
(PDB code 1e5w). Thus, the FERM domain of FRMD6/Willin does appear to contain 
the three previously identified subdomains: F1, F2 and F3 (Figure 1.4). This indicates 
that despite a low sequence identity (up to 25% for Moesin) between the FERM 
domains of FRMD6/Willin and the ERM protein family, the structural homology 
between these domains is high. 
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Figure 1.4 – Predicted 3D structure of the FERM domain of FRMD6/Willin. The predicted 3D 
structure of the FERM domain of willin is compared to the crystal structure of the FERM 
domain of moesin. F1= ubiquitin-like subdomain, F2= acyl-CoA binding-like subdomain and 
F3= phosphotyrosine binding (PTB)/pleckstrin homology (PH)-like subdomain. Figure adopted 
from Moleirinho et al., (2013c). 
As biochemical motifs, FERM domains are slightly unusual since they are able to bind a 
diverse range of molecules such as phosphoinositols (Martel et al., 2001), glycophorins 
(Kusunoki and Kohno, 2009), hyaluronate receptors CD44, CD43 (Tsukita et al., 1994, 
Hirao et al., 1996, Morrison et al., 2001, Bretscher et al., 2002), intracellular adhesion 
molecules 1, 2, and 3 (ICAM-1,2,3) (Ramesh, 2004), actin (Tsukita et al., 1994, Lee et 
al., 2004), neurofascin (Gunn-Moore et al., 2006), and the C-terminal domain of FERM 
containing proteins (Chishti et al., 1998). The interplay between phospholipids and 
proteins is thought to help control their activation and has been described previously 
(Lietha et al., 2007, Cai et al., 2008, Lemmon, 2008, Leonard and Hurley, 2011). At 
present, FRMPD2 and FRMD6/Willin are the only cases where there is any direct 
evidence that the FERM domain of the FRMD proteins binds the same phospholipids as 
the ERMs, but how these may control the binding of other proteins to the FERM 
domains is unknown. However, recently, Moleirinho and colleagues (Moleirinho et al., 
2013c) described the known biochemical events that these proteins have been now 
linked to and the range of different signalling events. 
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1.1.3. Willin – a novel FERM protein 
FRMD6/Willin was first identified by a yeast two hybrid screen of a rat sciatic nerve 
library using the neuronal transmembrane protein, neurofascin as bait (Gunn-Moore et 
al., 2005). Neurofascin is an essential receptor for the development of the mammalian 
nervous system including the formation of myelination and specifically the formation of 
the node of Ranvier (Tait et al., 2000, P Charles, 2002). From this yeast two hybrid 
screen, the C-terminal domain of neurofascin was found to bind to a number of different 
proteins: SAP102 (Davey et al., 2005), Ezrin (Gunn-Moore et al., 2006), and an 
unidentified new open reading frame encoding a novel FERM domain, which was 
named Willin (Gunn-Moore et al., 2005). As indicated below (Section 1.2.6.1), Willin 
was subsequently reported as the human homologue of the Drosophila protein 
Expanded (Ex) and was given the HUGO nomenclature gene name FRMD6 
(Hamaratoglu et al., 2006). 
FRMD6/Willin is a 614 amino acid protein with a predicted molecular weight of 
71kDa. It has high sequence similarity to Merlin and ERM proteins only within the 
highly conserved N-terminal FERM domain, specifically between residues 14 to 322 
(Gunn-Moore et al., 2005). Indeed, FRMD6/Willin´s FERM domain shares 43% protein 
homology with the FERM domain of Ezrin, 47% with that of Radixin, 45% with 
Moesin, and 46% with Merlin (Figure 1.5). FRMD6/Willin is widely expressed in both 
neuronal and non-neuronal tissues, for example gene card database evaluation 
(http://www.genecards.org/cgi-bin/carddisp.p1?gene=FRMD6) indicates potential 
expression in the brain, heart, lung, liver and prostate, whilst more direct analysis of 
tissue has indicated expression in peripheral nerves, and epithelial layers including skin 
(Gunn-Moore et al., 2005, Madan et al., 2006). Furthermore, cDNA clones of Willin 
have been reported in human placenta, uterus and cervix (Gunn-Moore et al., 2005). 
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Figure 1.5 – Willin shares high sequence homology to ERM proteins and Merlin within the N-
terminal FERM domain. Willin, Merlin and ERM proteins contain a highly conserved FERM 
domain within the N-terminus. The FERM domain of Willin shares 43% protein similarity with 
the FERM domain of Ezrin, 47% with that of Radixin, 45% with Moesin and 46% with Merlin. 
No proline-rich and actin binding domains are identified in Willin. Figure adopted from Angus, 
(2011). 
The intracellular distribution of FRMD6/Willin is dependent on the cellular context. 
Histological staining for FRMD6/Willin on normal human oral mucosa and in 
squamous cell carcinoma (SCC) indicated that it is localized in the cytoplasm and in 
some cases at the plasma membrane (Gunn-Moore et al., 2005, Madan et al., 2006). 
Interestingly, FRMD6/Willin protein was also present in the nucleus of almost all SCC 
of the upper aerodigestive tract (UADT-SCC) and this presence was exclusive for this 
protein and not members of the ERMs (Madan et al., 2006). Differential intracellular 
distribution is common in ERM proteins in response to the cellular environment via 
conformational changes in their structure. In fact, when cultured cells reach confluency, 
ERM proteins tend to locate at the plasma membrane performing roles in contact 
inhibition and adhesion (Batchelor et al., 2004). More recently, they too have been 
observed in the nucleus of cells, although their functions here are poorly understood 
(Batchelor et al., 2004, Di Cristofano et al., 2010). 
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Figure 1.6: Predicted 3D structure of the FERM domain of willin, compared
to the crystal structures of the FERM domain of ezrin, radixin and moesin. The
structural prediction was performed by V. Zaitsev (University of St. Andrews,
UK). F1= ubiquitin-like subdomain, F2= acyl-CoA binding-like subdomain and
F3= phosphotyrosine binding (PTB)/pleckstrin homology (PH)-like subdomain.
Actin binding domain FERM domain Proline rich domain 
Willin 
Ezrin 
Radixin 
Moesin 
Merlin 
43% 
47% 
45% 
46% 
Figure 1.7: Willin shares high sequence homology to ERM (ezrin, radixin and
moesin) protein nd merlin within the N-terminal FERM domain. Willin, merlin
a d ERM proteins contain a highly conserved FERM d m within the N-terminus.
The FERM domain of willin shares 43% protein similarity with the FERM domain
of ezrin, 47% with that of radixin, 45% with moesin and 46% with merlin. No
proline-rich and actin binding domains are identified in willin.
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In regions of cell-to-cell contact, FRMD6/Willin expression levels at the plasma 
membrane are increased (Gunn-Moore et al., 2005, Madan et al., 2006, Angus et al., 
2012) and this increase is augmented by the addition of growth factors (Gunn-Moore et 
al., 2005). Specifically in PC12 cells, under the influence of both epidermal growth 
factor (EGF) and nerve growth factor (NGF), FRMD6/Willin translocates from the 
cytoplasm to the plasma membrane in a manner independent of phosphatidylinositol 3-
kinase activity (Gunn-Moore et al., 2005). At present, the mechanism behind this 
redistribution is unknown, although studies with other FERM proteins may provide 
clues to a possible mechanism. In general, extracellular cues promote ERM protein 
activation via regulation of protein conformation changes. For example, after 
phosphatidylinositol 4,5-bisphosphate (PIP2) binding to ERM N-terminal domains 
(Hirao et al., 1996), ERM proteins located in the cytoplasm are activated by 
phosphorylation of a conserved C-terminal threonine residue by a range of different 
kinases: Rho kinases (ROCK) (Matsui et al., 1998, Oshiro et al., 1998), PKCα (Ng et 
al., 2001), PKCι (Wald et al., 2008), PKCθ (Pietromonaco et al., 1998), myotonic 
dystrophy kinase-related Cdc42-binding kinase (MRCK) (Nakamura et al., 2000), SLIK 
(Carreno et al., 2008, Kunda et al., 2008), and lymphocyte-oriented kinase (LOK) 
(Belkina et al., 2009). This phosphorylation prevents self-association between the N- 
and the C-terminus allowing the ERM proteins to interact with diverse binding partners 
(Fehon et al., 2010). Upon activation, ERM proteins can translocate to the plasma 
membrane where their FERM-domain binds to membrane-associated proteins (Fehon et 
al., 2010). In addition, the C-terminal 34 amino acids of the ERM proteins can bind F-
actin and the bridge between the actin cytoskeleton and the cell cortex is thus 
accomplished (Hamada et al., 2000, Liu et al., 2007) (Figure 1.6). 
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Figure 1.6 – Schematic representation of ERM proteins acting as scaffolding linkage protein. 
ERM proteins are dormant when the N-terminal FERM domain (N) binds to the C-terminal 
domain (C); forming a closed conformation. Upon activation (a), ERM proteins form an open 
conformation where the FERM domain is able to bind to other proteins. The FERM domain can 
bind to various upstream membrane receptors either directly (b) or indirectly (c) using adaptor 
proteins such as EBP50. The C-terminus binds to actin cytoskeleton. Figure adopted from 
Bretscher et al. (2002) and Angus, (2011). 
Due to the close homology between ERM proteins and FRMD6/Willin within the 
FERM domain it could be hypothesized that in PC12 cells, FRMD6/Willin is in an 
inactive state and the presence of growth factors such as EGF or NGF induces 
FRMD6/Willin phosphorylation. Consequently, FRMD6/Willin becomes “activated” 
and redistributes to the plasma membrane where it interacts with its binding partners. 
Notably, EGF is able to induce Ezrin phosphorylation and to activate the Rho GTPases 
family (Ma et al., 2009). 
With regard to the sub-cellular control of FRMD6/Willin distribution, there are many 
unknowns but tantalising clues are emerging. For example, FRMD6/Willin has been 
reported to bind phospholipids (Gunn-Moore et al., 2005) and there are a number of 
predicted phosphorylation sites in FRMD6/Willin (www.phosphosite.org). In addition, 
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Figure 1.3: Schematic representation of ERM proteins acting as sca⇥olding linkage
protein. ERM proteins are dormant when the N-terminal FERM domain (N) binds
to the C-terminal domain (C); forming a closed conformation. Upon activation (a),
ERM p oteins form an op n conforma ion where the FERM dom is able to bind
to other proteins. The FERM domain can bind to various upstream membrane
receptors either directly (b) or indirectly (c) using adaptor proteins such as EBP50.
The C-terminus binds to actin cytoskeleton. Image taken from Bretscher et al.
(2002).
Takeuchi et al. (1994) elegantly demonstrated the importance of ERM pro-
teins as cellular sca olding molecules by showing that the microvilli on thy-
moma cells completely disappear in the presence of a mixture of ezrin, radixin
and moesin anti-sense phosphorothioate oligonucleotides (PONs; Figure 1.4).
Depletion of individual ERM prote ns by anti-se se oligonu l otides results in
no significant phenotypic changes (Takeuchi et al., 1994). Cellular phenotypic
changes are only observed when the synthesis of all ERM proteins are sup-
pressed (Tsukita et al., 1994; Takeuchi et al., 1994). Functional redundancy
within the ERM protein family may potentially explain observations of ERM
protein compensation when another ERM protein is lost.
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FRMD6/Willin has also been shown to co-localise with actin. However, unlike the other 
ERMs and Merlin, there is no actin binding motif within FRMD6/Willin. Moreover, the 
actin cytoskeleton is not necessary for FRMD6/Willin to localize at the plasma 
membrane, since cytochalasin-D induced actin disruption did not alter FRMD6/Willin 
expression at the plasma membrane (Gunn-Moore et al., 2005). Also of note is that 
FRMD6/Willin protein redistribution stimulated by EGF or NGF was not observed in 
the other analysed cell lines (Gunn-Moore et al., 2005), highlighting the importance of 
cellular context. However, recent data shows that FRMD6/Willin localizes with Ezrin at 
the plasma membrane and co-immunoprecipitates with Ezrin, but surprisingly, not 
directly with Merlin (Angus, 2011). 
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1.2. The Hippo Signalling Pathway 
The coordination between cell proliferation and cell death is essential to maintain 
homeostasis within multicellular organisms. The Hippo signalling pathway is currently 
a pivotal research area in biological studies, as it defines a novel signalling cascade 
regulating organ size, cell growth, cell contact inhibition, proliferation, apoptosis, and 
cancer development. The evolutionary conservation between Drosophila and mammals 
highlights the notability of this signalling cascade, whose functions and interactions 
have been reported and summarised in many excellent reviews (Pan, 2007, Reddy and 
Irvine, 2008, Zeng and Hong, 2008, Badouel et al., 2009b, Kango-Singh and Singh, 
2009, Grusche et al., 2010, Pan, 2010, Sudol and Harvey, 2010, Zhao et al., 2010a, 
Halder et al., 2012, Ramos and Camargo, 2012, Barry and Camargo, 2013, Harvey et 
al., 2013, Lin et al., 2013). 
1.2.1. The core Hippo Pathway in Drosophila 
The Hippo Pathway was first characterized in Drosophila melanogaster through the 
analysis of genetic mosaic screens targeted to identify genes related with cell 
proliferation and growth. The first uncovered Drosophila Hippo pathway component 
was the tumour suppressor gene warts (wts), encoding a serine/threonine protein kinase 
(Justice et al., 1995). Warts (or LATS) is a nuclear Dbf-2-related (NDR) family protein 
kinase with a close relative in Dbf20 protein, wherein the Warts residues can be aligned 
to, except for the 20 C-terminal residues (Xu et al., 1995). Mutation of wts results in 
apical hypertrophy of epithelial cells and robust tissue overgrowth. In 2002, the 
salvador (sav or shar-pei) tumour suppressor gene was discovered (Kango-Singh et al., 
2002, Tapon et al., 2002). Sav encodes a WW domain-containing protein and the loss of 
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sav or wts leads to increased levels of the cell cycle regulator Cyclin E and the cell 
death inhibitor DIAP1 (Drosophila inhibitor of apoptosis protein 1) (Kango-Singh et al., 
2002, Tapon et al., 2002). Wu and collegues (2003) went further in the scaffold of the 
Hippo pathway with the finding of the hippo (hpo) tumour suppressor gene. This gene 
encodes a Ste-20 family protein kinase (polypeptide with an N-terminal kinase domain 
and a non-catalytic C-terminal domain). The C-terminal domain of Hpo was shown to 
associate with Sav SARAH domain, and to present Sav to the Hpo kinase. The direct 
interaction between Hpo and Sav promotes Wts phosphorylation by Hpo, therefore 
suggesting the existence of a cell growth and apoptosis-controlling pathway (Wu et al., 
2003). Other studies have shown similar evidence positioning Hpo upstream of Wts 
(Tapon et al., 2002, Pantalacci et al., 2003, Udan et al., 2003). Like sav and wts, hpo 
depletion results in increased expression of DIAP1, thus implying that the Hippo 
cascade regulates a transcription program (Wu et al., 2003). Furthermore, genetic 
epistasis and biochemical studies showed that Tao-1, a sterile-20 like kinase functions 
upstream of Hpo to activate the Wts kinase. Importantly, knockdown of Tao-1 
expression resulted in the overgrowth of several organs such as the wing, in Drosophila 
(Poon et al., 2011). The core machinery of this signalling pathway was complete with 
the discovery of Mats (Mob as tumour suppressor), belonging to the Mob superfamily 
of proteins (Lai et al., 2005). Mats and wts were shown to function together on growth 
inhibition and tumour suppression, with Mats physically interacting with Wts as an 
activating subunit (Wei et al., 2007). Hpo also phosphorylates Mats, thereby increasing 
Wts kinase activity and promoting the formation of a Wts/Mats protein complex (Lai et 
al., 2005, Wei et al., 2007, Shimizu et al., 2008). Like loss of sav, wts or hpo, loss of 
mats, also caused an overgrowth phenotype (Lai et al., 2005). 
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1.2.2. Downstream effectors in Drosophila 
The link between the Hippo kinase cascade and the transcriptional level was 
accomplished with the identification of Yorkie (Yki) transcription co-activator, using 
Wts as bait in a yeast two-hybrid screen (Huang et al., 2005). Yki was shown to be a 
Wts effector in growth regulation. Wts inactivates Yki by direct phosphorylation. Yki 
overexpression mimics the same overgrowth phenotype to that caused by mutations in 
any of the members of the Hippo pathway (Huang et al., 2005). Wts phosphorylates Yki 
– WW domains at three phosphorylation sites (S111, S168, and S250) (Huang et al., 
2005, Dong et al., 2007, Oh and Irvine, 2008, Oh and Irvine, 2009). All of these 
phosphorylation sites regulate Yki activity. However, S168 is the one responsible for 
promoting Yki cytoplasmic translocation, where it binds to 14-3-3 proteins and 
consequently, loses oncogenic potential (Huang et al., 2005, Dong et al., 2007, Oh and 
Irvine, 2008, Oh and Irvine, 2009, Ren et al., 2010). This mechanism is involved in cell 
cycle arrest and apoptosis. In addition, loss of any of the Hippo signalling components 
or the removing or deregulation of one of these phosphorylation sites, leads to nuclear 
accumulation of Yki and cell overproliferation – in Drosophila, epithelial imaginal 
discs overgrowth (Harvey and Tapon, 2007, Pan, 2007, Saucedo and Edgar, 2007, 
Badouel et al., 2009b, Pan, 2010). Yki co-activator, however, does not bind DNA 
directly. This binding is accomplished due to Yki association with the TEAD-domain 
transcription factor Scalloped (Sd), forming a transcriptional complex (Goulev et al., 
2008, Wu et al., 2008, Zhang et al., 2008b). They synergistically interact aiming to 
induce expression of the same genes that Sav, Hpo, Wts, and Mats intend to suppress. 
Notably, Sd abrogation restrains Yki induced overgrowth (Goulev et al., 2008, Wu et 
al., 2008, Zhang et al., 2008b). Importantly, Yki and the Hippo pathway functions more 
ubiquitously while Sd is expressed in a narrower spectrum of cells (Campbell et al., 
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1992). More recently, other transcriptional factors such as Homothorax (Hth), and 
Teashirt (Tsh) were shown to also complex with Yki (Peng et al., 2009). Importantly, 
two co-activators of Yki activity, Mask and Wbp2, were found to be required both in 
vivo and in vitro, to induce Yki target-gene expression (Zhang et al., 2011, Sansores-
Garcia et al., 2013, Sidor et al., 2013). Mask (Multiple ankyrin repeats single KH 
domain) protein complexes with Yki and Sd to target-gene promoters such as DIAP1 
(Sidor et al., 2013). However, Mask requirement for full Yki activity is independent of 
Wts phosphorylation (Sansores-Garcia et al., 2013). Accordingly, WW-domain binding 
protein-2 (Wbp2) was also found not to promote Yki activity by inhibiting Wts-
mediated phosphorylation of Yki (Zhang et al., 2011). Wbp2 promotes Yki tissue 
growth or transformed phenotypes by enhancing Yki’s transcriptional co-activator 
function, occurring after the binding of the Wbp2 to Yki in a WW domain- and PY 
motif-dependent manner (Zhang et al., 2011). In addition, both Yki co-activators were 
shown not to depend on the Hippo pathway for their subcellular–localization or 
expression (Zhang et al., 2011, Sansores-Garcia et al., 2013, Sidor et al., 2013). Finally, 
homeodomain-interacting protein kinase (Hipk) was recently displayed as the first 
kinase that positively regulates Yki-dependent tissue growth (Poon et al., 2012). 
However, Hipk does not enhance Yki activity by regulating Yki expression but rather 
by regulating its abundance or activity.  Hipk was shown to act downstream or in 
parallel to Wts and although it does not physically interact with Yki, this regulatory 
mechanism suggests the existence of intermediate proteins that upon phosphorylation 
by Hipk promote Yki activity or abundance (Poon et al., 2012). 
When Yki accumulates in the nucleus, it binds to transcriptional activators promoting 
the expression of target genes. Functions and transcriptional outputs of some of these 
genes have been well documented. Specifically, the apoptosis inhibitor diap1 (Tapon et 
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al., 2002); the cell cycle regulator cycE (Tapon et al., 2002); the cell-growth inducer, 
bantam microRNA (Nolo et al., 2006, Thompson and Cohen, 2006); cyclin A and cyclin 
B (Shimizu et al., 2008); the cell shape regulator ex (Hamaratoglu et al., 2006); the 
HSPGs morphogen regulators dally – division abnormally delayed and dlp - dally-like 
protein (Baena-Lopez et al., 2008), and four-jointed (fj) (Cho and Irvine, 2004). 
1.2.3. Upstream regulatory branches in Drosophila 
In Drosophila, although the core components and downstream effectors of the Hippo 
pathway are well characterized, less is known about the upstream components and how 
these link upstream inputs such as polarity and social cues, to the core Hippo signalling 
components. At least four upstream regulatory branches of the Hippo pathway exist in 
Drosophila: Mer-Ex-Kibra complex; Fat/Dachous; and the polarity complexes Crumbs 
and Lethal Giant Laarvae/atypical protein Kinase C (Grusche et al., 2010). 
1.2.3.1. The KEM complex 
Merlin and Expanded, two FERM domain-containing proteins, complex with Kibra, a 
WW domain-containing protein. Together, these adaptor proteins are thought to 
transduce growth-regulatory signals and to co-localize at the sub-apical interface of 
epithelial cells (Bennett and Harvey, 2006, Baumgartner et al., 2010, Yu et al., 2010, 
Genevet and Tapon, 2011). Although the main function of this upstream complex has 
not yet been fully elucidated, it is proposed to link extracellular signals mediated by cell 
surface molecules such as Fat, to the core Hippo components and thus, act as an apical 
scaffold to promote activation of the Hippo pathway (Bennett and Harvey, 2006, 
Baumgartner et al., 2010, Genevet and Tapon, 2011). Expanded and Merlin were the 
first of the upstream core Hippo pathway components to be identified (Hamaratoglu et 
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al., 2006). Although acting together, both mer and ex need to be mutated to mimic the 
phenotype observed upon loss or mutation of a core Hippo component. In this scenario, 
tissue overgrowth (such as antennae, thorax, wings and legs), cyclin E up-regulation, 
failure in cell cycle arrest, and high levels of DIAP1 protein are noted (Hamaratoglu et 
al., 2006). Therefore, Merlin and Expanded were shown to regulate apoptosis and cell 
proliferation. However, these proteins differently regulate these biological processes. 
Expanded was found to regulate essentially cell cycle exit whilst Merlin regulates 
apoptosis (Pellock et al., 2007). Expanded and Merlin act synergistically to induce Wts 
phosphorylation (Hamaratoglu et al., 2006). However, the slightly different aspects of 
the phenotype imply that they may act not only redundantly but also in parallel with one 
another to control the Hippo signalling (Hamaratoglu et al., 2006, Pellock et al., 2007). 
Kibra directly associates with Merlin and Expanded and the three proteins 
synergistically act to promote Hpo, Wts, and Yki phosphorylation (Yu et al., 2010). The 
Kibra-Ex-Mer (KEM) complex also interacts with the core Hippo components. In fact, 
Kibra binds to Sav, which also binds to Merlin via Sav’s FERM binding motif. 
Furthermore, Expanded associates with Hpo C-terminus SARAH domain as well as 
with Sav (Yu et al., 2010). Notably, Expanded PPXY motifs directly interact with the 
Yki WW domains, forming a complex and thus preventing Yki nuclear localization 
independently of its phosphorylation status (Badouel et al., 2009a, Oh and Irvine, 2009, 
Sudol and Harvey, 2010). Studies have suggested that loss-of-function mutant clones 
for these upstream regulators result in a comparatively milder overgrowth phenotype 
than Hpo core components mutants, whereas single mutants cause a mild overgrowth 
phenotype and double mutants display strong synergistic effects in some cases 
resembling those of Hpo mutants (Baumgartner et al., 2010). The Kibra-Ex-Mer 
complex therefore regulates the Hippo core kinase by interacting with the Hpo-Sav 
complex and promoting Hippo pathway activity. Recently Pez, a new upstream negative 
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regulator of Yki function, has been identified (Poernbacher et al., 2012). Pez’s 
biochemical structure is composed of a N-terminus FERM domain and a C-terminus 
protein tyrosine phosphatase (PTP) domain.  Although Pez does not bind to Merlin or 
Expanded it binds and colocalizes with Kibra in S2 cells. This interaction is mediated 
by WW domains in Kibra and, similarly to one of Expanded mechanisms of action 
(Badouel et al., 2009a, Oh and Irvine, 2009, Sudol and Harvey, 2010), is independent of 
its phosphorylation status (Poernbacher et al., 2012). 
1.2.3.2. The Fat/Dachous branch 
Fat/Dachous is another upstream regulatory branch in Drosophila. The protocadherin 
Fat is a transmembrane protein that regulates growth and planar cell polarity (PCP), 
localizing to the sub-apical region of the plasma membrane. Fat (Ft) extracellular 
domain interacts with its ligand Dachsous (Ds), and together they act upstream of the 
Hippo signalling (Willecke et al., 2006, Katoh, 2012). Fat and Dachsous localization is 
controlled by the cytoplasmic protein Lowfat, which not only directly interacts with Fat 
intracellular domain but also regulates the stability of this upstream branch (Mao et al., 
2009). The atypical cadherin Fat transduces signals to Expanded but not Merlin, 
suggesting that the role of this upstream receptor in the pathway is to control Expanded 
membrane localization (Bennett and Harvey, 2006, Silva et al., 2006, Willecke et al., 
2006). Fat and Expanded have been also shown to co-localize (Chan et al., 2011). ft 
mutant cell clones display overgrowth phenotypes, and inhibit Cyclin E and DIAP1 
expression levels. Furthermore, Fat induces Wts phosphorylation negatively regulating 
Yki’s activity (Bennett and Harvey, 2006, Cho et al., 2006, Silva et al., 2006, Willecke 
et al., 2006). Notably, Fat has been suggested to regulate the Hippo signalling pathway 
by two different mechanisms. Firstly, Fat – Ex – Hippo kinase cascade (Bennett and 
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Harvey, 2006, Silva et al., 2006, Willecke et al., 2006); secondly, by an Ex and Hpo 
independent mechanism. In the latter, Fat relays to the core kinase cassette through the 
unconventional myosin Dachs (Cho et al., 2006, Grusche et al., 2010). It has been 
shown that Fat, aiming to maintain cellular homeostasis, inhibits Dachs binding to Wts, 
and by that avoids Wts binding to proteins promoters of Wts degradation (proteolysis) 
(Cho et al., 2006). This model emerges as a way for Fat to control excessive Wts 
protein, while Fat-Ex-Hpo pathway controls its activity (Figure 1.7). Fat binding to Ds 
promotes phosphorylation by the kinase Four-Jointed (Fj), of the extracellular domains 
of both Fat and Ds (Cho and Irvine, 2004, Casal et al., 2006, Cho et al., 2006, Willecke 
et al., 2006, Simon et al., 2010, Katoh, 2012). Accordingly, interaction between Fat and 
Ds promotes phosphorylation of Fat’s intracellular domain by Discs overgrowth (Dco), 
an intracellular kinase (Feng and Irvine, 2009). The negative regulation of Fat by Ds 
causes the polarization of Fat activity, which seems to be essential in organ growth 
control (Grusche et al., 2010, Halder and Johnson, 2011, Katoh, 2012). Fat may, 
therefore, establish the link between extracellular signals and the intracellular 
environment, cues that can be relayed through the Hippo pathway (Halder and Johnson, 
2011, Katoh, 2012). 
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Figure 1.7 – Two possible models binding Fat to the Hippo kinase cascade. (A) Ft-Ex-Hp act in 
a linear pathway. (B) Ft and Hpo mediate parallel inputs into Wts, with Ft and Hpo regulating 
the quantity and activity of Wts, respectively. Solid lines indicate validated and direct 
biochemical interaction, and dashed lines indicate genetic interaction. Figure adopted from Pan 
et al., 2007. 
1.2.3.3. The Crumbs complex links the Hippo pathway with polarity 
The regulation of the polarized epithelium results from the finely tuned orchestration 
between cell-cell adhesion systems, the cytoskeleton, and polarity complexes. A 
concerted expression of these components guarantees the functional attachment of the 
polarity complexes to the epithelium, and the concomitant activation of the signalling 
pathways that control epithelium proliferation and cell growth. Therefore, changes in 
this orchestration by means of cell polarity loss may lead to cancer settings, firstly by 
loss of epithelium architecture, promoting invasion and metastasis; and secondly, by 
loss of cell-to-cell contact and the subsequent social cues (Grusche et al., 2010, Genevet 
and Tapon, 2011, Halder and Johnson, 2011). In Drosophila, Crumbs (Crb) has been 
recently added as an upstream component of the Hippo pathway acting as a potential 
receptor (Chen et al., 2010, Ling et al., 2010, Robinson et al., 2010). Crumbs proteins 
are apical transmembrane proteins composed by a small extracellular domain (13kDa), 
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and a short, well conserved cytoplasmic domain with a juxtamembrane FERM-binding 
motif (FBM), composed by 12 aminoacids including a GTY motif (Klebes and Knust, 
2000, Assemat et al., 2008), and a C-terminal PDZ-binding motif (PBM) composed by 
ERLI residues. Crumbs is a component of the apico-basal cell polarity regulator known 
as the Crumbs complex, composed by Drosophila Crumbs (CRB), Stardust (Sdt), and 
Dpatj (or Dlt) (Assemat et al., 2008, Robinson et al., 2010). Several lines of research 
elegantly described Crumbs interaction with the FERM-protein Expanded. The 
juxtamembrane FBM of Crumbs directly binds the FERM domain of Expanded and this 
assembly is required for Expanded localization within the cell. Indeed, loss of Crb or 
mutations within the FERM binding domain results in mislocalization of Expanded to 
the basolateral region (Chen et al., 2010, Ling et al., 2010, Robinson et al., 2010). 
Expanded intracellular localization has been observed mainly at the apical junction of 
epithelial imaginal disc cells (Silva et al., 2006, Willecke et al., 2006), and together with 
Merlin and Kibra acts upstream of the Hippo signalling pathway (Hamaratoglu et al., 
2006, Genevet et al., 2010, Yu et al., 2010). Expanded interaction with the signalling 
pathway occurs through Wts phosphorylation (Hamaratoglu et al., 2006, Yu et al., 
2010) and its Crumbs posttranslational dependency for sub-apical plasma membrane 
localization, establishes a critical link between the Hippo pathway and apico-basal cell 
polarity (Grzeschik et al., 2010, Parsons et al., 2010, Genevet and Tapon, 2011). In fact, 
an unbalanced expression of Crumbs results not just in the lost of Expanded expression 
but also in the concomitant disruption of the associated Hippo pathway complexes 
(Badouel et al., 2009b, Yu et al., 2010). Interestingly, changes in the intracellular 
distribution of Merlin, Kibra or Fat (a PCP / Hippo regulator) (Bennett and Harvey, 
2006, Cho et al., 2006, Silva et al., 2006, Willecke et al., 2006) were not observed in 
Crumbs mutant cells (Chen et al., 2010), although increased levels of Yki activity were 
noted in this scenario (Robinson et al., 2010). Abnormal expression of Crumbs in spite 
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of causing up-regulation of Ex expression, led to Ex mislocalization. This suggests that 
Crumbs deregulation triggers the aberrant localization of Ex causing a deficient 
activation of the Hippo pathway or inhibition of Yki’s direct repression by Ex 
(Robinson et al., 2010). In addition, no specific biochemical or genetic links were found 
between Crb and Mer or Crb and Kibra (Ling et al., 2010). This suggests the presence 
of different upstream signals regulating the Kibra-Merlin-Expanded complex. 
Furthermore, the fact that Crumbs PBM domain is necessary for epithelial polarity 
regulation, whereas the juxtamembrane FBM is involved in the Hippo pathway and 
hence, growth control, implies different and well-defined roles for this protein. 
1.2.4. The core Hippo pathway in mammals 
The Drosophila Hippo signalling pathway is highly conserved throughout evolution, 
with the majority of the components having direct orthologs in mammals. This 
functional conservation is confirmed by the ability of mammal orthologs to rescue the 
corresponding Drosophila mutants in vivo (Huang et al., 2005, Pan, 2007, Pan, 2010, 
Zhao et al., 2010a, Halder and Johnson, 2011, Barry and Camargo, 2013, Harvey et al., 
2013), although this is not observed in all cases (Angus et al., 2012). The Drosophila 
core component Hpo has as vertebrate homologues the Sterile 20-like kinases MST1 
and MST2. MST1/2 interact with its regulatory protein WW45 (Sav’s ortholog also 
known as Sav1) by the correspondent SARAH domains forming an active complex 
(Callus et al., 2006). MST1/2 kinases can be activated by different outputs including 
RASSF1A (Khokhlatchev et al., 2002, Praskova et al., 2004, Oh et al., 2006, Matallanas 
et al., 2007, Matallanas et al., 2008) or autophosphorylation (Lee and Yonehara, 2002). 
Recently, the mammalian homologue of Tao-1, TAO-1, was shown to phosphorylate 
and activate MST1/2 (Boggiano et al., 2011, Poon et al., 2011). MST1/2 as its 
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Drosophila homologue Hpo phosphorylates all the three other core components. In fact, 
MST1/2 promotes direct WW45 phosphorylation (Callus et al., 2006) and 
phosphorylates the mammalian Wts ortholog LATS1/2 (Chan et al., 2005). The kinases 
LATS1 and LATS2 are phosphorylated by MST1/2 on the hydrophobic motif and 
activation loop, the latter possibly occurring by an autophosphorylation event (Chan et 
al., 2005). MST1/2 also phosphorylates MOBKL1A/MOBKL1B (Mps One Binder 
kinase activator-like 1A/1B), the mammalian homologues of Mats in Drosophila. 
MOBKL1A/B was identified as MST1/2 kinases physiological substrates, with MST 
phosphorylating MOBKL1A/B at both Thr12 and Thr35, which then leads to LATS 
phosphorylation by promoting MOBKL1A/B binding to LATS (Praskova et al., 2008). 
1.2.5. Downstream effectors in mammals 
The primary downstream effectors of the mammalian Hippo signalling cascade are the 
two Yki orthologs YAP (Yes-associated protein) and TAZ (transcriptional coactivator 
with PDZ binding motifs). Both YAP and TAZ are kinase substrates of LATS1/2 (Zhao 
et al., 2007, Hao et al., 2008). Activated LATS1/2 phosphorylates YAP in vivo on five 
HXRXXS consensus sites – Ser61, Ser109, S127, S164, and Ser381 (Zhao et al., 
2010b), and TAZ on four HXRXXS motifs – Ser66, Ser89, S117, and Ser311 (Lei et al., 
2008). On TAZ, particularly the phosphorylation sites Ser89 and Ser311 were shown to 
inhibit its transcriptional activation (Lei et al., 2008) whilst on YAP, phosphorylation of 
Ser127 and Ser381 by LATS1/2 are the key events for its inhibition (Zhao et al., 
2010b). Phosphorylation of YAP Ser381 by LATS1/2 was shown to activate a SCF 
(Skp1, Cdc53 and F-box) E3 ligase, which promotes YAP’s proteosomal degradation 
(Zhao et al., 2010b). However, it is the phosphorylation of YAP at Ser127 residue and 
TAZ at Ser89, which promotes the creation of a 14-3-3 binding site, followed by 
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YAP/TAZ cytoplasmic sequestration through 14-3-3 binding, and concomitant 
depletion of YAP/TAZ from the nucleus (Kanai et al., 2000, Zhao et al., 2007). Failure 
of YAP/TAZ cytoplasmic sequestration results in their binding to nuclear 
transcriptional factors, which promotes activation of Hippo signalling target genes 
(Kanai et al., 2000, Dong et al., 2007, Zhao et al., 2007, Hao et al., 2008, Lei et al., 
2008, Oh and Irvine, 2008, Zhang et al., 2008a). Importantly, several groups have 
suggested that phosphorylation, thus inhibition of YAP by LATS1/2, is cell-type 
dependent. For example, LATS2 was shown to not functionally antagonize YAP in the 
non-tumourigenic, human epithelial cell line MCF10A (Zhang et al., 2008a). 
Furthermore, recently a direct negative regulator of LATS1, ITCH E3 ubiquitin ligase, 
was shown to interact with LATS1 both in vivo and in vitro, and to negatively regulate 
the Hippo pathway (Ho et al., 2011, Salah et al., 2011). ITCH first WW domain 
interacts with both PPxY motifs of LATS1, Y376, and Y559. This binding is required 
for ITCH-mediated LATS1 degradation. ITCH’s ligase activity catalyzes 
polyubiquitination of LATS1, which then causes its proteolysis by the 26S proteasome. 
The reduced levels of LATS1 kinase activity leads to decreased phosphorylation levels 
of YAP and TAZ and thus, to their nuclear accumulation and potential oncogenesis 
promotion (Ho et al., 2011, Salah et al., 2011). Highlighting the evolutionary 
conservation between Drosophila and mammals, Mask1 (also called ANKHD1) and 
Mask2 (also called ANKHD17), the human orthologs of Drosophila Mask were shown 
to bind and to co-localize with YAP in the nucleus (Sansores-Garcia et al., 2013, Sidor 
et al., 2013). This interaction is required for YAP’s full activity as it promotes activation 
of downstream target genes, such as CTGF. Importantly, Mask1 and YAP co-
expression was found in diverse human tissues and tumours, including breast cancer 
(Sansores-Garcia et al., 2013, Sidor et al., 2013). Furthermore, WBP2, the mammalian 
orthologue of Drosophila Wbp2, was shown to interact with YAP (Chen and Sudol, 
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1995, Chan et al., 2011b) and TAZ (Chan et al., 2011b) via WBP2’s PPXY motifs and 
YAP/TAZ’s WW domains. This interaction is pivotal for the activation of the 
transcriptional program and to promote the transforming ability of YAP and TAZ, as 
knocking down WBP2 suppressed the YAP/TAZ-induced transformed phenotype (Chan 
et al., 2011b). 
In agreement with the positive regulation displayed by Hipk on Yki (Poon et al., 2012), 
in mammals HIPK2 promotes YAP’s abundance not by suppressing YAP’s 
phosphorylation by LATS1/2, but by acting in parallel to these kinases (Poon et al., 
2012). Finally, the protein tyrosine phosphatase, non-receptor type 14 (PTPN14), which 
has an N-terminal FERM domain as well as two PPXY motifs, has been demonstrated 
to directly interact with YAP via the WW domains of YAP and the PPXY domains of 
PTPN14 (Liu et al., 2012, Wang et al., 2012b). PTPN14 protein level is elevated by an 
increase in cell density. Expression of PTPN14 leads to sequestration of YAP in the 
cytoplasm, in a phosphatase-independent manner, and inhibits YAP transcriptional co-
activator function, potentially through both direct and indirect effects on YAP. 
Conversely, knockdown of PTPN14 induces YAP nuclear retention and increases YAP-
dependent cell migration (Liu et al., 2012, Wang et al., 2012b). However, the effect of 
PTPN14 expression on the levels of pMST1/2 and pLATS1/2 was not tested. Further 
studies on KIBRA (WWC1) and AMOT, two potential PTPN14 interactors, may 
provide important information on how YAP localization is regulated by PTPN14 (Liu et 
al., 2012, Wang et al., 2012b) (Figure 1.8). 
Once in the nucleus, as neither YAP nor TAZ have a DNA-binding domain to trigger 
the pro-proliferative gene expression program, these downstream Hippo effectors 
associate with DNA binding transcription factors. The best characterized of those 
transcription factors are the TEA domain transcription factor (TEAD) family members. 
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Both YAP and TAZ bind and co-activate all of the four TEAD 1-4 proteins. Once co-
activated TEADs bind to MCAT (muscle C, A and T) elements located in the promoter 
or enhancer regions of key genes via TEADs DNA-binding domain, thus regulating 
gene expression (Yoshida, 2008, Judson et al., 2012). Importantly, these transcription 
factors are associated with the traits observed upon YAP/TAZ overexpression, such as 
cell proliferation, apoptosis repression, and Epithelial Mesenchymal Transition (EMT) 
(Section 1.3) (Saucedo and Edgar, 2007, Cao et al., 2008, Wu et al., 2008, Zhao et al., 
2008a, Fernandez et al., 2009, Zhao et al., 2011b, Ramos and Camargo, 2012). In 
addition to TEAD, YAP can interact with other transcription factors including Runx2, 
SMAD7, or ErbB4 cytoplasmic domain (Grusche et al., 2010, Zhao et al., 2011b) 
(Figure 1.8). Notably, YAP also binds to the tumour suppressor p73, thereby promoting 
pro-apoptotic effects such as upon occurrence of DNA damage (Strano et al., 2001, 
Strano et al., 2005). This apparently dual role of YAP has yet to be better understood. 
However, an attractive hypothesis is that YAP/p73 complex may function as a 
mechanism to restrict the oncogenic potential of YAP in some contexts (Huang et al., 
2005, Halder and Johnson, 2011, Varelas and Wrana, 2012). 
The target genes induced by YAP are not the same as those regulated by Yki in 
Drosophila. In fact whilst YAP does not induce the cell cycle regulator cycE, Bric5 and 
Birc2, homologues of Diap1, are expressed depending on cellular context (Dong et al., 
2007, Hao et al., 2008, Zhao et al., 2010a). Importantly, CTGF has been identified as a 
direct target gene of the complex YAP/TEAD (Leask and Abraham, 2006, Zhao et al., 
2008a). Other proteins are regulated by YAP such as IGFBP3, FGF1, BMP2, and 
ITGB2 (Hao et al., 2008, Angus et al., 2012, Moleirinho et al., 2013a). In addition, the 
EGFR ligand amphiregulin (AREG) has been recently identified as a transcriptional 
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YAP target, which upon YAP nuclear location induces, in vitro, cell proliferation by a 
non-cell-autonomous mechanism (Zhang et al., 2009). 
 
Figure 1.8 – Three scenarios of YAP1 signalling via protein complexes: (a) In high-density 
cells, YAP1 is localized in the cytoplasm and forms complexes with selected cellular proteins. 
These complexes tend to sequester YAP1 in the cytoplasm. (b) In low-density cells YAP1 is 
dephosphorylated on S127 by PP2A phosphatase and it is ready to be translocated to the 
nucleus. (c) YAP1 in the nucleus forms complexes with various transcription factors to regulate 
diverse transcriptional programs. Primarily it inter- acts with TEAD transcription factors to 
induce proliferative and anti-apoptotic genes. The WW domains of YAP1 will bind a number of 
transcription factors that contain PPxY motif (PPxY-TF) such as members of the RUNX family. 
Figure adapted from Sudol et al., unpublished. With permission from the author. 
1.2.6. Upstream Components in Mammals 
Less is known about the functioning of the proteins that regulate the mammalian Hippo 
pathway upstream of the core kinase cassette. Recently several advances have been 
made in the understanding of the function and regulation of the mammalian orthologues 
of Merlin (also called NF2), Kibra (KIBRA), and Expanded (Willin) as upstream 
components of the Hippo pathway. Although the components of the signalling cascade 
are conserved in mammals, there are some mechanistic differences for example, it has 
been suggested that the Fat/Dachous pathway does not control organ size and activity of 
the Yki orthologues, YAP and TAZ, in mice (Saburi et al., 2008, Mao et al., 2011, 
4 YAP1 Uses Its Modular Protein Domains and Conserved Sequence Motifs...
Fig. 4.2 Three scenarios of YAP1 signaling via protein complexes: (a) In high-density cells, 
YAP1 is localized in the cytoplasm and forms complexes with selected cellular proteins. These 
complexes tend to sequester YAP1 in the cytoplasm. Activation of MST and LAST kinases renders 
YAP1 phosphorylated on S127, which creates a binding site for 14-3-3 protein that anchors YAP1 
in the cytoplasm. In epidermal cells, an adherens junction protein, ?-catenin interacts with YAP1-
14-3-3 complex blocking PP2A access to dephosphorylate YAP1 on Serine 127, further stabilizing 
the complex. The interaction of WW d mains with LATS kinases, PTPN14 phosphatase, and 
Angiomotin also tends to sequester YAP1 protein in the cytoplasm. The C domain of YAP1 may 
very well interact with cytoplasmic proteins that contain coiled-coil domain (CYT-CP). One poten-
tial candidate is ROCK1 (Rho-associ ted, prote n kinase 1), which together with Rho-GTP-ase 
may mediate mechano-sensing signals to YAP1, independently from the canonical Hippo cassette 
(Dupont et al. 2011). ZO2 is known to bind to PDZ-BM of YAP1 and since ZO2 heterodimerizes 
with ZO1, they may also prevent YAP1 from nuclear localization. (b) In low-density cells YAP1 is 
dephosphorylated on S127 by PP2A phosphatase and it is ready to be translocated to the nucleus 
in complex with the ZO2 protein. In epidermal cells, ?-catenin can no longer maintain a complex 
with YAP1 and 14-3-3 to retain YAP1 in the cytoplasm. (c) YAP1 in the nucleus forms complexes 
with various transcription factors to regulate diverse transcriptional programs. Primarily it inter-
acts with TEAD transcription factors to induce proliferative and anti-apoptotic genes. The WW 
domains of YAP1 will bind a number of transcription factors that contain PPxY motif (PPxY-TF) 
such as members of the RUNX family. In addition WBP2 factor that is tyrosine phophorylated by 
c-Src and c-Yes kinases positively regulates YAP-1-TEAD complex in promoting cell prolifera-
tion. The C domain may act in concert with WW domains of YAP1 and interact with coiled-coil 
?????????????????????????????????????????????????????????????????????????????????????????????????
and ZONAB in Hippo signaling is still not clear but theoretically intriguing (see text)
 Chapter 1 – Introduction 
 32 
Saburi et al., 2012). In Drosophila, Ex and Mer form a tripartite complex with Kibra 
that regulates the Hippo Pathway (Baumgartner et al., 2010, Yu et al., 2010, Genevet 
and Tapon, 2011), but it is unclear at present if the FRMD6/Willin, Merlin, KIBRA 
multiprotein complex is conserved in mammals (Genevet and Tapon, 2011). Indeed 
recent data would argue against this possibility and instead suggest that KIBRA signals 
in a MST-independent manner directly to LATS1/2 (Xiao et al., 2011, Moleirinho et al., 
2013a). 
1.2.6.1. Willin 
FRMD6/Willin is the nearest human sequence homologue to the Drosophila protein Ex. 
In Drosophila the lack of Ex expression has been shown to be associated with 
overgrowth of certain structures such as the wing and imaginal discs (Boedigheimer and 
Laughon, 1993), reflecting a direct role in controlling cell growth in these tissues. 
Hamaratoglu and colleagues (2006) elegantly described the tumour suppressor roles of 
Mer and Ex and positioned these proteins as members of the Hippo pathway, acting 
upstream of the protein core kinase cassette. Two vertebrate homologues of Ex, Ex1 and 
Ex2, were also reported and of note was that the DNA sequence of human Ex1 is 
identical to FRMD6/Willin (Gunn-Moore et al., 2005, Hamaratoglu et al., 2006). Thus, 
Willin is the closest human sequence homologue of Ex, sharing 60% homology with the 
Ex FERM domain. While FRMD6/Willin shares similar subcellular localization with 
Ex, it was not able to compensate for the loss of Ex in Drosophila (Angus et al., 2012). 
The C-terminal region of Ex showed no similarity to FRMD6/Willin and indeed Ex is 
reported to be 1429 amino acid long, as compared to 614 amino acids for 
FRMD6/Willin (Gunn-Moore et al., 2005, Hamaratoglu et al., 2006). The C-terminal 
region of Ex possesses three PPXY motifs that are essential for its interaction with the 
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WW domains of Yorkie (Yki) (Badouel et al., 2009a). Badouel and colleagues (2009), 
demonstrated that Ex and Yki localize at the apical junctions of cells in the eye imaginal 
disc, and that Yki is a binding partner of Ex (Badouel et al., 2009a). 
Interestingly another protein called Angiomotin (AMOT) has three (L/P)PXY motifs 
(two PPXY and one LPXY), which bind to the WW domains found in Yes-Associated 
protein (YAP) (Chen et al., 1997, Kasanov et al., 2001, Pires et al., 2001, Zhao et al., 
2011a). Both structurally and in terms of sequence similarity, this resembles the binding 
of Yki to Ex. However, whether the LPXY motif, as well as the two PPXY motifs, is 
essential for the AMOT-YAP interaction is yet to be determined. Additionally 
Angiomotin like-1 and -2 (AMOTL1 and AMOTL2), proteins closely related to AMOT, 
also exist. The presence of both the LPXY and PPXY motifs has been shown to be 
essential for the interaction between AMOTL1 and YAP (Skouloudaki and Walz, 
2012). Silencing of AMOT resulted in higher mRNA levels of the YAP target gene 
CTGF and increased CTGF promoter activity, while the overexpression of AMOT 
caused a reduction in the protein levels of CTGF. However, this was not observed 
during the silencing of AMOTL1 (Chan et al., 2011a, Zhao et al., 2011a). Therefore, it 
is possible that the role of Ex has been split over evolutionary time into the combined 
actions of FRMD6/Willin and AMOT (Yin and Zhang, 2011, Angus et al., 2012), 
although at present there is no evidence of a direct interaction or co-operation between 
these two proteins (Figure 1.9). 
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Figure 1.9 – Schematic representation of FRMD6/Willin and Drosophila melanogaster 
Expanded (Ex). FRMD6/Willin is the closest human sequence homologue to Ex, sharing 60% 
similarity with the N-terminal FERM domain of Ex. AMOTp130 possess a coiled-coil domain 
(C-C) and 2 PPXY motifs that interacts with the WW domains of YAP, phenocopying the 
interaction of the C-terminal domain of Ex with Yorkie (Yki). Figure adapted from 
Hamaratoglu et al., 2006 and Zhao et al., 2011. 
Furthermore, recently three members of Nedd4-like ubiquitin E3 ligases, Nedd4, 
Nedd4-2, and ITCH were shown to negatively regulate the long isoform of AMOT, 
AMOT/p130 (Wang et al., 2012a). These ligases function redundantly in the regulation 
of AMOT/p130 polyubiquitination, and concomitant proteome degradation in vivo. 
Importantly, it was shown that Nedd4 competes with YAP in binding to the L/P-PXY 
motif of AMOT/p130, targeting AMOT/p130 for ubiquitin-dependent degradation 
(Wang et al., 2012a). Regulation of LATS1 by ITCH has been previously observed (Ho 
et al., 2011, Salah et al., 2011). Whether Willin is also regulated by the family of E3 
ubiquitin ligases remains to be determined. 
The FERM domain of FRMD6/Willin was recently shown to be sufficient to activate 
the Hippo pathway via MST1/2 and to antagonize YAP-induced phenotypes in 
mammalian cells (Angus et al., 2012). FRMD6/Willin activated the Hippo pathway, 
inducing the phosphorylation of MST1/2, LATS1, and YAP in MCF10A and HEK 
60% 
similarity 
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293T cells. FRMD6/Willin knockdown mimicked YAP overexpression with respect to 
inducing an Epithelial-Mesenchymal transition (EMT) (Section 1.3) phenotype in 
MCF10A cells and it decreased phosphorylation of MST1/2, LATS1 and YAP (Angus 
et al., 2012). Surprisingly, in contradiction to these findings, it has been reported that 
FRMD6/Willin acts independently of the Hippo pathway in MDA-MB-231 cells 
overexpressing FRMD6/Willin, with no observed phosphorylation of the core kinase 
cassette (Visser-Grieve et al., 2012). High cell confluency would have a significant 
effect on basal phosphorylation levels of the Hippo pathway components and it is 
unclear the level of confluency of the cells when tested and the methodology used in 
this report, such that high basal levels may have masked any increase. Unfortunately, 
Hippo pathway phosphorylation in MDA-MB-231 cells upon FRMD6/Willin 
knockdown was not addressed. Interestingly, the same report described an inverse 
relationship of taxol sensitivity and FRMD6/Willin expression, where increased levels 
of FRMD6/Willin increased the sensitivity of MDA-MB-231 cells to taxol (Visser-
Grieve et al., 2012). 
Willin was first discovered by a yeast two hybrid screening of a rat sciatic nerve library 
(Gunn-Moore et al., 2005), which is particularly rich in Schwann cells. The sciatic 
nerve is a major nerve of the human body and belongs to the peripheral nervous system 
(PNS). Schwann cells are essential for the promotion of axonal regrowth (Soares et al., 
2005) and, within the nerve, its localization is limited to the endoneurium. Fibroblasts, 
on the other hand, are located in all the three nerve compartments namely epineurium, 
perineurium and endoneurium (Figure 1.10). This major type of cells is known to 
promote extracellular matrix synthesis by Schwann cells (Li et al., 2004). 
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Figure 1.10 – Cross-sectional anatomy of the peripheral nerve. (Figure adopted from 
Indwelling Neural Implants: Strategies for Contending with the In Vivo Environment, Taylor & 
Francis Group; c2008). 
Willin was predicted to be expressed in primary rat Schwann cell cultures. The close 
relation of Expanded with ERM and their role in Schwann cells process tip formation 
(Gatto et al., 2007), led to the question of what could be the function of Willin in 
Schwann cells. However Moleirinho and colleagues recently showed that in the 
mammalian sciatic nerve, Willin is predominantly expressed in fibroblasts and that 
Willin expression activates the Hippo signalling cascade and induces YAP translocation 
from the nucleus to the cytoplasm (Moleirinho et al., 2013b; Chapter 5). In addition 
within these cells, although it inhibits cellular proliferation, Willin expression induces a 
quicker directional migration towards scratch closure and an increased expression of 
factors linked to nerve regeneration. These results show that Willin modulates sciatic 
nerve fibroblast activity indicating that Willin may have a potential role in the 
regeneration of the peripheral nervous system (Moleirinho et al., 2013b; Chapter 5). 
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1.2.6.2. KIBRA 
KIBRA (WWC1), the mammalian orthologue of Kibra, is a WW domain-containing 
protein present in diverse human, particularly in the kidney and brain (Kremerskothen et 
al., 2003). KIBRA has been largely associated mainly with memory performance and 
risk of Alzheimer’s disease (Papassotiropoulos et al., 2006, Schaper et al., 2008, Bates 
et al., 2009, Corneveaux et al., 2010). Therefore, many of the known KIBRA 
biochemical and physiological interactions do not involve proteins linked to the Hippo 
pathway (Kremerskothen et al., 2003). KIBRA is phosphorylated by Protein Kinase C ζ 
(PKCζ) (Buther et al., 2004), and previous reports established a role for KIBRA in cell 
migration (Duning et al., 2008, Rosse et al., 2009). KIBRA interacts with the PAR3-
aPKC-PAR6 complex and regulates epithelial cell polarity by suppressing aPKC kinase 
activity (Yoshihama et al., 2011, Yoshihama et al., 2012, Yoshihama et al., 2013). 
Moreover, KIBRA has been shown to interact with discoidin domain receptor 1 to 
modulate collagen-induced signalling (Hilton et al., 2008). 
It has been recently suggested that KIBRA acts upstream of the Hippo pathway since 
KIBRA physically interacts with and stimulates the phosphorylation of LATS1/2 
(Baumgartner et al., 2010, Moleirinho et al., 2013a). This mechanistic action is both 
MST1/2 dependent and independent, it regulates the phosphorylation of YAP (Yu et al., 
2010, Xiao et al., 2011, Moleirinho et al., 2013a), and it is also observed in Drosophila 
with Kibra interacting with Wts, either directly or through Hpo, thereby inactivating 
Yki (Xiao et al., 2011). Furthermore, KIBRA interacts with Merlin, which may suggest 
potential tumour suppressive functions of KIBRA in development of neurofibromas in 
humans (Genevet et al., 2010). In addition, loss of KIBRA expression displays 
epithelial-to-mesenchymal transition features phenocopying YAP overexpression, 
whilst KIBRA ectopic expression antagonizes YAP functional output by acting on YAP 
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serine 127 phosphorylation site ( Moleirinho et al., 2013a). The protein phosphatase 14 
(PTPN14) was recently shown to physically interact with both KIBRA and YAP 
through the PTPN14-PY motifs and KIBRA/YAP-WW domains (Liu et al., 2012, 
Wang et al., 2012b, Lin et al., 2013). PTPN14 is the mammalian orthologue of Pez, and 
negatively regulates YAP in context of high cell density. Importantly mediation of YAP 
regulation was shown by a mechanism involving the WW-domains and not due to 
phosphorylation events (Liu et al., 2012, Wang et al., 2012b, Lin et al., 2013). In 
addition, this mediation could also be due to PTPN14’s ability to repress YAP by 
inducing KIBRA activity and thus activation of the signalling cascade (Liu et al., 2012). 
Another proposed regulatory mechanism suggests competition between PTPN14 and 
WBP2, a positive regulator of YAP, for binding to YAP-WW domains (Chan et al., 
2011b, Zhang et al., 2011). The outcome of this competition dictates YAP translocation 
to the nucleus or to the cytoplasm. 
1.2.6.3. Orchestration between Upstream components and Polarity 
There is an emerging link between components of the cell polarity machinery and the 
upstream regulation of the mammalian Hippo pathway. There are three main polarity 
complexes, all of which are highly evolutionary conserved (Assemat et al., 2008, 
Yamanaka and Ohno, 2008). In mammals; 1) the apical PAR (partitioning defective) 
complex - composed by two scaffold proteins PAR6, PAR3, by the atypical protein 
kinase C, aPKC (with two isoforms – PKCλ (in mouse) / PKCι (in human) and PKCζ) 
and by the cell division control protein 42 (Cdc42); 2) the apical CRB complex 
composed by transmembrane protein CRB3, by the cytoplasmic scaffolding proteins 
PALS1 (protein associated with Lin seven-1) and PATJ (PALS1 associated tight 
junction protein); 3) and the basolateral SCRIB complex composed by SCRIB (scribble 
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homologue) – LGL (lethal (2) giant larvae homologue) - DLG (discs-large-homologue 
lethal). In Drosophila, 1) PAR complex - D-Par6, Bazooka, DaPKC; 2) Crumbs 
complex – Drosophila Crumbs (Crb), Stardust (Sdt), Dpatj (or Dlt); 3) Scrib complex – 
Scrib, Lgl and Dlg, respectively (Assemat et al., 2008, Martin-Belmonte and Perez-
Moreno, 2012). These polarity protein complexes can work together or antagonize each 
other´s action and by that they can maintain or establish cellular asymmetry, thus 
strictly regulating epithelial cell polarity. In fact one of the key events which promotes 
the separation between apical and basolateral domains is the antagonistic activity 
between the Scrib and the PAR complexes. It has been shown that LGL competes with 
PAR3 (Yamanaka et al., 2003) as the former, when in the inactive state, co-localizes at 
the cell-cell contact region with PAR6-aPKC by the PDZ domain and kinase domain, 
respectively. The establishment of this complex inhibits tight junctions’ formation. 
However, a cascade of events prevents this inhibition. Cadherins interaction activates 
Cdc42, which in turn activates aPKC and the subsequent phosphorylation of LGL by 
aPKC. Once in the active state, LGL dissociates from the PAR6-aPKC complex and 
localizes at the basolateral membrane where it interacts with the pertaining components 
of the Scrib complex (Scrib and Dlg). aPKC is thereby “free” to activate and 
phosphorylate PAR3. The active PAR complex is then able to localize at the apical end 
of the apical domain, endorsing the formation of the epithelial junctional complex 
(Yamanaka et al., 2003, Yamanaka et al., 2006). Competition between LGL and Crb for 
the control of the apical and basolateral domains has also been reported (Tanentzapf and 
Tepass, 2003). It was observed that the LGL-system is epistatic to Crumbs complex, as 
loss of Crb does not change the functional activity of the Scrib-complex. Importantly, 
when the LGL pathway is lost, Crumbs pathway is not required to conserve epithelial 
polarity, whilst PAR3-complex redundantly acts with the Crumbs-system to confer 
apical character. Surprisingly in Drosophila, polarity is still maintained when in the 
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presence of Crb/Sdt mutants or epithelial cells mutants for Crb and Lgl pathways. Here, 
although polarity is re-established, the overall tissue architecture remains highly 
disorganized (Tanentzapf and Tepass, 2003, Fletcher et al., 2012). The phenotypes 
associated with mutations in one of the apical or basolateral components also differ, 
resulting in expanded basolateral or apical domains respectively (Kaplan et al., 2009). 
Events in the Hippo pathway upstream of FRMD6/Willin are slowly being elucidated. 
FRMD6/Willin has recently been shown also to physically interact with Par3 and 
cooperatively regulate epithelial apical constriction through atypical protein kinase C 
(aPKC)-mediated ROCK phosphorylation (Ishiuchi and Takeichi, 2011). 
FRMD6/Willin co-localized with Par3 in MDCK cells and co-immunoprecipitated with 
Par3 and aPKC in MDCK and EpH4 cells. The FERM domain and a region of the 
carboxyl-terminal domain adjacent to the FERM domain (termed juxta-FERM domain 
region, JFR) of FRMD6/Willin were sufficient to recruit aPKC to AJs. Surprisingly, in 
FRMD6/Willin–GFP expressing MDCK cells, aPKC remained at the AJs even when 
Par3 was depleted, suggesting that FRMD6/Willin recruits aPKC to the AJs 
independently of Par3 (Ishiuchi and Takeichi, 2011). These data are important since 
they link FRMD6/Willin to components of the cell polarity machinery. Finally, it has 
been shown that the association of the JFR of FRMD6/Willin with AJs is dependent on 
the nectin 1-afadin complex in L fibroblast cells (Ishiuchi and Takeichi, 2012). 
Other functional interactions between complexes and their activation underlie the 
organization and maintenance of epithelial polarity (Sotillos et al., 2004). In epithelial 
mammalian cells, the direct binding of CRB3 cytoplasmic tail (by CRB3 C-terminus 
ERLI residues) to Par6 PDZ domain has been shown (Lemmers et al., 2004). Par6 PDZ 
domain was proved to also bind to PALS1 amino terminus, one interaction which is 
Cdc42-GTP dependent and pivotal in the assembly of the tight junctions (Hurd et al., 
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2003a, Hurd et al., 2003b). CRB3 is the Crb mammalian homologue with 54% 
homology with Drosophila Crb (Lemmers et al., 2002) and it is expressed in 
mammalian epithelial cells (Lemmers et al., 2002, Makarova et al., 2003, Lemmers et 
al., 2004). Besides the well conserved cytoplasmic domain with a juxtamembrane 
FERM-binding motif (FBM) (Klebes and Knust, 2000, Assemat et al., 2008), and a C-
terminal PDZ-binding motif (PBM) composed by ERLI residues, CRB3 has an extra 
SH3 binding domain composed by PxxP residues, not found in any of the other Crb 
mammalian homologues (Lemmers et al., 2004). CRB3-ERLI residues interact with 
Pal1 PDZ-binding domain (Roh et al., 2003, Fogg et al., 2005), functioning upstream of 
Pal1, an association also observed in the Drosophila Crumbs and Stardust (Roh et al., 
2002). This interaction is essential for tight junctions formation and hence, epithelial 
polarity. Less is known about CRB3 – FBM. It has been postulated CRB3 - FBM 
cooperation with an unknown FERM protein (Fogg et al., 2005). FERM domain-
containing proteins bridge transmembrane proteins with the cortical actin cytoskeleton 
(Chishti et al., 1998, Sun et al., 2002, Frame et al., 2010). This event is thought to be 
paramount to stabilize CRB3 to the plasma membrane. Ezrin was shown not to be the 
FERM-binding partner, though increased levels of CRB3 resulted in Ezrin redistribution 
(Roh et al., 2003). In Drosophila, since the FERM domain of Ex is recruited to the 
plasma membrane by its interaction with Crb (Chen et al., 2010, Ling et al., 2010, 
Robinson et al., 2010), and loss of Crb or mutations within its FBM results in 
mislocalization of Ex to the basolateral region (Chen et al., 2010, Ling et al., 2010, 
Robinson et al., 2010), it is interesting to speculate that the FERM domain 
FRMD6/Willin may also associate with mammalian Crumbs proteins. 
 Chapter 1 – Introduction 
 42 
1.2.6.4. Upstream of the upstream 
Although many studies have described the upstream regulation of the core signalling 
cascade, how the extracellular environment regulates the upstream branches of the 
Hippo pathway remains largely unknown. The leukemia inhibitory factor receptor 
(LIFR) was recently identified as a membrane receptor pivotal for activation of the 
Hippo pathway by increasing YAP phosphorylation, and its concomitant inactivation in 
breast cancer cells (Chen et al., 2012, Piccolo, 2012). It was found that LIFR acts as a 
metastasis suppressor by promoting localization at the plasma membrane of the cell 
polarity factor Scribble as well as phosphorylation of the core kinases MST1/2 and 
LATS1 (Chen et al., 2012, Piccolo, 2012). Scribble as a pivotal factor for regulation of 
the Hippo pathway had been previously described. In fact its delocalization from the 
plasma membrane activates TAZ, the YAP paralogue, by inhibiting the assembly of a 
complex between LATS, MST, and TAZ and for activation of the LATS kinase by 
MST (Cordenonsi et al., 2011) (Figure 1.11). Interestingly, in embryonic stem cells, LIF 
signalling was found to inhibit YAP’s phosphorylation by the core kinase cascade, 
supporting the notion of context-dependent regulation (Lian et al., 2010). 
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Figure 1.11 – LIFR is an upstream regulator of the Hippo pathway. The activity of YAP and 
TAZ is held in check in normal and transformed mammary cells by cell-cell junctions, 
maintained by E-cadherin, and by correct apico-basal cell polarity that leads to membrane 
localization of Scribble (left). This activates the Hippo kinase cascade, leading to 
phosphorylation and inactivation of YAP and TAZ, by either cytoplasmic sequestration or 
degradation. In this condition, cancer cells are poorly tumourigenic, differentiated, hardly self-
renewing and unable to colonize distant organs. Sole activation of LIFR signalling in E-
cadherin–negative breast cancer cells is sufficient to oppose YAP activity, blunting cancer cell 
invasiveness and capacity to form metastases (right). ECM, extracellular matrix. Figure adopted 
from Piccolo, 2012. 
Furthermore, CD44 a major cell surface hyaluronan receptor was shown to function 
upstream of Merlin and of the core kinase cassette (Xu et al., 2010). However, by 
inducing tumour cell resistance to reactive oxygen species-induced and cytotoxic agent-
induced stress, CD44 attenuates activation of the Hippo pathway rather than promoting 
it (Stamenkovic and Yu, 2010, Xu et al., 2010). Finally, the G-protein-coupled receptors 
(GPCR), by altering actin cytoskeleton dynamics were recently showed to regulate the 
Hippo pathway (Yu et al., 2012, Lin et al., 2013, Yu and Guan, 2013). Diverse 
extracellular signals such as lysophosphatidic acid (LPA), sphingosine 1-phosphatase 
(S1P) or epinephrine signal through the GPCRs-coupled proteins G12/G13, Gq/11 or 
Gi/o either repressing or inducing YAZ/TAZ phosphorylation. Importantly, although 
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future studies. For example, the cellular con-
text in which all of this is proposed to occur 
remains unclear. Which cells are preferentially 
losing LIFR in human cancers (for example, 
pros pective cancer stem cell (CSC) popula-
tions)? Does loss of LIFR expression associate 
to YAP or TAZ activation in the same cell? 
Another unknown is whether the E-cadherin/
EMT and LIFR axes are independent, ‘double- 
assurance’ systems that control epithelial 
plasticity and metastasis (Fig. 1) or whether 
they regulate each other as segments of a self- 
regulating network. Is endogenous LIFR 
required for epithelial integrity in normal r 
transformed mammary cells? It would be inter-
esting to determine whether TAZ-promoting 
CSC traits8 and YAP-promoting metastasis2 
correspond to truly distinct functions between 
the two factors, or whether the roles of YAP 
and TAZ in cancer are actually overlapping. 
Although YAP target genes involved in meta-
stasis promotion were not uncovered, Chen 
et al.2 suggest CTGF as a possible function-
ally relevant target. However, their data in this 
regard are only based on overexpression, and 
there is no evidence that CTGF levels correlate 
with the clinical parameters here at stake.
A particularly exciting research avenue is 
the crosstalk with other signals feeding on 
YAP and possibly TAZ activity. The data of 
Chen et al.2 indicate that only a subset of 
primary tumors lacking LIFR will ultimately 
metastasize. This supports previous observa-
tions, whereby miR-9–overexpressing cells 
could effectively undergo EMT in vitro, but 
the same cells became invasive only at the 
tumor margin when implanted in vivo9. 
Collectively, these lines of evide ce suggest 
that other inputs from tumor microenviron-
ment must be in place to effectively activate 
the pro-metastatic effects of YAP; these 
cues should be largely independent from 
the Scribble-Hippo-YAP phosphorylation 
pathway, as this is already disabled by miR-9 
(Fig. 1). Intriguingly, epithelial plasticity 
and YAP and TAZ activity are also regulated 
by biomechanical properties of the cell’s 
microenvironment, such as the rigidity of the 
extracellular matrix, the stretched cell shape 
and the tension of the cytoskeleton, which 
only partially depend on the Hippo kinases5,6. 
Cues emerging from the tumor’s aberrant 
stiffness and mechanical homeostasis may 
thus be essential to permit and spatially local-
ize the effects of reduced LIFR signaling.
The wo k of Chen et al.2 also carries impor-
tant clinical implications. By delineating the 
appropriate cutoffs, the detection of LIFR 
might be implemented in clinical settings as a 
 prognostic marker of metastatic relapse, ideally 
to spare women carrying indolent forms of 
disease from the t xicities of antineoplastic 
therapies. In addition, the new findings suggest 
that drugs able to foster LIFR signaling might 
be a useful strategy to blunt YAP and/or TAZ 
activity and tumor aggressiveness. Chen 
et al.2 showed LIFR activity in a metastasis-
‘preventing’ experimental setup. This is an 
initial proof-of-principle observation whose 
translational utility is limited, given that 
patients with cancer already harbor dissemi-
nated malignant cells at the time of diagnosis.
Figure 1  LIFR is an upstream regulator of the Hippo pathway. The activity of YAP and TAZ is held in check in normal and transformed mammary cells by 
cell-cell junctions, maintained by E-cadherin, and by correct apico-basal cell polarity that leads to membrane localization of Scribble (left). This activates the 
Hippo kinase cascade, leading to phosphorylation and inactivation of YAP and TAZ, by either cytoplasmic sequestration or degradation4. In this condition, 
cancer cells are poorly tumorigenic, differentiated, hardly self-renewing and unable to colonize distant organs5,8. Chen et al.2 show that the sole  
activation of LIFR signaling in E-cadherin–negative breast cancer cells is sufficient to oppose YAP activity, blunting cancer cell invasiveness and capacity 
to form metastases (right). miR-9 is an upstream regulator of LIFR2 and E-cadherin9. miR-9 upregulation, in concert with extracellular signals inducing 
EMT or disturbing cell polarity5,10, leads to inhibition of Scribble and of the Hippo kinases2. This leads to TAZ and YAP nuclear accumulation, which causes 
induction of metastasis and of CSC-r lated traits, respectively2,8. ECM, extracellular matrix.
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this mechanism is LATS dependent, MST1/2 kinase activity does not mediate the 
GPCR-dependent regulation of YAP/TAZ (Yu et al., 2012, Lin et al., 2013, Yu and 
Guan, 2013). Figure 1.12 depicts a simplified representation of the Hippo signalling 
pathway in Drosophila and mammals. 
 
Figure 1.12 – Models of the Hippo pathway in Drosophila and mammals. Figure adapted from 
Zhao et al., 2010. 
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1.3. Epithelial-Mesenchymal Transition (EMT) 
YAP is a potent oncogene that promotes cell growth, oncogenic transformation, and 
epithelial-mesenchymal transition (EMT). Epithelial-mesenchymal transition is a 
cellular programme explaining the biological mechanism beneath cancer and metastatic 
progression, in epithelial cancer cells (Hanahan and Weinberg, 2000, Hanahan and 
Weinberg, 2011). It involves a cellular transition where polarized epithelial cells lose 
their archetypical phenotype and acquire mesenchymal characteristics. In EMT, cells 
undergo several biochemical changes gaining increased mobility and invasiveness, thus 
facilitating the spread of cancerous cells. Furthermore, cancer cells present an enhanced 
resistance to apoptosis and the morphological phenotype reverts from a cobblestone to a 
more spindle-like morphology. This cell scattering also results in failure to form acinar-
like structures in three-dimensional cultures of reconstituted basement membrane. In 
molecular terms, cells modify their protein expression patterns also enabling the 
screening for EMT occurrence (Figure 1.13) (Kalluri, 2009, Kalluri and Weinberg, 
2009, Tomaskovic-Crook et al., 2009). 
 
Figure 1.13 – Contribution of EMT to cancer progression. Progression from normal epithelium 
to invasive carcinoma goes through several stages. The invasive carcinoma stage involves 
epithelial cells losing their polarity and detaching from the basement membrane. The 
composition of the basement membrane also changes, altering cell-ECM interactions and 
signalling networks. The next step involves EMT and an angiogenic switch, facilitating the 
malignant phase of tumour growth. Progression from this stage to metastatic cancer also 
involves EMTs, enabling cancer cells to enter the circulation and exit the blood stream at a 
remote site, where they may form micro- and macro-metastases, which may involve METs and 
thus a reversion to an epithelial phenotype. Figure adopted from Kalluri et al., 2009. 
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The inverse process is also possible, namely, mesenchymal-epithelial transition, by 
which mesenchymal cells convert to an epithelial phenotype. This trait reflects the high 
plasticity ability of certain epithelial cells. The EMT program is acknowledged to occur 
in early stages of development at gastrulation and neural crest formation, in which the 
former is essential to the formation of the peripheral nervous system (Gans and 
Northcutt, 1983). However, the activation of such an “embryonic” system can be 
triggered again in completely developed tissues. In fact, EMT mechanism is now 
generally accepted to have three general subtypes accordingly to the biological context 
where it occurs. Type 1 explains EMT during implantation, embryogenesis, and organ 
development; type 2 concerns wound healing, organ fibrosis, and tissue regeneration 
(Choi and Diehl, 2009). Finally, type 3 explains cancer progression occurring in 
neoplastic cells and metastasis (Kalluri, 2009, Kalluri and Weinberg, 2009, Zeisberg 
and Neilson, 2009). Several biomarkers have been used to analyze EMT in all the three 
different types. In the type 3 EMT, associated with cancer progression and metastasis, a 
classical epithelial marker is E-cadherin. This cell surface protein is pivotal for cell 
adhesion. Therefore, down-regulation of its expression implies a hampered attachment 
between cells, allowing them to acquire more mesenchymal traits, such as cellular 
motility (Condeelis and Segall, 2003). 
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1.4. Pathological settings 
YAP involvement in human cancer and the acceptance of YAP as a mammal oncogene 
was established after it was shown to be in chromosome 11q22 amplicon, present in a 
broad variety of cancers (Overholtzer et al., 2006, Zender et al., 2006). YAP 
overexpression induces a considerable growth in the mouse liver and high levels of 
YAP have been described at the nuclear level, in numerous types of cancer (Zender et 
al., 2006, Camargo et al., 2007, Dong et al., 2007, Zhao et al., 2007). Zhao and 
colleagues (2009), describe the increased ability of YAP with mutated WW domains, to 
transform the immortalized, non-tumourigenic, mammary epithelial cell line MCF10A. 
Furthermore, overexpression of YAP induces EMT by causing loss of cell contact 
inhibition, restriction of apoptosis, anchorage-independent growth in soft agar, up-
regulation of the mesenchymal markers N-cadherin, vimentin, and fibronectin, and 
down-regulation of E-cadherin and occludin (Overholtzer et al., 2006). Similarly, 
mutation of specific phosphorylation sites in TAZ overexpressing MCF10A cells was 
shown to promote EMT (Lei et al., 2008). It was also previously reported that TAZ 
protein is highly expressed in some invasive ductal carcinomas (Chan et al., 2008), with 
TAZ activity correlating to tumour grade in primary breast tumours (Cordenonsi et al., 
2011). 
Intriguingly GWAS studies have linked FRMD6/Willin to both asthma and Alzheimer’s 
disease. One SNP in the FRMD6/Willin gene (rs3751464) has provided evidence for an 
association of FRMD6/Willin with asthma (OR =1.43 (1.18–1.75); p=3x10-4), even 
with correction for multiple testing (Ungvari et al., 2012). Additionally, the expression 
level of the FRMD6/Willin gene was consistently lower in the lungs of mice with 
allergic airway inflammation and it was significantly lower in human asthmatics 
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compared with controls (Ungvari et al., 2012). From a meta-analysis of Alzheimer’s 
disease, 4 intronic/ promoter variants of the FRMD6/Willin gene achieved strong study-
wide significance (Hong et al., 2012). FRMD6/Willin had been highlighted in two 
previous genome-wide association studies, and in each case, they were related to brain 
function. The first was a study of hippocampal atrophy (Potkin et al., 2009) and the 
second study used genotyping linked to 3D images of structures throughout the brain 
(Stein et al., 2010). 
While there are currently no reports of FRMD6/Willin inactivation in cancer, FRMD6/ 
Willin is antagonized by Ezrin in its ability to phosphorylate MST1/2 (Angus et al., 
2012) and so in a wider context, Ezrin may counteract the effects of FRMD6/Willin on 
the Hippo pathway and so act as an oncogene. The Willin gene is located on 
chromosome 14, open reading frame 31 (Accession No.: BC020521) of the human 
genome (Gunn-Moore et al., 2005). The 14q region has been described as being 
involved in several pathological conditions such as renal carcinoma gastric cancer 
(Buffart et al., 2012), uterine leiomyoma (Bowden et al., 2009), meningiomas (Perez-
Magan et al., 2010, Alahmadi and Croul, 2011), gliomas (Dichamp et al., 2004, 
Dahlback et al., 2011), neuroblastomas (Volchenboum et al., 2009) and gastrointestinal 
stromal tumours (Pelz et al., 2011, Ylipaa et al., 2011). Loss of heterozygosity and 
mutations on 14q have been associated with chromosomal abnormalities on 
chromosome 22q (Yamamoto et al., 2009, Alexiou et al., 2011), which is where Merlin 
gene NF2 is located. This suggests that FRMD6/Willin, like Merlin, might act as a 
tumour suppressor. 
Importantly, KIBRA was found to be significantly less expressed in the recently 
described sub-type of breast cancer Claudin-low an aggressive with a poor prognosis 
sub-group of breast cancer (Moleirinho et al., 2013a). Claudin-low tumours are an 
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intrinsic breast cancer sub-type characterized by a lack of luminal differentiation 
markers, a high enrichment for epithelial-mesenchymal transition (EMT) markers, 
immune response genes, and cancer stem cell-like features (Creighton et al., 2009, 
Hennessy et al., 2009, Prat et al., 2010, Herschkowitz et al., 2012). 
Several genetic, biochemical, and cell biology studies emphasize the importance of the 
novel Hippo tumour-suppressor pathway. The characteristics and mechanisms of 
regulation described in this chapter show the highly pertinent role of the Hippo 
signalling cascade for the control of development and progression of cancer both in vivo 
and in vitro. Future studies should aim to address the missing pieces of this puzzle. 
Contents of this chapter were published in the following invited review: Susana 
Moleirinho, Andrew Tilston-Lunel, Liselotte Angus, Frank Gunn-Moore & Paul A. 
Reynolds. 2013. The expanding family of FERM proteins. Biochemical Journal Jun 1; 
452(2): 183-93. doi: 10.1042/BJ20121642. 
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1.5. Thesis Aims 
The Hippo signalling pathway defines a novel signalling cascade composed by multiple 
proven or candidate tumour suppressors regulating cell contact inhibition, organ size, 
proliferation, and cancer development. 
Here I present data suggesting that Willin, in MCF10A cells and primary fibroblasts 
isolated from the sciatic nerve, is an upstream component of the signalling cascade 
regulating YAP by a MST1/2 dependent mechanism. In MCF10A cells, loss of Willin 
expression displays EMT transition features by antagonizing YAP on Ser127 
phosphorylation site, and in sciatic nerve fibroblasts Willin activity may have a 
potential role in the regeneration of the peripheral nervous system. Furthermore, I show 
that KIBRA, in both MCF10A and HEK 293T cells, is another upstream component of 
the Hippo pathway antagonizing YAP via phosphorylation of Ser127 residue, by a 
MST1/2 and MOBKL1A/B independent mechanism. In addition, I show that KIBRA 
expression antagonizes a YAP-induced EMT phenotype in MCF10A cells. 
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2.1. Molecular Cloning 
2.1.1. Knockdown plasmids 
2.1.1.1. Short-hairpin oligonucleotides 
The oligonucleotides sequences for specific short-hairpin (sh) RNA knockdown of 
Willin, Merlin, MST1, and KIBRA were designed using Psicologomaker 1.5 program 
(http://web.mit.edu/jacks-lab/protocols/pSico.htmL) (Table 2.1). Two different shRNA 
vectors were each developed for Willin and KIBRA corresponding to different target 
sequences within the Open Reading Frames (ORF) – shWillin-A/B and shKIBRA-A/B. 
2.1.1.2. Annealing of short-hairpin oligonucleotides 
To generate double stranded short-hairpin oligonucleotides, 1µl of each forward and 
reverse oligonucleotide, at a concentration of 0.1 nmoles/µl, was added to 5µl of 10x 
NEBuffer 2 (500 mM NaCl, 100 mM Tris-HCl, 100 mM MgCl2, 10 mM Dithiothreitol 
(DTT), New England Biolabs, Hertfordshire, UK), and 43µl of Milli-Q water. The 
reaction was incubated for 4 minutes (min) at 950C; followed by 10 min incubation at 
exactly 700C. The oligonucleotides were allowed to gradually anneal to room 
temperature (RT). The annealed oligos were kept on ice if immediately used or stored at 
-200C. 
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Table 2.1 – Short-hairpin RNA Oligonucleotides sequences (Invitrogen) 
 
2.1.1.3. Restriction Digest and Alkaline phosphatase treatment 
An AgeI/EcoRI restriction digest reaction was performed on 1µg of lentiviral vector 
pLKO.1puro (Plasmid 8453, Addgene, Cambridge, MA, USA) generating a two site 
digested plasmid with sticky-ends compatible with the oligonucleotides (Figure A.1, 
Appendix A). The plasmid was digested at 370C for 1hour (h) with the restriction 
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enzymes AgeI and EcoRI (NEB), using NEB 10x restriction buffer 1 (10mM Bis-Tris-
Propane-HCl, 10 mM MgCl2, 1 mM DTT) and treated with 0.5µl of calf intestinal 
alkaline phosphatase (CIAP, 1 unit/µL, Promega, Southampton, UK) to prevent the re-
ligation of compatible ends. The digested DNA products were then run on a 1% (w/v) 
agarose gel for extraction and purification. 
2.1.1.4. Agarose gel electrophoresis 
Agarose gels 1% (w/v) were prepared by melting 0.5g of agarose (Bioline, London, 
UK) in 50 mL 1x TBE buffer  (89 mM Tris-Borate, 2 mM EDTA, pH 8.3 (Sigma-
Aldrich, Dorset, UK). The solution was microwaved for 3 min and left to cool for 
approximately 10 min. Ethidium bromide (Sigma-Aldrich) was then added to the gel to 
a final concentration of 0.5 µg/mL, poured into a horizontal gel chamber and left to set 
for 20 min at RT. DNA samples were prepared by adding an appropriate amount of 
Bromophenol Blue 6x DNA sample loading buffer (NEB, Hitchin, UK) (11 mM EDTA, 
3.3 mM Tris-HCl, 0.017% SDS, 0.015% Bromophenol Blue, pH 8.0). 20µl of each 
sample was loaded into each well. In a separate lane, 5µl Hyperladder I (Bioline) was 
loaded as a molecular weight marker. DNA bands were separated at 60V for 30-45 min 
and visualized under UV light using a Bio-Rad Molecular Imager Gel Doc XR System 
(Bio-Rad, Hertforshire, UK). 
2.1.1.5. DNA Extraction and Purification from agarose gel 
The DNA bands were visualized under UV light at 360 nm and excised from the 
agarose gel using a sterile razor blade. DNA bands were weighted and purified using a 
QIAquick Gel Extraction Kit (Qiagen, Crawley, UK) according to manufacturer’s 
protocol. 
CHAPTER 2 – Material and Methods 
 55 
2.1.1.6. Ligation 
Each short-hairpin insert was ligated into the previously digested and CIAP treated 
lentiviral vector pLKO.1puro (Figure A.1 and A.2, Appendix A) using 5U T4 DNA 
Ligase in 10µl of 2x Ligation buffer and 2µl of 5x DNA ligation buffer, accordingly to 
the manufacturer’s protocol (Rapid DNA Ligation Kit, Roche, Burgess Hill, UK). 
Reactions were set up using three different molar ratios of insert to plasmid DNA (1:10, 
1:100, 1:1000), and a control reaction was performed by adding 2µl of purified 
pLKO.1puro vector (1 µg/µl) in the absence of DNA insert. The ligation reactions were 
conducted at 160C overnight. 
2.1.1.7. Transformation of E. coli 
20µl of each ligation reactions were added to 50µl of Subcloning Efficiency™ DH5α™ 
Competent Cells (Invitrogen, Paisley, UK), gently mixed and incubated on ice for 30 
min. The cells were then heat shocked for 45 sec at 420C and subsequently left on ice 
for 10 min. 400µl of Luria-Broth (LB) medium (1% Tryptone, 0.5% Yeast extract, 0.5% 
NaCl; Sigma-Aldrich) were added and the mix was incubated in a 15 mL canonical 
tubes at 370C, shaking at 200 rpm for 1h. LB-agar (1% Tryptone, 0.5% Yeast extract, 
0.5% NaCl, 1.5% Agar; Sigma-Aldrich) plates were prepared containing the antibiotic 
carbenicillin (100 µg/mL) and the transformed cells were spread and grown for 16h at 
370C. 
2.1.1.8. Plasmid Purification 
Single colonies grown for 16h at 370C were picked from the agar plates using a sterile 
yellow pipette tip and added into 3 mL of LB medium containing carbenicillin (100 
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µg/mL). Each colony was incubated in 14 mL polystyrene round-bottom tube for 16h at 
370C, shaking at 200 rpm. DNA purification was then conducted using QIAGEN Spin 
Miniprep Kit (Qiagen) accordingly to the manufacturer’s protocol. Purified plasmid 
DNA concentrations were measured in a NanoVue™ Spectrophotometer (Fisher 
Scientific, Loughborough, UK) at an absorbance of 260 nm. The ratio of absorbance at 
260 nm and 280 nm was used to assess DNA purity. A ration between 1.8-1.9 was 
considered as pure DNA. The purified DNA was stored at -200C in TE Buffer (10 mM 
Tris, 1mM EDTA, pH 8.0). To verify that the target short hairpin oligonucleotides had 
been successfully cloned into pLKO.1puro, the DNA samples were digested (AgeI and 
SpeI) and run on a 1% agarose gel. 1 miniprep plasmid DNA sample of shWillin-A, 3 
miniprep plasmid DNA samples of shWillin-B, 2 miniprep plasmid DNA samples of 
shMerlin, 2 miniprep plasmid DNA samples of shMST1, 3 miniprep plasmid DNA 
samples of shKIBRA-A, and 3 miniprep plasmid DNA samples of shKIBRA-B were 
then sequenced at the DNA Sequencing Service (University of Dundee, UK). 
2.1.1.9. Generation of Glycerol stocks 
Glycerol stocks of the bacterial cultures containing sequence-validated plasmids were 
prepared by gently mixing 750µl of fresh overnight bacterial cultures with 250µl of 
sterile 80% glycerol (20% final concentration). The glycerol stocks were stored at -
800C. 
2.1.1.10. MaxiPrep 
To obtain higher quantities of pure plasmid DNA (µg) maxipreps were prepared from 
the starter cultures. 300µl of bacterial culture were added to 600 mL of LB Broth 
medium supplemented with carbenicillin (100 µg/mL) and grown for 16h at 370C, 
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shaking at 200 rpm. Endo-Free Plasmid Maxi Kit (Qiagen) was used accordingly to the 
manufacturer’s protocol. Since pLKO.1puro is a low copy number plasmid, 
chloramphenicol (Sigma-Aldrich) working solution (170 µg/mL), prepared from a 34 
mg/mL stock (1:200), was added to the respective bacterial culture for the last two 
hours of the 16h of growth. Purified plasmid DNA concentrations were measured in a 
NanoVue™ Spectrophotometer (Fisher Scientific) at an absorbance of 260 nm. The 
ratio of absorbance at 260 nm and 280 nm was used to assess DNA purity. A ration 
between 1.8-1.9 was considered as pure DNA. The purified DNA was stored at -200C in 
TE Buffer. 
2.1.2. Previously developed Plasmids 
Dr. Paul Reynolds developed the expression plasmids used in the project as follows: the 
human Willin-HA ORF was excised and cloned into pBabe puro vector (Addgene 
plasmid 1764) as an BamHI-EcoRI fragment: both the forward and the reverse primers 
were designed and the later with an EcoRI site followed by a stop codon and one HA 
tag in frame to the end of the Willin sequence in order to create an in frame C-terminal 
tag; Flag-YAP1 ORF from pBabe-YAP-Flag (Addgene plasmid 15682) was excised 
and cloned into pBabe-Hygro (Addgene plasmid 1765); pBabe YAP1S127A ORF (a kind 
gift from Dr. Daniel Haber (Harvard University, Boston, MA, USA) was excised and 
cloned into pBabe-Hygro; human KIBRA cDNA from the untagged expression plasmid 
pcDNA3.1(+) (a kind gift from Dr. Ormandy (Garvan Institute of Medical Research, 
Sydney, Australia) was excised and cloned into pBabe-puro vector. The expression 
plasmid pBabe-puro Nf2 (Addgene plasmid 14116) as well as the knockdown plasmid 
pLKO.1puro shScramble (Addgene plasmid 1864) were purchased ready for 
downstreamapplications. 
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2.2. Cell Culture 
2.2.1. Cell Lines and Culture conditions 
The MCF10A non-tumourigenic human breast epithelial cell line (a kind gift from Dr. 
Jay Debnath), Phoenix A packaging cells, HEK 293T cell line [ATCC CRL-11268], 
primary fibroblasts, and Schwann cells isolated from rat’s sciatic nerve (kind gift from 
Prof Susan Barnett, University of Glasgow, UK), were cultured at 37ºC in a humidified 
atmosphere of 5% (v/v) CO2. The growth mediums used for the different cell lines are 
presented in Tables 2.2, 2.3, and 2.4, respectively. 
Table 2.2 – MCF10A cells Culture Medium. Adapted from (Debnath et al., 2003). 
	  
	  
	  
	  
 
Component Growth Medium Resuspension Medium
DMEM/F12
(Invitrogen) 500 mL 400 mL
Horse Serum
(Gibco)
25 mL
(5% Final)
100 mL
(20% Final)
Epidermal Growth Factor (EGF) 
(1mg/mL stock, Invitrogen)
10 µl
(20 ng/mL) -
Hydrocortisone
(Sigma-Aldrich)
250 µl
(0.5µg/mL) -
Cholera Toxin
(1.66 mg/mL stock Sigma-Aldrich)
31.25 µl
(100 ng/mL) -
Human Insulin 
(10 mg/mL stock Sigma-Aldrich)
500 µl
(10 µg/mL) -
Penicillin/Streptomycin 5 mL(1% Final)
5 mL
(1% Final)
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Table 2.3 – PhoenixA and 293T cells Culture Medium 
 
Table 2.4 – Primary Fibroblasts and Schwann Cells Culture Mediums 
 
 
Cell culture was performed in a class II biosafety cabinet under local rules. Cells were 
quickly thawed from liquid nitrogen, resuspended in 9 mL of pre-warmed complete 
medium and pelleted at 1200 rpm (cell lines) or 900 rpm (primary cells) for 3 min. The 
pellet was then resuspended in 5 mL of complete or resuspension medium (MCF10A 
Component Growth Medium
DMEM + Glutamax, 4.5 g/L D-
glucose pyruvate
(Invitrogen)
500 mL
(90% Final)
Fetal Bovine Serum
(Lonza)
50 mL
 (9% Final)
Penicillin/Streptomycin
(100x solution, Gibco)
5 mL
(1% Final)
Primary Fibroblasts Schwann Cells
DMEM + Glutamax, 4.5 g/L D-
glucose pyruvate
(Invitrogen)
500 mL 500 mL
Fetal Bovine Serum
(Lonza)
100 mL
(16.5% Final)
50 mL
(10% Final)
Penicillin/Streptomycin
(100x solution, Gibco)
5 mL 5 mL
Forskolin
(R&D Systems)
- 10 µM
Heregulin
(R&D Systems)
- 20 ng/mL
Growth Medium
Component
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cell line, Table 2.2) and plated into standard cell culture flasks (Nunc Nunclon) 
containing fresh complete culture medium. Cells were grown until reached confluency 
and passaged when appropriate. When confluent, the culture medium was removed and 
the cultures were rinsed once with sterile 0.05% or 0.25% (primary fibroblasts) Trypsin-
EDTA solution (Invitrogen). Trypsin-EDTA was removed and 2 mL of the same 
solution was added. Cells were trypsinized at 370C, aspirated with 8 mL of pre-warmed 
complete medium, transferred to 15 mL centrifuge tubes and pelleted at 1200 rpm (cell 
lines) or 900 rpm (primary cells), for 3 min. Cell counting was performed using a 
microscope counting chamber (haemocytometer) and the cells were resuspended at a 
final concentration of 1 x 106 cells/mL, unless stated otherwise, and plated into either a 
fresh plate or flask containing fresh complete medium. Cells were grown at 37ºC in a 
humidified atmosphere of 5% (v/v) CO2. 
2.2.2. Transduction by Retroviral Infection 
Retroviral infections were performed on MCF10A cells and primary fibroblasts. Willin-
HA, YAP, YAPS127A, Merlin, and KIBRA ORFs cloned into pBabe-puro retroviral 
vector were used for transduction. pBabe contructs were packaged into  PhoenixA cells 
for viral production; PhoenixA cells were grown in standard cell culture flasks and after 
4 days, 4 x 106 cells were plated into 10 cm plates for 24h. After 24h, for each 
PhoenixA cells plate, 43µl of Mirus LT1 (Cambridge Bioscience, Cambridge, UK) were 
added to 1.5 mL reduced serum OPTI-MEM (Invitrogen) followed by gentle mix and 
incubation for 20 min at room temperature. 20µg of pBabe vector containing the gene of 
interest or pBabe vector only, used as a control, were added to the Mirus LT1-OPTI-
MEM solution followed by gentle mix and incubation for 30 min at room temperature. 
1.5 mL of DNA-Mirus LT1-OPTI-MEM solution was then added slowly drop-by-drop 
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to each PhoenixA cells plate containing 10 mL of complete medium (Table 2.3) and 
incubated at 37ºC in a humidified atmosphere of 5% (v/v) CO2. 24h post-transfection, 
the medium was removed and 4 mL of complete, pre-warmed, fresh PhoenixA cells 
medium was added to each plate. With the start of virus production, the cells were 
handled in a designated biosafety cabinet, following specific rules for viral tissue 
culture and kept in designated “viral” incubators. 48h post-transfection, the retroviral 
supernatant was carefully collected, transferred to 15 mL centrifuge tubes, and stored at 
4ºC. 4 mL of complete, pre-warmed, fresh PhoenixA cells medium were then added to 
each plate. 72h post-transfection, the second batch of virus-containing medium was 
carefully collected and added to the 4 mL of virus-containing medium collected at 48h. 
Approximately 8 mL of virus-containing medium were filtered through a sterile 0.45 
µm syringe driven filter (Elkay, Hampshire, UK) in order to remove debris. Polybrene 
(Invitrogen) at a final concentration of 8 µg/mL was added to the viral supernatant. The 
viral supernatant was directly used for retroviral infection of the target cells. 
Target cells to be transduced by retroviral infection, either low passage MCF10A cells 
or primary fibroblasts, were previously plated on 10 cm plates containing 10 mL of 
complete medium (Table 2.2 and Table 2.4), at a final concentration of 5 x 105 
cells/mL. After a 24h incubation period at 37ºC in a humidified atmosphere of 5% (v/v) 
CO2, the medium was removed and 4 mL per plate of viral supernatant containing 
polybrene (8 µg/mL) was added. Cells were left incubating for 8h at 37ºC in viral tissue 
culture incubator. The viral-containing medium was then removed and 10 mL of 
complete, pre-warmed, fresh medium were carefully added. 48h after retroviral 
infection, transduced cells were trypsinized, transferred to T-75 flasks and selected with 
2.5µg/mL puromycin (pBabe expressing Willin-HA, KIBRA, Merlin or vector only) or 
with 300 µg/mL hygromycin (pBabe expressing YAP or YAPS127A). The selections 
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continued for 5 (puromycin) or 8 days (hygromycin) after which cells were used for 
subsequent experiments. Primary fibroblasts were selected for 5 (puromycin) or 10 days 
(hygromycin) using the same antibiotic concentrations as for MCF10A cell lines, as 
determined by a “kill” curve assay (Section 2.4.8.4). The retroviral infection protocol 
was followed for the creation of 13 stable cell lines (Table 2.5). For the creation of 
MCF10A-YAP / MCF10A-YAPS127A cells overexpressing Willin, KIBRA, Merlin or an 
empty vector, viral supernatant was added to stable MCF10A-YAP/MCF10A-YAPS127A 
cell lines and retroviral infection performed as described. When working with virus, 
adherence to health and safety regulation was maintained at all times. 
Table 2.5 – Stable cell lines created by retroviral infection protocol 
 
2.2.3. Transduction by Lentiviral Infection 
Short-hairpin RNA for WillinA, WillinB, Merlin, MST1, KIBRA-A, KIBRA-B, and 
Scramble cloned into pLKO.1puro lentiviral vector were used for transduction. The 
constructs were packaged into HEK 293T cells for viral production; 4 x 106 cells of 
HEK 293T cells were seeded into 10 cm plates. The following day, each 10 cm plate 
was transfected as follows: the appropriate amount of Mirus was added to 1.5 mL of 
serum-free OPTI-MEM, gently mixed and incubated for 20 min at room temperature. In 
Primary Fibroblasts -
YAP YAP S127A Willin
empty vector YAP S127A- empty vector YAP
YAP-Willin YAP S127A- Willin empty vector
YAP-KIBRA YAP S127A- KIBRA
YAP-Merlin
YAP-empty vector
Cell Lines
MCF10A -
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sterile 1.5 mL microcentrifuge tubes, the appropriate amount of shRNA transfer 
pLKO.1 plasmid, final concentration 1 µg/µl, was added to 6.3µl pSD16 (1 µg/µl) 
(packaging plasmid) and to 2.1µl pSD11 (1 µg/µl) (gag-pol). Specifically, 2.9µl of 
pLKO.1 (shWillin-A), 2.8µl of pLKO.1 (shWillin-B), 1.7µl of pLKO.1 (shMerlin), 
7.0µl of pLKO.1 (shMST1), 2.0µl of pLKO.1 (shKIBRA-A), 1.7µl of pLKO.1 
(shKIBRA-B), and 5.9µl of pLKO.1 (shScramble). The DNA mix was then transferred 
to the 15 mL centrifuge tubes containing the Mirus LT1- OPTI-MEM solution and left 
incubating for 30 min at room temperature. The DNA-Mirus LT1-OPTI-MEM solution 
was added slowly drop-by-drop to HEK 293T cells 10 cm plates containing 10 mL of 
HEK 293T complete medium (Table 2.3) and incubated at 37ºC in a humidified 
atmosphere of 5% (v/v) CO2. After this point, the lentiviral protocol is similar to the 
retroviral infection procedure described in Section 2.2.2, except for the period of time 
the viral supernatant containing polybrene (8 µg/mL) was left incubating with the 
MCF10A cells. Briefly, cells were left incubating for 4h at 37ºC in viral tissue culture 
incubator. The transduced cells were then selected with 2.5 µg/mL puromycin. The 
lentiviral infection protocol was followed for the creation of 8 stable cell lines (Table 
2.6). For the creation of double knockdown cells (MCF10A-shKIBRA-B-shMerlin), 
viral supernatant was added to stable MCF10A-shKIBRA-B cell line and lentiviral 
infection performed as described. When needed, several 10 cm plates of HEK 293T 
cells were seeded to obtain a higher viral titer for transduction of target cells. When 
working with virus, adherence to health and safety regulation was maintained at all 
times. 
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Table 2.6 – Stable cell lines created by lentiviral infection protocol 
 
2.2.4. Cell Line transfection 
2.2.4.1. Transfection with siRNA duplexes 
MCF10A stable cell lines (shScramble, shWillin-A, shKIBRA-B or YAPS127A) and rat 
primary fibroblasts were transfected using Lipofectamine 2000 (Invitrogen, Paisley, 
UK). siRNA duplexes targeting MST1 (ID #s8993 and s8994), LATS1 (ID #s17392 and 
s17393) and YAP (ID #s20366 and s20367) (Ambion, Warrington, UK) were 
transfected into the MCF10A stable cell lines previously mentioned, and  siRNAs 
targeting Willin/FRMD6 (ID #s141256, s141257, and s141258) (Ambion) were 
transfected into primary fibroblasts. A non-targeting siRNA duplex (ID #4390844) was 
used as a control. siRNA duplexes (at a concentration of 20 µM) were transfected to a 
final concentration of 20 nM. Cells were seeded onto either 10 cm or 6-well plates one 
day prior to transfection such that cells were 50-60% confluent on the following day. 
For each transfection sample, oligomer-Lipofectamine complexes were prepared by 
diluting Lipofectamine 2000 in the appropriate amount of OPTI-MEM reduced serum 
medium (Table 2.7), followed by gentle mix and incubation for 5 min at room 
temperature. Another tube was prepared by adding siRNA duplex (20 nM final 
concentration) into the appropriate amount of OPTI-MEM. After 5 min incubation, the 
diluted oligomer was combined with the Lipofectamine 2000, gently mixed and the 
solution was incubated for 20 min at room temperature. The transfection mix was then 
added slowly drop-by-drop to MCF10A or primary fibroblasts cells. The cells were 
shWillinA shKIBRA-A 
shWillinB shKIBRA-B
Cell Lines
MCF10A shMerlin shMST1 shScramble shKIBRA-B + 
shMerlin
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incubated for 24h after which the procedure was repeated to increase the transfection 
yield. On the following day, the cell medium was replaced and cells were incubated in 
the respective complete medium for another 48h before further analysis. 
Table 2.7 –Volumes of reagents used in siRNA transfection 
 
2.2.4.2. Transfection of plasmid DNA 
HEK 293T cells were transfected with plasmid DNA using GeneJammer reagent 
(Stratagene, Cheshire, UK). 2 x 106 cells were seeded in 10 cm plates 24h before 
transfection such that cells were 50-60% confluent at the time of the procedure. 
GeneJammer in a ratio of 3:1 (i.e. 3µl of reagent per each 1µg of DNA) was diluted in 
750µl of OPTI-MEM, gently mix and incubated for 5 min at room temperature. 10µg of 
DNA (pLKO.1-shScramble, pLKO.1-shKIBRA-B, pBabe-puro-empty vector or pBabe-
puro-KIBRA) were added directly into the GeneJammer-OPTI-MEM solution and the 
mix was incubated for 30 min at room temperature.  The transfection mix was then 
added slowly drop-by-drop to HEK 293T cell plates containing 10 mL of complete 
medium. Cells were harvest 48h post-transfection. 
Number of cells OPTI-MEM Lipofectamine siRNA (20nM)
10 cm Plate 8 x 105
800µl
(2x400µl) 16 µl 10 µl
6-well Plate 8 x 105
240µl
(2x120µl) 4.8 µl 3 µl
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2.3. RNA and Protein Analysis 
2.3.1. RNA Detection 
2.3.1.1. RNA extraction 
1 x 106 cells were plated on 10 cm plates containing 10 mL of the respective complete 
medium and incubated for 24-48h at 37ºC in a humidified atmosphere of 5% (v/v) CO2. 
Before starting RNA work, surfaces and equipment were cleaned with autoclaved water 
containing 0.1% Diethylpyrocarbonate (DEPC, Sigma-Aldrich). Filtered tips were used 
at all times. Extraction of RNA from cell lysates was performed using PeqGold 
MicroSpin Total RNA kit (PeqLab, Sarisbury Green, UK) according to the 
manufacturer’s protocol. Concentrations of the extracted RNAs were measured in a 
NanoVue™ Spectrophotometer (Fisher Scientific) at an absorbance of 260 nm. All 
extracted RNA samples were digested with 1.5µl of RNase-free DNase I (20Kuitz 
units/µl) diluted in OBI DNase I Digestion buffer (DNase I digest Kit, PeqLab). The 
DNase I digestion reaction mix was incubated for 15 min at room temperature 
according to the manufacturer’s protocol. DNase digested RNA samples were stored at -
80ºC. 
2.3.1.2.  Reverse Transcriptase PCR (RT-PCR) 
cDNA synthesis of 1µg DNase-digested RNA was conducted using First Strand cDNA 
Synthesis kit for RT-PCR (AMV) (Roche, Lewes, UK), according to the manufacturer’s 
protocol. Each PCR tube containing the reaction mix made up to a final volume of 20µl 
was incubated at 25ºC for 10 min followed by 60 min at 42ºC. AMV reverse 
transcriptase was then inactivated by heating the reaction mixture to 99ºC for 5 min. 
The PCR reaction was performed in a S1000 Thermal Cycler (Bio-Rad, Hertfordshire, 
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UK). The cDNA products were stored at -20ºC or immediately used for real-time 
quantitative RT-PCR (qPCR) (Section 2.3.3). 
2.3.1.3. Real Time Quantitative RT-PCR (qPCR) 
Quantitative PCR of the synthesized cDNA was conducted using SYBR Green 2x 
Master Mix (Agilent, Wokingham, UK) according to the manufacturer’s protocol. Each 
qPCR reaction contained in a final volume of 20µl: 12.5µl 2x Master mix, 0.5µl of 
forward and reverse primers (at a concentration of 10 µM), 10.5µl of nuclease-free 
water and 1µl of template cDNA produced from DNase-digested total RNA. Sequence 
of the qPCR primers is described in Table B.1 (Appendix B). Real-time quantitative 
RT-PCR reactions were performed on a Mx3005P machine (Agilent) and analysed 
using the MXPro QPCR software. No template controls (NTCs) reactions were added to 
evaluate the background signal. All measurements were conducted in triplicate unless 
otherwise indicated and standardized to the levels of β-actin. Relative changes in gene 
expression were calculated according to the 2−∆∆CT algorithm. The qPCR thermal cycle 
was set as described in Table 2.8. 
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Table 2.8 – Real-Time qPCR Thermal Cycling conditions 
 
* Annealing Temperature 
2.3.2. Protein Detection 
2.3.2.1. Protein Extraction and quantification 
Cell lysates were prepared after seeding 1 x 106 cells in 10 cm plates containing 10 mL 
of the respective complete medium. 48h later, the culture medium was removed and 
plates were washed twice with sterile PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 2.0 mM KH2PO4, pH 7.4, Sigma-Aldrich).  Cells were then lysed in a lysis 
buffer composed of 10 mM Tris at pH 8.0, 150 mM NaCl, 1% Na Deoxycholate, 1% 
Nonidet P-40, 1% Sodium Dodecyl Sulfate, 1 mM EDTA, and 1:25 protease inhibitor 
cocktail (Aprotinin, Bestatin, Calpain Inhibitor I and II, Chymostatin, E-64, Leupeptin, 
α2-Macroglobulin, Pefabloc SC, Pepstatin, PMSF, TLCK-HCl, Trypsin inhibitor 
(chicken, egg white and soybean)) (Roche, Burgess Hill, UK). Cells were scrapped off 
using a sterile plastic scraper and transferred to 1.5 mL micro-centrifuge tube. The 
Segment Temperature (ºC) Duration (min) Nb of Cycles
1 95 10 1
95 0.5
51-55* 1
72 0.5
95 1
55 0.5
95 0.5
4 25 0.5 1
5 4 + ∞
2 45
3 1
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protein lysates were sheared around 20 times by passing the lysate through a sterile 
needle/syringe.  A bicinchoninic acid (BCA) assay (BCA Protein Assay Kit, Thermo 
Scientific, Northumberland, UK) was performed according to the manufacturer’s 
protocol to standardize the protein concentration (30µg/ 20µl). The purple-coloured 
reaction product between BCA and protein was determined by measuring the 
absorbance at 570 nm using a MRX Microplate Reader (DYNEX Technologies, West 
Sussex, UK). A standard curve was generated based on the absorbance values of known 
concentrations of BSA (bovine serum albumin) (0.0 to 2.0 mg/mL). Concentration of 
diluted (1:10) protein lysates was assayed by comparison to the standard curve. After 
quantification, protein lysates were stored at -80ºC.  
2.3.2.2. Extraction and quantification of phosphorylated proteins 
When the phosphorylated state of extracted proteins had to be preserved, cells were 
immediately washed with 1 mL of TBS 1x (50 mM Tris, 138 mM NaCl, 2.7 mM KCl, 
pH 8.3). Protein extraction was performed by adding 400µl per 10 cm plate of fresh ice-
cold phospho-lysis extraction buffer (50 mM Tris, 0.1 M EGTA, 1 mM EDTA, 1% 
Triton-X-100, 1 mM Na3VO4, 50 mM NaF, 5 mM Na-PyroPO4, 0.27 M sucrose, 0.1% 
beta-mercaptoethanol, and 2.5 mM PMSF (all chemicals from Sigma-Aldrich)) 
supplemented with protease (Roche), and 1:100 halt phosphatase inhibitor cocktail 
(#78420, Thermo Scientific). The protein extracts were briefly sonicated on ice for one 
10 second burst, and the protein concentration measured using Bradford quantification 
method. For this assay, 10µl of pre-diluted protein samples and known concentrations 
of BSA (bovine serum albumin) (0.0 to 1.4 mg/mL) were added in duplicate to a 96-
well microplate followed by addition of 250µl Bradford reagent. The microplate was 
incubated for 5 min, in the dark, at room temperature and absorbance measured at 595 
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nm using a MRX Microplate Reader (DYNEX Technologies). A standard curve was 
generated based on the absorbance values of the known BSA concentrations. 
Concentration of the phospho-lysates was assayed by comparison to the standard curve. 
2.3.2.3. SDS-PAGE  
10% Tris/Glycine polyacrylamide gels for Sodium Dodecyl Sulfate PolyAcrylamide 
Gel Electrophoresis (SDS-PAGE) were prepared by first setting the separating gel (2 M 
Tris-HCl, pH 8.8 (Sigma-Aldrich); 30% (w/v) acrylamide/methylene bisacrylamide 
solution (37.5:1 ratio) (National Diagnostics, Yorkshire, UK); 1% ammonium persulfate 
(BDH); 1% SDS; 0.1% TEMED (Fisher Scientific)), and then the stacking gel (1 M 
Tris-HCl, pH 6.8; 30% (w/v) acrylamide/methylene bisacrylamide solution (37.5:1 
ratio); 1% ammonium persulfate; 1% SDS; 0.1% TEMED). Lower percentage 
Tris/Glycine polyacrylamide gels (8%) were used for resolving high molecular weight 
proteins, while higher percentage gels (15%) were produced to resolve smaller proteins. 
Protein samples (30µg/20µl) were prepared by combining the appropriate amounts of 
protein and distilled water with 3.33µl of 6x loading dye (375 mM Tris-HCl pH 6.8, 4% 
SDS, 40% Glycerol, 0.2M DTT, 0.03% Bromophenol blue). Molecular weight markers 
were included by adding 5µl of marker (Rainbow markers, GE Healthcare, Amersham, 
UK) to 5µl of 6x loading dye. All the samples were denatured for 5 min at 100ºC. Gels 
were put into a BioRad electrophoresis chamber filled with SDS-running buffer (25 mM 
Tris base, 190 mM glycine, 0.1% Glycine, 0.1% SDS, pH 8.3) and run for 90-120 min 
at 85 V. 
When indicated, pre-cast polyacrylamide NuPAGE® Novex® 4-12% Bis-Tris Gels (1.0 
mm thick, 10-well) were used (Life Technologies, Paisley, UK). Gels were put into a 
Novex Mini-cell (Invitrogen) electrophoresis chamber filled with NuPAGE® MES SDS 
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Running Buffer (50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3). 
500µl of NuPAGE® Antioxidant was added to the running buffer in the upper (cathode) 
buffer chamber and run for 35 min at 200 V. Samples were prepared as previously 
described. 
2.3.2.4. Western Blotting 
After running on SDS-PAGE gel, protein lysates were transferred onto PVDF transfer 
membrane by blotting in 1x Transfer buffer (25 mM Tris Base, 190 mM glycine, 0.1% 
SDS, 20% methanol) for 90 min at 80V. To confirm the successful protein transfer onto 
the PVDF membrane, a 0.1% (w/v) Ponceau S (Sigma-Aldrich) staining was performed 
followed by membrane washing in 1x TBS-T (33.3 mM Tris-HCl, 16.68 mM Tris base, 
138 mM NaCl, 2.7 mM KCl, pH 8.3, 0.1% Tween-20 (Sigma-Aldrich)). To prevent 
nonspecific binding, membranes were blocked in 5% skimmed dried milk in 1x TBS-T, 
with gentle agitation for 1h at room temperature. The blocking solution was removed 
and the membranes were immediately incubated with specific primary antibodies (Table 
C.1; Appendix C) diluted in either 5% BSA or skimmed dried milk in 1x TBS-T, 
according to the manufacturer’s instructions. Membranes were left overnight, shaking at 
4ºC. Blots were then washed three times, 10 min each, with 1x TBS-T at room 
temperature. Membranes were incubated with 10 mL of either mouse or rabbit 
horseradish peroxidase (HRP) conjugated secondary antibodies (Table C.3; Appendix 
C) diluted in 5% skimmed dried milk in 1x TBS-T, with gentle agitation for 1h at room 
temperature. The secondary antibodies solution was removed and the blots were washed 
three times, 10 min each, with 1x TBS-T at room temperature. Protein bands were 
detected by applying 1 mL of enhanced chemiluminescent (ECL) substrate (150µl of 
both SuperSignal Luminol/Enhancer and SuperSignal stable Peroxidase solutions 
CHAPTER 2 – Material and Methods 
 72 
diluted in 700µl of 1x TBS without 0.1% Tween 20) onto the membranes for 1 min 
(SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific). Protein bands 
were visualized and analyzed using LAS-3000 Intelligent Dark Box system (Fujifilm).  
When needed, membranes were reprobed with different antibodies. To remove the 
bound antibody membranes were washed four times, 10 min each, with 10% acetic acid, 
followed by three washes, 10 min each, with 1 x TBS-T at room temperature. Blots 
were then blocked, for 1h, and probed with primary and secondary antibodies as 
previously described. 
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2.4. Cell Assays 
2.4.1. Immunocytochemistry 
For F-actin filaments staining, cells were grown on glass-coverslips in 6-well plates 
with an initial density of 8x104. 24h after, coverslips were washed once in 2 mL PBS 
(10 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4, Sigma-Aldrich) at room 
temperature and directly fixed with 4% paraformaldehyde (Thermo Scientific), followed 
by two 5 min washes in 2 mL PBS. After permeabilized in PBS/1% NP40 (Igepal CA-
630, Sigma-Aldrich), coverslips were washed twice in 2 mL PBS, 5 min each, and 
incubated in Alexa Fluor® 568 Phalloidin (Invitrogen) (1:100 in PBS), for 20 min. 
Coverslips were then washed twice in PBS, 5 min each and mounted onto microscope 
slides in Mowiol-488 mounting medium (10% Mowiol-488, 25% glycerol, 100 mM tris, 
pH 8.5) containing 1.5% propyl-gallate as an antifade. 4',6-diamidino-2-phenylindole 
(DAPI, Sigma-Aldrich) was directly added at a final concentration of 1 µg/mL as 
nuclear counterstain. Coverslips were also mounted onto microscope slides in 
Vectashield mounting medium containing DAPI (Vector Laboratories, Peterborough). 
Slides were examined with DeltaVision Spectris Deconvolution microscope (60x 
objective). Optical sections were collected using a binning of 2 x 2.  Digitalized images 
were assembled using LCS Lite V2.61 Build 1538, Adobe Photoshop, and Volocity 
software (Improvision). Slides were also analysed in the super-resolution OMX 
Structured Illumination microscope, University of Dundee, as described in (Posch et al., 
2010). Briefly, images were acquired using a UPlanSApochromat 100x 1.4NA, oil 
immersion objective lens (Olympus, Center Valley, PA) and back-illuminated Cascade 
II 512 x 512 electron-multiplying charge-coupled device (EMCCD) camera 
(Photometrics, Tucson, AZ) on the OMX version 3 system (Applied Precision) 
equipped with 405, 488, and 593 nm solid-state lasers. 
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2.4.2. Flow Cytometry 
Flow cytometric analysis was performed to determine expression levels of E-cadherin, 
occludin, vimentin, and N-cadherin in MCF10A-YAP and YAPS127A cells 
overexpressing either an empty vector or Willin (Table 2.5). 1.5 x 106 cells were 
resuspended in 2% formaldehyde in PBS. Cells were stained with primary antibodies 
diluted in PBS/1% BSA/ 0.2% saponin solution (final concentrations according to 
manufacturer’s instructions (Table C.2; Appendix C)), for 1h in the dark, at 4ºC, and 
incubated with 50µl (2 µg/mL) goat anti-mouse antibody conjugated to FITC 
(fluorescein isothiocyanate) (0.5 mg/mL, Sigma-Aldrich) for 30 min at 4ºC. Cells 
stained with secondary antibody only were used as negative controls. Samples were 
analyzed on a FACScan Flow Cytometer (BD Biosciences, Oxford, UK) and were 
assessed using BD Biosciences CellQuest software. Where possible, a minimum of 
10000 events were collected for analysis. 
2.4.2.1. BrdU / PI labeling for flow cytometry 
For cell cycle progression analysis, cells were cultured until the desired confluence and 
pulse-labeled with 10 µM BrdU (Sigma-Aldrich) for 1h at 370C. After trypsinization 
and two PBS/ 1% BSA washes, cells were fixed in 70% ethanol at 40C for at least 30 
min, centrifuged at 500g for 10 min at 100C and the pellet was resuspended in 2N HCl 
for 30 min on ice for DNA denaturation. Cells were centrifuged at 500g for 10 min at 
100C and washed with 0.1M of Sodium tetraborate pH 8.5, centrifuged again, and 
stained with anti-BrdU (# 347580, BD Biosciences) for 1h at room temperature, in the 
dark. Cells were then washed and stained with Dylight 488-goat anti-mouse IgG (#115-
485-062, Stratech, Newmarket, UK) for 1h at RT. Stained cells were resuspended in 
PBS containing 20 µg/mL of propidium iodide (Sigma-Aldrich) and RNase at 100 
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µg/mL for 30 min at RT. For cell cycle analysis using propidium iodide, cells were 
washed twice in ice-cold PBS, fixed in 70% ethanol at 40C for at least 30 min, washed 
twice in ice-cold PBS and then resuspended in PBS containing 4 µg/mL of propidium 
iodide and RNase at 100 µg/mL for 30 min at RT, in the dark. Cells were then analysed 
on a FACScan (BD Biosciences) using CELLQUEST software. 
2.4.3. Nuclear and cytoplasmic fractionation 
After reaching the desired confluency primary fibroblasts were harvested, pelleted at 
228g for 4 min, washed with PBS, and pelleted again at 228g for 4 min. The pellet was 
resuspended in 0.5 mL ice-cold cytoplasmic extraction buffer (10 mM HEPES pH 7.9, 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and cocktail of protease inhibitors) and kept 
on ice for 5 min. Cells were lysed with 20 strokes using a pre-chilled Dounce 
homogenizer and the lysate was centrifuged at 228g for 5 min at 40C. The pellet 
(nuclear fraction) was resuspended in 1mL of ice-cold nuclear extraction buffer (0.25 
mM sucrose, 10 mM MgCl2, and cocktail of protease inhibitors), layered over a sucrose 
bed (0.88 mM sucrose, 0.5 mM MgCl2, and a cocktail of protease inhibitors) and 
centrifuged for 10 min at 40C. Pellet was resuspended in 500µl of 1x RIPA buffer (50 
mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0,5% Sodium deoxycholate, and a cocktail 
of protease inhibitors), briefly sonicated on ice and centrifuged at 2800g for 5 min at 
40C. The supernatant (cytoplasmic fraction) was transferred to a new 1.5 
microcentrifuge tube, 300µl of 1x RIPA buffer was added and the lysate centrifuged at 
2800g for 10 min at 40C to pellet any solids. The supernatant was transferred to a new 
tube. Protein sample buffer was added to both nuclear and cytoplasmic fractions and 30 
µg (30µg / 20µl) of protein lysates run on an SDS/10% polyacrylamide gel (Section 
2.3.2). 
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2.4.4. In vitro Wound Healing Assay 
Stable pools of infected cells were seeded at 8x105 per well (6-well plates) and allowed 
to grow until they reached confluency. For the primary fibroblasts knockdown analysis, 
3x105 cells per well were seeded and when they reached 60% confluency, cells were 
transfected on two consecutive days with either siRNAs targeting Willin/FRMD6 (ID 
#s141256) or non-targeting siRNA duplex (ID #4390844), used as a control (Section 
2.2.4.1). Cells were allowed to grow until reaching confluency (3 days after the initial 
transfection). Monolayers of confluent cultures were gently scratched with a sterile 
micropipette tip and migration towards the wound was monitored at different time 
points. Phase-contrast images were captured after the scratch for each one of the time 
points. The percentage of scratch covered by cells was measured as the percentage of 
the invaded area with respect to the initial wound area and calculated using Image J 
software. 
2.4.5. Anchorage-Independent growth 
Cells were seeded at 2 x 104 per well (6-well-plates) in 2 mL of growth medium 
(2xDMEM:F12, 1x penicillin/ streptomycin, and 10% FBS) and 0.7% agarose (final 
concentration 0.35% agarose), onto pre-prepared lower layer of 2 mL of complete 
growth medium with 1% agar (final concentration 0.5% agarose). Once the agarose was 
set, a layer of DMEM:F12 complete medium was added above the agarose layers. 
Medium was replaced every other day and the number of colonies (≥ 5 cells represented 
a colony) assessed every 7 days, for 21 days. 
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2.4.6. Migration Assay using Boyden Chamber 
0.5 mL aliquots of serum-free cell suspension (5 x 105 MCF10A cells) were added to 
the top chamber of 24-well chambers with 8.0 µm pores (BD Biosciences) and 
MCF10A cells pre-warmed, complete media supplemented with 20% serum (Table 2.2), 
was added to the lower chamber. Cells were incubated for 24h at 37ºC in a humidified 
atmosphere of 5% (v/v) CO2. After 24h, the top of the insert membrane was scrubbed 
free of cells by using a cotton swab and three PBS washes. The bottom side was stained 
with 0.3% crystal violet (Sigma-Aldrich) in 80% PBS/ 20% ethanol solution previously 
filtered through a sterile 0.22 µm syringe driven filter (Elkay). The number of cells on 
the lower surface of each chamber was counted using a Zeiss Axiovert 40CFL 
microscope and representative images of migration Boyden chambers taken when 
indicated. 
2.4.7. Adhesion Assay 
96-well plates were coated with 10 µg/mL Laminin (#L2020; Sigma-Aldrich) for 1h at 
37ºC. Some wells were left uncoated for negative controls. Wells were washed twice 
with washing buffer (0.1% BSA in complete cell growth medium) and blocked with 
0.5% BSA in complete cell growth medium, for 1h at 37 ºC. Wells were then washed 
once with washing buffer and the 96-well plates were placed on ice. 50µl of cells (4 x 
105 cells/ mL) were added per well and incubated at 37ºC in a humidified atmosphere of 
5% (v/v) CO2 for 30 min. Plates were shaken at 2000 rpm for 10 seconds followed by 
two washes with washing buffer. Cells were fixed with 4% paraformaldehyde for 10 
min at room temperature and washed once with washing buffer. Cells were then stained 
with crystal violet (5 mg/mL) in 98% PBS/ 2% ethanol solution previously filtered 
through a sterile 0.22 µm syringe driven filter, for 10 min at room temperature. The 
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total number of cells in the wells was counted using a Zeiss Axiovert 40CFL 
microscope. 
2.4.8. Proliferation analysis 
2.4.8.1. MTT Assay 
1 x 104 cells were seeded in 200µl complete medium in 96-well flat bottom plates and 
incubated for 24h at 37ºC in a humidified atmosphere of 5% (v/v) CO2. For each day (1-
7), a triplicate of wells per cell line was analysed. Complete medium was removed and 
20µl of fresh, 0.22 µm filtered MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) solution (5 mg/mL in sterile PBS) was added to 200µl 
sterile PBS, for 4h at 37ºC in a humidified atmosphere of 5% (v/v) CO2. PBS and MTT 
solution were then removed and cells were lysed by adding 100µl of Dimethyl sulfoxide 
(DMSO, Sigma-Aldrich). Plates were gently shaken in the dark for 15 min at room 
temperature. Reduction of yellow MTT by mitochondrial dehydrogenase enzymes to 
purple formazan was determined by measuring the absorbance at 570 nm using a MRX 
Microplate Reader (DYNEX Technol). 
2.4.8.2. Growth Curve Analysis 
2 x 105 cells were seeded in 3 mL of complete cell growth medium in 6-well plates and 
incubated for 24h at 37ºC in a humidified atmosphere of 5% (v/v) CO2. For each day (1-
7), a triplicate of wells per cell line was analysed. In each day, complete medium was 
removed and cells were detached by adding either 0.05% (MCF10A cells) or 0.25% 
(primary fibroblasts) trypsin-EDTA. Cells were counted using a haemocytometer and a 
Zeiss Axiovert 40CFL microscope. 
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2.4.8.3. Dojindo Cell Proliferation Assay 
100µl per well of cell suspensions at 5 x 105 cells/mL were added to 5 replicate wells in 
96-well flat bottom plates. Four plates were prepared (one per day) and incubated for 
24h at 37ºC in a humidified atmosphere of 5% (v/v) CO2. Medium only was added to 5 
replicate wells per plate as a control. For each day, cells were added with 10µl of Cell 
Counting Kit-8 solution reagent (Dojindo Laboratories, Cambridgeshire, UK) and 
incubated for 3h at 37ºC. Reduction of Dojindo’s highly water-soluble tetrazolium salt 
(WST-8) by dehydrogenase enzymes to yellow formazan was determined by measuring 
the absorbance at 450 nm using a MRX Microplate Reader (DYNEX Technol). 
2.4.8.4. Primary fibroblasts Kill Curve Analysis 
The minimal inhibitory concentration of puromycin and hygromycin selection agents 
required to kill non-transformed primary fibroblasts (Section 2.2.2) and allow 
transformed cells to survive was determined as follows. 8 x 104 cells were seeded in 3 
mL of complete cell growth medium in 6-well plates. Puromycin (stock solution 10 
mg/mL) was added to the concentrations of 0, 1.5, 2, 2.5, 3 and 3.5 µg/mL; and 
hygromycin (stock solution 50 mg/mL) was added to the concentrations of 0, 100, 150, 
200, 250, 300, 350, 400, 450, 500, 600 and 700 µg/mL. For each condition, a triplicate 
of wells was analysed. Cells were incubated at 37ºC in a humidified atmosphere of 5% 
(v/v) CO2. Cells were monitored for 5 (puromycin) or 10 days (hygromycin) and phase-
contrast images taken using a Zeiss Axiovert 40CFL microscope. 
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3.1. Introduction 
In Drosophila melanogaster Expanded and Merlin, members of the 4.1. superfamily of 
proteins, act together and upstream of the Hippo signalling pathway (Edgar, 2006, 
Hamaratoglu et al., 2006, Harvey and Tapon, 2007). These proteins have different roles 
in the upstream regulation of the Hippo cascade, with Expanded essentially regulating 
cell cycle exit and Merlin apoptosis (Pellock et al., 2007). Expanded was shown to 
interact with Merlin. This interaction results in these proteins co-localizing at the apical 
membrane domain through the conserved N-terminal region of Expanded (FERM 
domain) and the C-terminal domain of Merlin (McCartney et al., 2000). The DNA 
sequence of Willin is composed of 614 amino acids and was previously shown to be 
identical to the predicted vertebrate homologue of Expanded, Ex1 (Hamaratoglu et al., 
2006). This 60% homology occurs within their N-terminal FERM domain; yet, in 
mammals, Willin does not share the same type of interaction with Merlin, although the 
structural homology between Willin and Expanded is precisely within the FERM 
domain (Hamaratoglu et al., 2006). In HEK 293 cells Merlin expression resulted in the 
displacement of Willin from the plasma membrane (Angus, 2011). This suggests a 
competitive upstream mechanism regulating the Hippo pathway. However, Willin was 
shown to co-localize with Ezrin (Angus, 2011), a protein belonging to the 4.1. 
superfamily of proteins, which might suggest that Ezrin binds to Willin in a head-to-tail 
conformation typically observed during the interaction of ERM proteins (Chishti et al., 
1998). When Ezrin, Merlin, and Willin were over-expressed in HEK 293 cells, an 
indirect association between Willin and Merlin was observed, suggesting that Ezrin 
could modulate the upstream competition of the core kinase cascade upstream 
components (Angus, 2011). 
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The expression of both Willin and Merlin were reported to inactivate the transcriptional 
co-activator YAP by an unknown mechanism (Zhao et al., 2007). In fact, the initial 
mechanistic link to the Hippo pathway was made by the finding that Willin expression 
was able to activate the Hippo kinase cascade in HEK 293 cells by promoting MST1/2, 
LATS1, and YAP phosphorylation, therefore inducing YAP translocation from the 
nucleus to the cytoplasm (Angus et al., 2012). Importantly, although Merlin excluded 
Willin at the plasma membrane (Angus, 2011), co-expression of Merlin and Willin 
caused a synergistic effect on MST phosphorylation, with Willin increasing Merlin’s 
ability to induce MST phosphorylation. Furthermore, Ezrin was found to have an 
inhibitory effect on MST1/2 phosphorylation when co-expressed with either Merlin or 
Willin or with both Willin and Merlin (Angus et al., 2012). In Drosophila, Expanded 
interacts with Yki via WW-domain-PY motifs present at the C-terminal domain of the 
protein, which are absent in Willin. This might explain that although Willin presents the 
same intracellular localization of the Drosophila Expanded at high cell density, it is 
unable to rescue Drosophila ex mutants (Angus et al., 2012). 
The functional characterization of components belonging to the Hippo signalling 
pathway has been studied in the non-tumourigenic, but immortalized, mammary 
epithelial cell line MCF10A. It has been shown that, in this cell line, YAP 
overexpression or deregulation of Hippo pathway members is able to induce known 
hallmarks of tumourigenesis (Hamaratoglu et al., 2006, Hao et al., 2008, Zhang et al., 
2008b, Zhao et al., 2008a, Zhang et al., 2009, Zhao B, 2009). Gain of anchorage-
independent growth, loss of contact inhibition, and the ability to induce epithelial-
mesenchymal transition (EMT) are some of these well-described hallmarks (Hanahan 
and Weinberg, 2000, Hanahan and Weinberg, 2011). 
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3.2. Aims of the Chapter 
The question of whether Willin regulates the Hippo signalling pathway, and therefore 
negatively regulates YAP, had not been described in detail. Therefore, I aimed to 
uncover the downstream functional changes induced by Willin. My first aim was to 
determine if Willin knockdown suppressed activation of the Hippo pathway in 
MCF10A cells and to establish whether shRNA-mediated knockdown of Willin 
phenocopied YAP overexpression. The analysis was extended to Merlin (an upstream 
counterpart of the Hippo signalling) as well as to MST1 (a component of the core kinase 
cassette). My second aim was to probe if the observed biological outputs were YAP 
dependent. Thirdly, I investigated the effects of ectopic expression of Willin by 
determining whether Willin effectively suppressed YAP-induced EMT phenotypes and 
whether the antagonistic effect on YAP by Willin is via phosphorylation of Ser127 
residue. 
These aims contributed towards the understanding of the potential role of Willin as a 
tumour suppressor in the Hippo signalling pathway. 
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3.3. Willin knockdown inhibits activation of the Hippo pathway and 
induces features of EMT in MCF10A cells 
In order to uncover the role of Willin in the Hippo signalling cascade, the potential 
interactions of this protein with other Hippo components and how this regulation 
influenced the activity of YAP, was investigated by knocking down Willin, Merlin, and 
MST1 expression.  
Specific short-hairpin RNA sequences were cloned into an AgeI and EcoRI digested 
and CIAP treated lentiviral pLKO.1puro vector (Section 2.1.1.3; Table 2.1). Four 
constructs were obtained: shWillin-A, shWillin-B, shMerlin, and shMST1 (Figure A.1 
and A.2, Appendix A). The knockdown plasmids shWillin-A and shWillin-B 
correspond to different target sequences within the Willin ORF. To test the cloning 
effectiveness, minipreps of the four knockdown plasmid DNAs from independent 
bacterial colonies were digested with AgeI and SpeI, and analysed on 1% agarose gels. 
Specifically, 3 miniprep plasmid DNA samples of shWillin-A, 4 miniprep plasmid 
DNA samples of shWillin-B, 5 miniprep plasmid DNA samples of shMerlin, and 3 
miniprep plasmid DNA samples of shKIBRA-B were analysed. When visualized, loss 
of the expected 469 bp fragment was observed upon cloning of the oligonucleotides 
known to destroy the AgeI restriction site. This was the case in 1 out of the 3 minipreps 
containing the knockdown plasmid shWillin-A. A fragment around 469 bp was still 
present in the empty lentiviral vector pLKO.1 puro, used as a positive control for the 
AgeI digestion. Oligonucleotide sequences starting with 5` CCGGT and thereby not 
destroying the AgeI restriction site were used for the remaining three knockdown 
plasmids (Figure A.1 and A.2, Appendix A). Therefore, analytical restriction digests of 
these three plasmids showed the anticipated shift from a 469 bp to a 528 bp fragment in 
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agarose gel in 3 out of the 4 miniprep plasmid DNA samples of shWillin-B, in 2 out of 
the 5 miniprep plasmid DNA samples of shMerlin, and in 2 out of the 3 miniprep 
plasmid DNA samples of shMST1analysed. 
The DNA sequencing of sample 1 (shWillin-A), sample 2 (shWillin-B), sample 5 
(shMerlin), and sample 2 (shMST1) confirmed the successful cloning of the four 
lentiviral shRNA constructs (Figure 3.1). 
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Figure 3.1 – DNA sequencing of the obtained constructs. All the 5`sense oligonucleotides 
sequences, composed by 59 bp, were identified confirming the cloning of the annelead short 
hairpin oligonucleotides into the lentiviral vector, pLKO.1. 
HEK 293T cells were seeded and transiently transfected with shWillin-A, shWilin-B, 
shMerlin, and shMST1, as previously described (Section 2.2.4.2). Non-targeting shRNA 
(shScramble (shScr)) was used as a control. 48h post-transfection, cells were harvested 
and due to lacking a functional antibody against Willin, quantitative RT-PCR on HEK 
293T cells expressing shWillin-A, shWillin-B or shScramble was performed. At the 
mRNA expression level, both shWillin-A and shWillin-B resulted in a knockdown of 
approximately 80% when compared with the control shScramble (Figure 3.2). Cell 
lysates of HEK 293T cells expressing shMerlin, shMST1, and shScramble were also 
prepared 48h post-transfection, and equal amounts of protein were separated on a 10% 
AgeI EcoRI
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SDS-PAGE (Figure 3.3). Western blotting analysis confirmed the knockdown of Merlin 
and MST1 in HEK 293T cells. 
 
Figure 3.2 – Expression of shWillin-A and shWillin-B in HEK 293T cells 48h post-
transfection. Quantitative RT-PCR analysis of the expression of Willin mRNA in HEK 293T-
shWillin-A and HEK 293T-shWillin-B confirmed decreased Willin levels. β-actin was used to 
normalize for variances in input cDNA. Error bars represent ±SD (n=3). HEK 293T-shScr vs 
HEK 293T-shWillin-A or HEK 293T-shWillin-B: *** p < 0.001; One-way ANOVA and 
Bonferroni post-hoc test. 
 
Figure 3.3 – shMerlin and shMST1 efficient knockdown in HEK 293T cells. 48h post-
transfection, cell lysates were harvested, and equal amounts of protein separated on a 10% SDS-
PAGE. Immunoblots show knockdown of both Merlin and MST1 compared with HEK 293T-
shScramble control cells. β-actin was used as a loading control. 
After validating the effective knockdown of the constructs in HEK 293T cells, the 
analyses of Willin knockdown functional outputs were performed in MCF10A cells. 
These cells were transduced with lentiviruses containing the above-mentioned 
knockdown plasmids, as previously described (Section 2.2.3). Both quantitative RT-
PCR and western blotting confirmed the successful knockdown of the endogenous 
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proteins in transduced MCF10A cells. For this purpose, after 4 days puromycin 
selection, stable pools of cells were seeded and harvested 48h later. Quantitative RT-
PCR on MCF10A cells expressing shWillin-A, shWillin-B or shScramble was 
performed (Figure 3.4). Importantly, MCF10A-shWillin-A cells presented an mRNA 
knockdown of approximately 80%, in agreement with the levels observed in HEK 293T 
cells (Figure 3.2). However, MCF10A-shWillin-B cells, harvested 48h after seeding, 
displayed just a slight decrease in the Willin mRNA expression levels (shWillin-B 
(early)). It was hypothesized that within this time frame, MCF10A-shWillin-B cells 
could have high mRNA turnover. To test this hypothesis, cells were incubated and 
passaged until reaching later passage numbers. Cells were then harvested and RNA 
extracted (Section 2.3.1.1). In fact, at this later time MCF10A-shWillin-B cells showed 
an mRNA knockdown of approximately 50% (shWillin-B (late)) (Figure 3.4). 
Furthermore, cell lysates of MCF10A cells expressing shMerlin, shMST1, and 
shScramble were harvested 48h after incubation, and equal amounts of protein were 
separated on a 10% SDS-PAGE. Western blotting analysis confirmed the knockdown of 
Merlin and MST1 in MCF10A cells (Figure 3.5). 
 
Figure 3.4 – Expression of shWillin-A and shWillin-B in MCF10A cells. Quantitative RT-PCR 
analysis of the expression of Willin mRNA in MCF10A cells confirming knockdown of Willin 
mRNA expression by 80% for shWillin-A and by 20% for shWillin-B in early passage cells, 
which increased to 50% knockdown in late passage cells. β-actin was used to normalize for 
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variances in input cDNA. Error bars represent ±SD (n=3, except shWillin-B (late) where n=2). 
MCF10A-shScr vs MCF10A-shWillin-A or MCF10A-shWillin-B (late): *** p < 0.001; One-
way ANOVA and Bonferroni post-hoc test. MCF10A-shScr vs MCF10A-shWillin-B (early): p 
= 0.65; One-way ANOVA. 
 
Figure 3.5 – shMerlin and shMST1 efficient knockdown in MCF10A cells. Cell lysates were 
harvested, quantified, and separated on a 10% SDS-PAGE. Immunoblots show knockdown of 
both Merlin and MST1 compared with MCF10A-shScramble control cells. β-actin was used as 
a loading control. 
3.3.1. Willin knockdown suppresses activation of the Hippo Pathway  
The mammalian Hippo signalling pathway consists of a series of kinases and adaptor 
proteins forming a core kinase cassette. This cassette phosphorylates and inactivates the 
transcriptional co-activator YAP, thereby suppressing expression of genes that promote 
cell survival, growth, and proliferation (Huang et al., 2005). To uncover whether 
knockdown of Willin modulates the activation of the core Hippo pathway components, 
MCF10A cells were lentivirally infected with either shWillin-A or shScramble (control 
cells). Cells were seeded and 48h later harvested as described in Section 2.3.2.2. Equal 
amounts of protein were separated on a 10% SDS-PAGE. The subsequent PVDF 
membranes were probed with antiepitope antibodies for both phosphorylated and total 
core Hippo pathway components, MST1/2, LATS1, and YAP. LATS2 was not 
investigated as in MCF10A cells LATS2 was shown not to be a major regulator of the 
YAP phenotype (Zhang et al., 2008a). Knockdown of Willin expression resulted in a 
statistically significant decrease in the phosphorylation of MST1/2, LATS1, and YAP 
(Figure 3.6). 
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Figure 3.6 – Willin knockdown decreases phosphorylation of MST1/2, LATS1, and YAP in 
MCF10A cells. Relative phosphorylation to total proteins (MST1/2, LATS1 or YAP) is shown 
and background phosphorylation (in MCF10A-shScr) is set to 1. Means were calculated from 
three independent experiments using Image J software. Error bars represent ±SD (n=3). 
MCF10A-shScr vs MCF10A-shWillin-A: * p < 0.05; *** p < 0.001, Student’s t-test. 
3.3.2. Willin knockdown induces morphological changes in MCF10A cells 
resembling YAP-induced EMT 
The emerging concept of EMT inducers, such as YAP, as potential oncogenes is 
consistent with the EMT phenotype observed by YAP overexpression (Overholtzer et 
al., 2006). The fact that deregulation of Hippo pathway components such as LATS1 in 
MCF10A cells induces EMT (Zhang et al., 2008a), prompted the analysis of phenotypic 
changes observed by down-regulation of Willin expression. 
Morphological changes in MCF10A-shWillin cells compared with the morphological 
phenotype observed by YAP overexpression were verified by phase-contrast images of 
cells growing in monolayers. MCF10A-shMerlin and MCF10A-shMST1 cells were also 
probed as Merlin is an upstream component of the Hippo pathway (Hamaratoglu et al., 
2006), and MST1 belongs to the core kinase cassette (Chan et al., 2005, Callus et al., 
2006). Although MCF10A cells expressing a non-targeting control (shScramble) grew 
in epithelial-type islands on monolayer cultures, MCF10A-shWillin-A displayed 
abnormal features resembling YAP-induced EMT (Figure 3.7). Furthermore, MCF10A-
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shMerlin and MCF10A-shMST1 cells also exhibited a spindle-shaped mesenchymal 
appearance and increased cell scattering. Importantly, MCF10A-shWillin-B cells 
morphological phenotype was not as pronounced as the one observed with MCF10A-
shWillin-A (Figure 3.7). This is consistent with the quantitative RT-PCR data showing 
that in these cells Willin mRNA is knocked down by 50% and not by 80% as verified in 
MCF10A-shWillin-A cells (Figure 3.4). 
 
Figure 3.7 – Willin loss induces a morphology change in MCF10A cells that resembles YAP-
induced EMT. Representative phase-contrast images of cells growing in monolayer cultures and 
transduced with either non-targeting shRNA (shScr) or shRNA targeting Willin (shWillin), 
Merlin (shMerlin), MST1 (shMST1) or MCF10A cells expressing empty vector (MCF10A-
vector) or YAP (MCF10A-YAP). 1 – MCF10A-vector, MCF10A-shScr, and MCF10A-
shWillin-B cells grew in epithelial-type islands whereas 2 – MCF10A-YAP, MCF10A-
shWillin-A, MCF10A-shMerlin, and MCF10A-shMST1 cells exhibited a spindle-shaped 
mesenchymal appearance and increased cell scattering. Scale bar = 20 µm except for MCF10A-
shMST1 were scale bar = 50 µm. 
The morphological changes were also confirmed by phalloidin staining for F-actin 
analysed by OMX three-dimensional structured illumination microscopy (3D-SIM). The 
limited resolution of classical light microscopes makes it difficult to resolve and display 
structures below about 250 nm in size. 3D-SIM allows for a two-fold improvement of 
lateral (x-y) resolution (and almost 3x axially - in the z-dimension); several publications 
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have shown great improvements in the imaging of the cytoskeleton as actin fibres are 
below the 250 nm limit (Schermelleh et al., 2008, Posch et al., 2010). OMX 
methodology acquires 15 individual images (illuminated with structured light – a stripe 
pattern about 200nm apart) per image section. The stripes are translated laterally 5x, 
then the orientation rotated by 60° and another 5 lateral shifts are imaged, before 
another rotation to image another 5 shifted images – giving 15 images per section. 
Having 15 images (in different orientations) substantial additional spatial information is 
thus collected.  
Compared with MCF10A-shScr cells (Figure 3.8A), MCF10A-shWillin-A cells 
presented a dramatic increase in stress fibers with pronounced loss of internal cortical 
actin organization (Figure 3.8B). Potential filopodia extensions are perceived suggesting 
pro-migratory behaviour. As before, MCF10A-shWillinB cells did not present such a 
prominent morphological phenotype (Figure 3.8C). MCF10A-shMerlin cells showed 
lower internal actin disorganization compared with the remaining cell lines, closer to the 
morphology observed in MCF10A-shScr (Figure 3.8D). This could possibly be due to 
Merlin’s involvement in pathways other than the Hippo kinase cascade; hence its 
deregulation could be compensated by biochemical factors extrinsic to the Hippo 
pathway (McClatchey and Fehon, 2009, Stamenkovic and Yu, 2010). The most striking 
alteration in the cytoskeleton framework was observed in MCF10A-shMST1 cells, with 
a manifested disorganization of the actin filaments at cortical sites adjacent to cell-to-
cell interface (Figure 3.8E). This is consistent with MST1 role as a component of the 
core kinase cassette. 
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Figure 3.8 – 3D-SIM images of F-actin organization patterns in MCF10A-expressing (A) 
shScramble (B) shWillin-A (C) shWillin-B (D) shMerlin or (E) shMST1. Willin knockdown 
induces 3 - loss of internal cortical actin organization, 4 - the presence of potential filopodia 
extensions, and antagonizing the 1 - higher internal cortical actin arrangement and 2 - the 
absence of potential filopodia extensions seen in MCF10A-shScr. Cells were stained with Alexa 
Fluor® 568 phalloidin (grey channel). Scale bar = 5 µm. 
3.3.3. Knockdown of Willin induces the expression of EMT markers 
To test whether knockdown of Willin expression induced an EMT-like phenotype 
resembling YAP overexpression in MCF10A cells, western blotting was performed to 
examine the expression of EMT markers. Cell lysates were harvested, quantified, and 
separated on a 10% SDS-PAGE. The subsequent PVDF membranes were probed with 
epithelial and mesenchymal markers. Consistent with the EMT-like phenotype, the 
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mesenchymal markers N-cadherin and vimentin were up-regulated by YAP 
overexpression or by Willin knockdown, whereas the epithelial markers, E-cadherin and 
occludin, were down-regulated by both of these manipulations (Figure 3.9). Knockdown 
of Merlin (shMerlin) also displayed a similar phenotype, yet occludin expression levels 
were maintained in these cells as compared to MCF10A-shScr cells. This might suggest 
differences in the regulation of the upstream components of the Hippo pathway. 
Together, these data indicate that Willin knockdown induces EMT in MCF10A cells. 
 
Figure 3.9 – Willin knockdown causes EMT of MCF10A cells. Immunoblot analysis of E-
cadherin and occludin (epithelial markers), N-cadherin and vimentin (mesenchymal markers), 
shows loss of the epithelial markers and gain of the mesenchymal markers in MCF10A-
shWillin-A cells. β-Actin was used as a loading control. 
3.3.4. Knockdown of Willin expression promotes anchorage-independent growth 
Cells that are capable of forming colonies in soft agar are frequently correlated with 
oncogenic potential. This is the case with YAP, which induces anchorage-independent 
growth in soft agar (Overholtzer et al., 2006, Zhang et al., 2008a, Zhao B, 2009). 
Therefore, the following step in this analysis was to investigate whether Willin 
knockdown promotes MCF10A cell transformation by forming colonies in soft agar, 
and whether this transformation resembles YAP’s ability to induce anchorage-
MCF10A
Vector YAP
MCF10A
shScr shW-A
E-cad
Vimentin
β-actin
N-cad
shW-B
(early)
shMer
Merlin
E-cad
Vimentin
β-actin
N-cad
YAP
OccludinOccludin Ep
ith
eli
al
M
es
en
ch
ym
al
CHAPTER 3 – Willin is an upstream component of the mammalian Hippo pathway 
 96 
independent growth. Both MCF10A-shMerlin and MCF10A-shMST1 cells were 
included in this analysis. MCF10A cells expressing shScramble, shWillin-A, shWillin-
B, shMerlin, shMST1, YAP or an empty vector were seeded and grown in soft agar for 
21 days (Section 2.4.5). The number of formed colonies was counted; a colony being 
defined as a group of 5 or more cells. Remarkably, MCF10A cells expressing either 
shWillin-B, shMerlin or shMST1 showed a threefold increase (MCF10A-shWillin-B 
and MCF10A-shMerlin cells) to fourfold increase (MCF10A-shMST1 cells) in the 
potential tumourigenic ability of anchorage-independent growth in soft agar (Figure 
3.10). The number of colonies was very similar to those observed in YAP transduced 
MCF10A cells. Importantly, whilst MCF10A-shWillin-A cells did not produce a 
significantly increased number of colonies compared with MCF10A-shScr control cells, 
MCF10A-shWillin-B cells did form a significantly increased number of colonies 
compared with MCF10A-shScr control cells (Figure 3.10). 
 
Figure 3.10 – Willin knockdown in MCF10A cells promotes anchorage-independent growth in 
soft agar. MCF10A-shScramble, MCF10A-shWillin-A, MCF10A-shWillin-B, MCF10A-
shMerlin, MCF10A-shMST1, MCF10A-YAP, and MCF10A-vector cells were seeded and 
grown on soft agar for 21 days. One colony was scored if it was ≥ 5 cells. Means were 
calculated from three independent experiments conducted in triplicate. Error bars equal ±s.e. 
(n=9). MCF10A-shScr vs MCF10A-shWillin-B; MCF10A-shMerlin; MCF10A-shMST1: *** p 
< 0.001; One-way ANOVA and Bonferroni post-hoc test. MCF10A-shScr vs MCF10A-
shWillin-A: p = 0.8; Student’s t-test. MCF10A-YAP vs MCF10A-vector: *** p < 0.001; 
Student’s t-test. 
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3.3.5. Knockdown of Willin expression induces cell migration 
Previously, it was reported that shRNA-mediated knockdown of LATS1 resulted in 
increased cell migration of MCF10A cells (Zhang et al., 2008a). However, no studies 
addressed whether knocking down upstream components of the Hippo signalling 
cascade influences EMT induction in MCF10A cells. It was therefore determined 
whether knockdown of Willin induced cell migration of MCF10A cells. It was 
hypothesized that a similar cell migration pattern to YAP transduced MCF10A cells 
would be observed. MCF10A cells expressing shScramble, shWillin-A, shWillin-B, 
shMerlin, shMST1, YAP or an empty vector were cultured in 24-well Boyden chambers 
with 8.0 µm pores. 24h later, cells were stained and the cells that migrated through the 
8.0 µm pores were counted (Section 2.4.6). MCF10A-shWillin-A cells showed a 
threefold increased migration compared with MCF10A-shScr cells (Figure 3.11). 
MCF10A-shMerlin cells also showed increased cell migration, showing the ability of 
upstream components to promote a similar migratory behaviour to the one observed by 
knocking down constituents of the core kinase cassette (Zhang et al., 2008a). Notably, 
MCF10A-shMST1 cells prompted the higher cell migration with approximately a 
fivefold increase compared with MCF10A-shScr (Figure 3.11). 
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Figure 3.11 – Willin knockdown promotes cell migration in MCF10A cells. MCF10A-
shScramble, MCF10A-shWillin-A, MCF10A-shWillin-B, MCF10A-shMerlin, MCF10A-
shMST1, MCF10A-YAP, and MCF10A-vector cells were cultured in Boyden chambers and 
migration was assessed after 24h. Means were calculated from three independent experiments 
conducted in triplicate. Error bars represent ±s.e. (n=9). MCF10A-shScr vs MCF10A-shWillin-
A; MCF10A-shMerlin; MCF10A-shMST1: *** p < 0.001; One-way ANOVA and Bonferroni 
post-hoc test. MCF10A-shScr vs MCF10A-shWillin-B: * p < 0.05; One-way ANOVA and 
Bonferroni post-hoc test. MCF10A-YAP vs MCF10A-vector: *** p < 0.001; Student’s t-test. 
3.3.6. Knockdown of YAP suppresses the effect of Willin knockdown 
In Section 3.3 striking biological outputs were observed upon knocking down Willin. 
These results prompted investigating whether the ability of Willin knockdown to induce 
features of EMT are due to YAP loss of regulation, or if it is due to other factors. To 
determine if the increased migration phenotype of Willin knockdown is YAP 
dependent, small interfering RNAs (siRNAs) targeting YAP were introduced into 
MCF10A-shWillin-A cells. Remarkably, the Willin knockdown migratory phenotype 
was abrogated by the siRNA-mediated reduction of YAP expression (Figure 3.12). 
Collectively, these data suggest the effects perceived in MCF10A-shWillin cells upon 
migration are YAP dependent. 
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Figure 3.12 – Effect of shWillin is YAP dependent. MCF10A-shScr or MCF10A-shWillin-A 
were transfected with two independent siRNA duplexes targeting YAP. Cells were cultered in 
Boyden chambers and migration assessed after 24 h. Error bars equal ±s.e. (n=9). MCF10A-
shWillin-A-siCtr vs MCF10A-shWillin-A-siYAP1 or MCF10A-shWillin-A-siYAP2: *** p < 
0.001; One-way ANOVA and Bonferroni post-hoc test. Immunoblot analysis of efficient 
knockdown of YAP was carried out using two independent siRNA duplexes (siYAP1 and 
siYAP2). siControl refers to a non-targeting siRNA duplex. β-Actin was used as a loading 
control. 
3.3.7. Knockdown of Willin expression suppresses cell adhesion to the basement 
membrane 
During the EMT process, cells develop modifications in their shape as well as in their 
attachment to other cells and to the extracellular matrix (ECM) (Hanahan and 
Weinberg, 2000, Hanahan and Weinberg, 2011). The polarized epithelial cell detaches 
from the basement membrane, acquiring increased capacity of motility and invasiveness 
(Hanahan and Weinberg, 2011). Laminin is one of the principal basement membrane 
constituents and its down-regulation is observed during the EMT process (Giannelli et 
al., 2005). Loss of cell adhesion to ECM is therefore a hallmark of EMT (Zeisberg and 
Neilson, 2009). 
To verify how knocking down Willin expression affected cell adhesion to the basement 
membrane, stable pools of MCF10A cells expressing shScramble, shWillin-A or 
shWillin-B were seeded onto laminin coated 96-well plates. Cells were left incubating 
for 30 min, fixed, and stained. The number of cells adherent to the laminin plate was 
then counted (Section 2.4.7). Cell adhesion analysis of both MCF10A-shMerlin and 
MCF10A-shMST1 cells was also conducted. Knockdown of Willin expression inhibited 
cell adhesion to laminin by 20% compared with MCF10A-shScr control cells (Figure 
3.14). Notably, MCF10A-shMST1 cells hindered cell adhesion by 50%, which could be 
expected since MST1 is a component of the core kinase cascade (Figure 3.13). 
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Figure 3.13 – Willin knockdown inhibits cell adhesion to the basement membrane. MCF10A-
shScramble, MCF10A-shWillin-A, MCF10A-shWillin-B, MCF10A-shMerlin, and MCF10A-
shMST1 cells were seeded in laminin-coated plates and the number of adherent cells was 
counted. Means were calculated from two independent experiments conducted in triplicate. 
Error bars represent ±s.e. (n=6). MCF10A-shScr vs MCF10A-shWillin-A; MCF10A-shWillin-
B: ** p < 0.01; One-way ANOVA and Bonferroni post-hoc test. MCF10A-shScr vs MCF10A-
shMerlin; MCF10A-shMST1: *** p < 0.001; One-way ANOVA and Bonferroni post-hoc test. 
3.3.8. Knockdown of Willin expression does not promote cell proliferation 
It was explored if knockdown of Willin, Merlin or MST1 expression had an impact on 
cell proliferation, as the Hippo signalling pathway was shown to promote cell-contact 
inhibition at high cell densities (Camargo et al., 2007, Dong et al., 2007, Zhao et al., 
2007). An equal number of cells were seeded onto 96-well plates. Cell proliferation was 
assessed by MTT assay as previously described (Section 2.4.8.1), every 24 h for 6 days. 
The average reduction of MTT to purple formazan product absorbing at 570 nm during 
the time course is shown in Figure 3.14. The MTT assay revealed no statistically 
significant differences in cell proliferation between MCF10A-shWillin-A and 
MCF10A-shScr control cells. Surprisingly, MCF10A-shMerlin cells, rather than MST1-
transduced MCF10A cells, showed the highest proliferation rate. This could be expected 
considering the aforementioned phenotypes displayed by the MCF10A-shMST1 cell 
line (Figure 3.14). Therefore, it was concluded that MCF10A-shMerlin is the only cell 
line capable of inducing increased cell proliferation rates. However, the MTT assay is 
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not the most accurate assay to determine cell proliferation rates. Elaboration of a growth 
curve using a haemocytometer or a Dojindo proliferation assay (Sections 2.4.8.2 and 
2.4.8.3, respectively) are assays that provide higher precision; yet these analyses were 
not conducted within the present scenario. 
 
Figure 3.14 – Knockdown of Willin expression does not promote cell proliferation. 
Proliferation rates of MCF10A cells expressing shScramble, shWilin-A, shWillin-B, shMerlin 
or shMST1 were measured by MTT assay every 24h for 6 days. Means of absorbance at 570 nm 
were calculated from one experiment conducted in triplicate. Error bars represent ±SD (n=3). 
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3.4. Ectopic Willin expression antagonizes a YAP-induced EMT 
phenotype in MCF10A cells 
To test whether expression of Willin could influence the activity of YAP, MCF10A-
YAP or MCF10A cells expressing the constitutively active YAP, YAPS127A (MCF10A-
YAPS127A) were infected with a retrovirus containing either pBabe-Willin-HA or pBabe-
empty vector expression plasmids as previously described (Section 2.2.2) (Figure 3.15).  
 
Figure 3.15 – The immortalized, non-tumourigenic MCF10A cell line was infected with either 
pBabe-Hygro-YAP or YAPS127A by retroviral transduction. These stable cell lines were then 
submitted to a second retroviral transduction with either pBabe-Puro-Willin-HA or empty 
vector expression plasmids. Drug-selected pools of infected cells were used in all the 
experiments to avoid clonal selection effects. 
At the time of the experiments there was no functional antibody available against 
Willin. To overcome this problem, the epitope tag human influenza haemagglutinin 
(HA) was cloned in frame to Willin by Dr. Paul Reynolds. However, although Dr. 
Liselotte Angus was able to detect Willin-HA expression in MCF10A cells (Angus, 
2011; Angus et al., 2012) subsequent attempts were unsuccessful despite using two 
different anti-HA monoclonal antibodies (#H-9658, Sigma-Aldrich; #MMS-101P, 
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Cambridge Biosciences). This could possibly be due to conformational changes 
masking the HA epitope. Therefore, the successful overexpression of the constructs in 
MCF10A-YAP or MCF10A-YAPS127A cells was assessed through quantitative RT-PCR 
(Figure 3.16). 
 
Figure 3.16 – Expression of Willin-HA tagged in MCF10A-YAP and MCF10A-YAPS127A cells. 
Quantitative RT-PCR analysis of the expression of FRMD6 mRNA in Willin expressing 
MCF10A-YAP or MCF10A-YAPS127A cells confirmed increased Willin levels. β-actin was used 
to normalize for variances in input cDNA. Error bars represent ±SD (n=3). MCF10A-YAP-
vector vs MCF10A-YAP-Willin: *** p < 0.001; Student’s t-test. MCF10A-YAPS127A-vector vs 
MCF10A-YAPS127A-Willin: *** p < 0.001; Student’s t-test. 
Dr. Liselotte Angus showed that Willin expression caused increased phosphorylation 
levels of the core Hippo pathway components in MCF10A cells (Angus, 2011; Angus et 
al., 2012) (Figure 3.17). Immunoblot analysis confirmed that Willin-HA was expressed 
in MCF10A cells retrovirally transduced with pBabe-Willin-HA. In fact, this was the 
only time that detection of the HA epitope was successful. These results further confirm 
the observations shown in Figure 3.6. Taken together, these results show that Willin 
regulates the activation of the Hippo pathway. 
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Figure 3.17 – Willin overexpression in MCF10A cells results in an increase of phosphorylated 
MST1/2, LATS1, and YAP. Relative phosphorylation to total protein levels (MST1/2, LATS1 
or YAP), and background phosphorylation (in MCF10A-YAP-vector) is set to 1. Means were 
calculated from three independent experiments using Image J software. Error bars represent 
±SD (n=3). Work done by Dr. Liselotte Angus. 
3.4.1. Willin antagonizes YAP-induced EMT markers expression in MCF10A 
cells. 
The induction of an epithelial-mesenchymal transition (EMT) by YAP overexpression 
in MCF10A cells has been previously described (Overholtzer et al., 2006). Similarly, 
the core Hippo pathway components were reported to suppress a YAP-induced EMT 
(Overholtzer et al., 2006, Zhang et al., 2008a, Zhao B, 2009). Therefore, Willin’s ability 
to antagonize a YAP-induced mesenchymal phenotype in MCF10A cells 
overexpressing YAP (MCF10A-YAP), was assessed by examining the expression of 
well-characterized EMT markers. These analyses were conducted by immunoblotting as 
well as by flow cytometry (FACS). 
For immunoblotting analysis, cell lysates were harvested and equal amounts of protein 
were separated on a 10% SDS-PAGE. The subsequent PVDF membranes were probed 
for epithelial and mesenchymal markers. Expression of Willin in MCF10A-YAP cells 
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resulted in a decrease of the mesenchymal markers N-cadherin and vimentin, with the 
concomitant increase of the epithelial markers E-cadherin and occludin. Importantly, no 
changes were observed in the mutant cell line MCF10A-YAPS127A (Figure 3.18). 
Collectively, these results suggest that the changes observed in the expression of these 
EMT markers, were due to activation of the Hippo pathway converging through 
phosphorylation of YAP Ser127 residue (Figure 3.18). 
 
Figure 3.18 – Willin expression antagonizes YAP-induced EMT markers expression in 
MCF10A cells. Immunoblots show increased E-cadherin, occludin and decreased vimentin, N-
cadherin in MCF10A-YAP cells expressing Willin, but no changes in MCF10A- YAPS127A cells 
expressing Willin compared with vector control cells. β-actin (42 KDa) was used as a loading 
control. 
Furthermore, the relative fluorescence intensity of the epithelial as well as the 
mesenchymal markers was evaluated by flow cytometry. Since occludin is a 
transmembrane protein localized to tight junctions, it was first determined if the 
occludin epitope for the available antibody was intracellular or extracellular.  MCF10A-
YAP-Willin cells were tested since the immunoblotting analysis confirmed the up-
regulation of occludin in these cells (Figure 3.18). Occludin’s fluorescence intensity 
was higher in the intracellular fraction rather than in the extracellular fraction of the 
protein (Figure 3.19A). Due to the intracellular location of the epitope for the antibody 
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used, FACS methodology for intracellular proteins was applied (Section 2.4.2) and 
extended to the mesenchymal marker vimentin. MCF10A-YAP-Willin cells caused an 
increase in occludin staining intensity compared with MCF10A-YAP-vector cells 
(Figure 3.19B). On the contrary, upon Willin expression, vimentin staining intensity 
was decreased in these cells (Figure 3.19C). 
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Figure 3.19 – Phenotype analysis of the epithelial marker occludin and the mesenchymal 
marker vimentin in Willin expressing MCF10A-YAP cells. (A) Willin MCF10A-YAP cell line 
was stained for transmembrane protein occludin to determine epitope localization for the used 
antibody. FL1-H in the X-axis displays log green fluorescence intensity. The same cell line 
(dark grey line) as well as vector expressing MCF10A-YAP cells (light grey line) were stained 
for (B) occludin and (C) intermediate filament protein vimentin. Histograms correspond to the 
medium fluorescence intensity of MAb staining. The grey histograms represent secondary 
antibody anti-mouse FITC alone. 
The analysis by flow cytometry was repeated and extended to another two EMT 
markers, E-cadherin and N-cadherin, both also with intracellular epitopes for the 
antibodies used. MCF10A-YAP cells expressing Willin induced up-regulation of the 
epithelial markers E-cadherin and occludin, with a down-regulated expression of the 
mesenchymal markers vimentin and N-cadherin (Figure 3.20). Although in the 
presented histograms the variations seem to be marginal, the logarithmic scale displayed 
on the X-axis masks differences in the fluorescence intensity of the analysed markers 
between the cell lines. Importantly, the mutant MCF10A-YAPS127A cells showed no 
changes to the effect of Willin expression (Figure 3.20). These results are in agreement 
with the data obtained by immunoblotting analysis. 
Taken together, these results show that Willin promotes a transition from typical 
mesenchymal protein expression patterns induced by YAP overexpression towards a 
more epithelial phenotype, characteristic of non-transformed cells. 
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Figure 3.20 – Phenotype analysis of the epithelial markers occludin and E-cadherin and the 
mesenchymal markers vimentin and N-cadherin in either MCF10A-YAP or MCF10A-YAPS127A 
cells expressing Willin. Both Willin (dark grey line) and vector (light grey line) expressing cell 
lines were stained for E-cadherin, N-cadherin, occludin, and vimentin, respectively. Histograms 
correspond to the medium fluorescence intensity of MAb staining (FL1). The grey histograms 
represent second antibody anti-mouse FITC alone. 
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3.4.2. Willin induces morphological changes in MCF10A-YAP cells towards a 
more epithelial phenotype 
YAP overexpression phenotype is characterized by a cellular arrangement consisting of 
a spindle shaped mesenchymal appearance and cellular dispersion with disorganized 
adherens junctions (Overholtzer et al, 2006; Zhang et al., 2008a). Therefore, the ability 
of Willin to hinder the mesenchymal-like morphology observed in MCF10A-YAP-
vector cells was investigated. Phalloidin staining for F-actin was performed in 
MCF10A-YAP-Willin and MCF10A-YAP-vector cells, and slides analysed in a 
Deltavision deconvolution microscope. F-actin expression pattern was clearly different 
between the two cell lines (Figure 3.21). In MCF10A-YAP-Willin cells the switch from 
stress fibres to cortical actin is evident, with the absence of possible filopodia 
extensions. 
The cytoskeleton framework was additionally probed by OMX three-dimensional 
structured illumination microscopy (3D-SIM). MCF10A-YAP or MCF10A-YAPS127A 
cells expressing either Willin or vector cDNAs displayed high variations concerning the 
organization of actin filaments. Specifically, expression of Willin antagonized the 
internal cortical actin pattern observed in MCF10A-YAP-vector cells. Furthermore, the 
absence of potential filopodia extensions thought to function as antennae by cancer cells 
to investigate the stromal environment (Mattila and Lappalainen, 2008), suggests a non-
migratory phenotype (Figure 3.22). Importantly, the mutant MCF10A-YAPS127A cell 
lines displayed loss of adherens junction’s at cortical sites adjacent to cell-to-cell 
interface (Figure 3.23). Willin expression did not promote any changes in these 
phenotypes. Collectively, these data indicate that Willin is able to modify the F-actin 
cellular organization from a mesenchymal appearance promoted by YAP 
overexpression towards a more epithelial morphology. 
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Figure 3.21 – Willin suppresses YAP-induced F-actin disorganization. The images display 
projections combining information from multiple Z sections (A) MCF10A-YAP-vector cells 1 - 
loss internal cortical actin organization. 2 - The presence of potential filopodia extensions 
suggests migratory ability. (B) MCF10A-YAP-Willin cells present a 3 - higher internal cortical 
actin arrangement as well as at the cortical sites adjacent to cell-to-cell interface. 4 - Absence of 
potential filopodia extensions. Cells were stained with Alexa Fluor® 568 phalloidin (red and 
grey channel), and 4',6-diamidino-2-phenylindole (DAPI – blue). Objective x 60. Scale bar = 22 
µm. 
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Figure 3.22 – 3D-SIM images of F-actin organization patterns in MCF10A-YAP cells 
expressing (A) vector or (B) Willin. Note the 1 – loss of cortical actin organization in vector 
expressing cells and the 2 - presence of potential filopodia projections compared with the 3 - 
increased internal cortical actin organization and the 4 - absence of potential filopodia 
projections in Willin expressing cells. Cells were stained with Alexa Fluor® 568 phalloidin 
(grey channel). Scale bar = 5 µm. 
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Figure 3.23 – 3D-SIM images of F-actin organization patterns in MCF10A-YAPS127A cells 
expressing (A) vector or (B) Willin. Note the 1 - increased loss of internal cortical actin 
arrangement as well as at the cortical sites adjacent to cell-to-cell interface in MCF10A-
YAPS127A cells expressing Willin. 2 - The presence of potential filopodia extensions suggests 
migratory ability. Cells were stained with Alexa Fluor® 568 phalloidin (grey channel). Scale 
bar = 5 µm. 
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3.4.3. Willin antagonizes YAP-induced anchorage-independent growth 
To verify whether Willin expression could antagonize YAP-induced anchorage-
independent growth in soft agar, stable MCF10A-YAP cells expressing either empty 
vector or Willin were seeded and grown in soft agar, for 21 days. The number of formed 
colonies was counted; a colony being defined as a group of 5 or more cells. Notably, 
MCF10A-YAP cells expressing Willin produced approximately 50% fewer colonies in 
soft agar than MCF10A-YAP-vector cells (Figure 3.24). The potential tumourogenicity 
showed by MFC10A-YAP-vector control cells was therefore greatly altered. 
Importantly, Willin was unable to antagonize a YAPS127A mutant under the same 
conditions (Figure 3.24). Taken together these results show that Willin suppresses YAP 
induced anchorage-independent growth. 
 
Figure 3.24 – Willin expression antagonizes YAP-induced anchorage-independent growth in 
soft agar. MCF10A-YAP-Willin, MCF10A-YAP-vector, MCF10A- YAPS127A-Willin or 
MCF10A- YAPS127A-vector cells were seeded and grown on soft agar for 21 days. One colony 
was scored if it was ≥ 5 cells. Means were calculated from two independent experiments 
conducted in triplicate. Error bars represent ±s.e. (n=6). MCF10A-YAP-vector vs MCF10A-
YAP-Willin: *** p < 0.001; Student’s t-test. MCF10A-YAPS127A-vector vs MCF10A- 
YAPS127A-Willin: p = 0.75; Student’s t-test. 
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3.4.4. Willin suppresses YAP-induced cell migration 
Previous studies showed that in MCF10A cells, YAP promotes a dramatic increase in 
cell migration (Overholtzer et al., 2006; Zhao et al., 2007). Furthermore, core Hippo 
pathway components, such as LATS1, have been shown to effectively abrogate the 
increased cell migration associated with YAP overexpression (Zhang et al., 2008a). 
Therefore, the ability of Willin in suppressing YAP-induced cell migration, was probed. 
MCF10A-YAP or MCF10A-YAPS127A cells expressing either Willin or an empty vector 
were cultured in 24-well Boyden chambers with 8.0 µm pores. 24h later, cells were 
stained and the cells that migrated through the 8.0 µm pores were counted. Strikingly, 
MCF10A-YAP-Willin cells showed attenuated migration by approximately 50% 
compared with MCF10A-YAP-vector cells (Figure 3.25). Importantly, MCF10A-
YAPS127A cells expressing either Willin or an empty vector were unaffected by Willin 
expression. However, MCF10A-YAPS127A-Willin cells did show a statistically 
significant increase in cell migration compared to MCF10A-YAPS127A-vector cells 
(Figure 3.25). This could possibly be due to off-target effects of pBabe-Willin in 
MCF10A-YAPS127A cells in the context of cell migration. This had not been observed in 
any of the other assays performed. 
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Figure 3.25 – Willin expression antagonizes YAP-induced cell migration in MCF10A cells. 
MCF10A-YAP-Willin, MCF10A-YAP-vector, MCF10A-YAPS127A-Willin or MCF10A- 
YAPS127A-vector cells were cultured in Boyden chambers and migration assessed after 24h. 
Means were calculated from three independent experiments conducted in triplicate. Error bars 
represent ±s.e. (n=9). MCF10A-YAP-vector vs MCF10A-YAP-Willin: *** p < 0.001; Student’s 
t-test. MCF10A-YAPS127A- vector vs MCF10A- YAPS127A-Willin: * p < 0.05; Student’s t-test. 
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3.5. Discussion 
Although the Hippo pathway core kinase cassette has been well characterized in 
mammalian cells, upstream events are far less well understood. The data provided in 
this chapter show that Willin expression regulates the Hippo signalling pathway in 
mammalian cells. Firstly, it was found that knocking down Willin expression led to the 
suppression of the Hippo pathway activation. Secondly, it was found that the reduction 
of endogenous Willin expression was able to induce an EMT in MCF10A cells with a 
similar phenotypic trend to YAP overexpression in terms of morphological changes, 
cell marker expression, and functional outputs. These effects were YAP dependent, as 
determined by the migration assay. Thirdly, overexpression of Willin antagonized a 
YAP-induced EMT phenotype in the non-tumourigenic mammary epithelial cell line, 
MCF10A. Finally, it was shown that the action of Willin on YAP is by Ser127 
phosphorylation. 
This analysis started with the finding that knocking down endogenous expression of 
Willin inhibited the phosphorylation of MST1/2, LATS1, and YAP in MCF10A cells. 
This is in agreement with the studies conducted by Dr. Liselotte Angus who showed an 
increase of MST1/2, LATS1, and YAP phosphorylation levels in Willin expressing 
MCF10A-YAP cells. Notably, these phosphorylation events were observed in MCF10A 
cells expressing full-length Willin or its truncated FERM domain. It was therefore 
concluded that the conserved FERM domain of Willin is sufficient to activate the Hippo 
pathway via MST1/2 in both MCF10A and HEK 293T cells (Angus et al., 2012). 
Recently, in contradiction with the present findings, it has been reported that Willin acts 
independently of the Hippo pathway in MDA-MB-231 cells overexpressing Willin, with 
no changes observed in the phosphorylation levels of the core components of the kinase 
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cassette (Visser-Grieve et al., 2012). The function of Willin may therefore be cell type 
specific, a scenario already described for YAP. In fact, previous studies described YAP 
to function as a tumour suppressor rather than an oncogene: YAP was shown to be pro-
apoptotic through p73 in breast tumours (Yuan et al., 2008) and in MCF7 cells by a 
RASSF1A-mediated mechanism (Matallanas et al., 2007). This highlights the view that 
proteins can exert different functions depending on both cellular and stimuli-dependent 
contexts. 
Located on the human chromosome 11q22 amplicon, the YAP oncogene has a well-
documented ability to induce EMT in healthy, non-transformed epithelial cells 
(Overholtzer et al, 2006; Zender et al., 2006; Zhang et al., 2008a). EMT consists of 
cellular and molecular processes by which epithelial cancer cells acquire competences 
enabling them to dissociate and migrate from the primary epithelial carcinoma. This 
metastatic progression model involves a striking regulation of epithelial cells plasticity, 
with the loss of epithelial cell traits and the acquisition of mesenchymal cell features 
(Section 1.3; Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). Ectopic 
Willin expression in MCF10A-YAP cells induced the up-regulation of the epithelial 
biomarkers E-cadherin and occludin, promoting a change from the YAP-induced 
mesenchymal phenotype towards an epithelial appearance. The epithelial phenotype 
was consistently observed by different experimental analyses with the concomitant 
down-regulation of the mesenchymal biomarkers vimentin and N-cadherin. 
Furthermore, knockdown of Willin expression induced an EMT-phenotype, specifically 
with the down-regulation of epithelial markers and the concomitant up-regulation of the 
mesenchymal markers. Regulation of E-cadherin by Willin in MCF10A cells is in 
agreement with reported studies where other components of the Hippo pathway, such as 
LATS1, were investigated (Zhang et al., 2008a). Furthermore, within a YAP or TAZ 
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overexpression scenario, this epithelial biomarker is found down regulated, highlighting 
these oncogenes’ ability to promote EMT (Overholtzer et al., 2006, Lei et al., 2008, 
Zhao et al., 2008a, Zhang et al., 2009). E-cadherin is localized at the adherens junctions 
of epithelial cells, representing a pivotal factor in the maintenance of the epithelial 
junction formation. The functional loss of E-cadherin expression, encoded by CDH1, is 
associated with tumour invasiveness and with the induction of a mesenchymal 
phenotype (Birchmeier and Behrens, 1994). The loss of occludin, a component of tight 
junctions (Furuse et al., 1996) further aids in the acquirement of both increased cell 
migration and decreased cell adhesion to the basement membrane, as well as the 
induction of a transformed-like anchorage-independent growth EMT phenotype. The 
analysis of these functional outputs, known hallmarks of EMT (Hanahan and Weinberg, 
2000; Hanahan and Weinberg, 2011), additionally confirmed the ability of Willin to 
negatively regulate EMT development. In fact, Willin knockdown resulted in increased 
cell migration, decreased cell adhesion, and promotion of anchorage-independent 
growth. The antagonistic effect was consistently observed upon Willin expression in 
MCF10A-YAP cells. Although neither Willin nor MST1 knockdown had an effect on 
the proliferation of MCF10A cells, both resulted in a strong promotion of anchorage-
independent colony formation in soft agar, resembling YAP overexpression. Induction 
of anchorage-independent growth by oncogenes such as YAP or TAZ is a trait of 
transformed cells correlated with tumourigenicity and metastatic potential (Overholtzer 
et al., 2006; Chan et al., 2008). Previous studies have described the ability of LATS 
(Zhang et al., 2008a), a component of the core kinase cassette, to antagonize the YAP-
induced EMT phenotype and this is consistent with the results presented. 
LATS is a kinase which phosphorylates YAP in the consensus phosphorylation 
sequence HX(R/H/K)XX(S/T) (Hao et al., 2008). Phosphorylation by LATS1 of one of 
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YAP phosphorylation sites, Ser127, leads to YAP cytoplasmic localization through the 
creation of a protein 14-3-3 binding site (Ubersax and Ferrell, 2007, Zhao et al., 2007). 
Remarkably, Willin could not antagonize a constitutively active YAP mutant 
(YAPS127A) in all the probed functional outputs assays, showing that the action of Willin 
on YAP is by S127 phosphorylation. Moreover, the downstream EMT effects observed 
by knocking down endogenous Willin were shown to be YAP dependent, presenting a 
clear evidence that YAP is the primary target of Willin. 
Pronounced morphological changes were observed by either overexpressing or 
knocking down Willin (Section 3.3.2 and 3.4.2). Epithelial cancer cells undergoing 
EMT exhibit strong morphological changes allowing them to detach from the basement 
membrane, to acquire a fibroblast-like appearance and to migrate to a distance site, 
where they reconstitute the initial epithelial morphology. This process, known as 
mesenchymal epithelial transition (MET) is also characterized by the up-regulation of 
epithelial biomarkers (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). 
Willin expressing MCF10A-YAP cells showed a higher level of adherens junction’s 
organization, as well as the absence of potential filopodia extensions (Figure 3.22). The 
opposite morphology was observed by Willin knockdown (Figure 3.8). Importantly, 
Willin could not antagonize morphological changes in a constitutively active YAP 
mutant (YAPS127A) (Figure 3.23). Actin filaments represent an important component of 
the cytoskeleton framework. Diverse proteins are involved with the attachment of actin 
filaments to the plasma membrane as well as with the regulation of actin organization 
(Harvey et al., 2013). On the contrary, the initial detachment by invasive carcinoma 
cells from the basement membrane is regulated by matrix metalloproteinases (MMPs), 
which are able to degrade the extracellular matrix, forming small membrane 
perforations (Gumbiner, 1996). MMPs accumulate at invadopodia, F-actin-rich plasma-
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membrane protrusions, which occur at the ventral surface of cancer cells (Linder, 2007, 
Poincloux et al., 2009). Invadopodia formation was shown to require both lamellipodia 
and filopodia associated proteins (Schoumacher et al., 2010) such as fascin, Arp2/3, 
VASP or mDia2. Filopodia are thought to function as antennae, which allow cancer 
cells to investigate the stromal environment during metastasis progression (Mattila and 
Lappalainen, 2008).  Thus, the presence of long potential filopodia extensions in either 
vector expressing MCF10A-YAP or MCF10A-shWillin cells further suggests the 
occurrence of EMT in these cells (Section 3.3.2 and 3.4.2). On the contrary, the absence 
of extensions in the cells overexpressing Willin reinforces its potential to suppress EMT 
and therefore, Willin may have a prominent role in the suppression of tumour 
progression. Moreover, Schoumacher and colleagues (2010) found that invadopodia 
also contain microtubules and vimentin intermediate filaments. The latter were 
described as being required for invadopodia elongation but not for their formation. This 
is in agreement with the finding that down-regulation of vimentin endowed a decrease 
of cellular motility as well as invasiveness, in prostate cancer cells (Zhao et al., 2008b). 
The same pattern was observed in the present analysis. In fact, vimentin was found to be 
down regulated in Willin expressing MCF10A-YAP cells (Section 3.4.1), and this could 
be related to the absence of filopodia extensions and reduced motility. Worth noting, 
Maeda and colleagues (2005) showed that the switch of E- and N-cadherins occurs after 
the morphological changes associated with actin rearrangement. This analysis was made 
within a TGF-β1-mediated EMT scenario (Maeda et al., 2005). Importantly, the Rho 
subfamily of GTP-binding proteins may have an important role in this matter (Thiery, 
2002). Taking these studies into consideration, this may suggest that the observed 
ability of Willin to change the mesenchymal phenotype towards a more polarized 
epithelial morphology is neither dependent on cadherins switch nor on vimentin 
CHAPTER 3 – Willin is an upstream component of the mammalian Hippo pathway 
 121 
expression. However, this analysis was not conducted in the present study and future 
studies should address this possibility. 
To conclude, the data provided in this chapter presents clear evidence of Willin’s ability 
to antagonize oncogenic YAP via phosphorylation of YAPS127 phosphorylation site. 
Also, either loss or overexpression of Willin was shown to regulate the 
induction/inhibition of epithelial-mesenchymal transition features in MCF10A cells. 
Finally, Willin was shown to be upstream of the mammalian core kinase cassette by 
influencing the Hippo signalling pathway activity in MCF10A cells. The observed 
modulation of YAP activity could be accomplished by the combined effect of Willin, 
Merlin and other effectors acting upstream of the core components of the emerging 
Salvador/Warts/Hippo pathway. Figure 3.26 depicts the schematic representation of the 
proposed model for the action of Willin, Merlin, and Ezrin (Section 3.1) on Hippo 
signalling. 
 
Figure 3.26 – Willin activates the Hippo signalling pathway and is an upstream component of 
the core kinasse cassette. Schematic representation of a model for the action of Willin, Merlin, 
and Ezrin on Hippo signalling. Image adopted from Angus et al., 2012. 
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S, Herron L, Sinha A, Zhang X, et al. 2012. Willin/FRMD6 expression activates the 
Hippo signalling pathway kinases in mammals and antagonizes oncogenic YAP. 
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4.1. Introduction 
In Drosophila, Kibra, Expanded (Ex), and Merlin function upstream of the Hippo 
signalling core kinase cascade, activating the pathway by an unknown mechanism via 
Hpo and Wts phosphorylation (Hamaratoglu et al., 2006, Genevet et al., 2010, Yu et al., 
2010). At least four upstream regulatory branches of the Hippo pathway exist in the 
fruit fly: Fat/Dachsous, Kibra/Ex/Mer, Lethal Giant Larvae/atypical protein Kinase C, 
and Crumbs (Grusche et al., 2010). Studies suggest that loss-of-function mutant clones 
for these upstream regulators result in a comparatively milder overgrowth phenotype 
than Hpo core component mutants. Whilst single mutants cause a mild overgrowth 
phenotype, double mutants display strong synergistic effects in some cases resembling 
those of Hpo mutants (Baumgartner et al., 2010). Studies have also shown that Ex and 
Mer may account for slightly different aspects of the phenotypes, implying that they 
may act not only redundantly but also in parallel with one another to control Hippo 
signalling (Hamaratoglu et al., 2006; Pellock et al., 2007). 
KIBRA (WWC1), the mammalian orthologue of Kibra, shows enriched expression in 
the kidney and brain (Kremerskothen et al., 2003), and has been associated with 
memory performance and an age-dependent risk of Alzheimer’s disease 
(Papassotiropoulos et al., 2006; Schaper et al., 2008; Bates et al., 2009; Cornevaux et 
al., 2010). KIBRA is phosphorylated by Protein Kinase C ζ (PKCζ) (Buther et al., 
2004), and previous reports established a role for KIBRA in cell migration (Duning et 
al., 2008; Rosse et al., 2009). KIBRA interacts with the PAR3-aPKC-PAR6 complex 
and regulates epithelial cell polarity by suppressing aPKC kinase activity (Yoshihama et 
al., 2011). Moreover, KIBRA has been shown to interact with the discoidin domain 
receptor 1 to modulate collagen-induced signalling (Hilton et al., 2008). Importantly, 
KIBRA was found to be significantly less expressed in the recently described “Claudin-
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low” sub-type of breast cancer, an aggressive type with a poor prognosis (Moleirinho et 
al., 2013a). Claudin-low tumours are an intrinsic breast cancer sub-type characterized 
by a lack of luminal differentiation markers, a high enrichment for epithelial-
mesenchymal transition (EMT) markers, immune response genes, and cancer stem cell-
like features (Creighton et al., 2009; Hennessy et al., 2009; Prat et al., 2010; 
Herschkowitz et al., 2012). In addition, KIBRA was reported to function as an upstream 
member of the Hippo pathway, since KIBRA interacts with and stimulates the 
phosphorylation of LATS1/2 and so regulates the subsequent phosphorylation of YAP 
(Yu et al., 2010; Xiao et al., 2011), but the functional significance of these biochemical 
changes has not been addressed to date. 
In the previous chapter, Willin knockdown in MCF10A cells was shown to mimic YAP 
overexpression with respect to inducing an EMT phenotype, and to inhibit 
phosphorylation of MST1/2, LATS1, and YAP. Furthermore, ectopic Willin expression 
antagonized YAP functional output by acting on YAP serine 127 phosphorylation site. 
These findings together with the data depicted by Angus et al. (2012), placed Willin as 
an upstream component of the core Hippo pathway kinase cassette (Angus et al., 2012). 
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4.2. Aims of the Chapter 
While the role of Kibra in the Hippo pathway in Drosophila as a tumour suppressor and 
negative regulator of Yki has been well defined and characterized, the question of 
whether its mammalian counterpart KIBRA shares a conserved function in Hippo 
signalling still remains to be answered. Therefore, I aimed to determine whether 
KIBRA influences activation of the Hippo pathway and if this regulation mimics the 
one observed by Willin. Secondly, I analysed whether KIBRA loss is able to induce an 
EMT in MCF10A cells, and if KIBRA overexpression results in a functional phenotype, 
which is YAP serine 127 dependent. Finally, I investigated whether the upstream 
components of the mammalian core kinase cascade KIBRA, Willin, and Merlin 
differently regulate YAP downstream targets. 
These aims contributed towards the understanding of the potential role of KIBRA as a 
tumour suppressor as well as to uncover the upstream regulation of the Hippo signalling 
pathway. 
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4.3. KIBRA knockdown inhibits activation of the Hippo pathway and 
induces features of EMT in mammary epithelial cells 
The functional regulation of the Hippo signalling pathway by KIBRA was first probed 
by knocking down the expression of KIBRA in MCF10A cells using two independent 
lentiviral shRNA constructs. Specific short-hairpin RNA sequences were cloned into an 
AgeI and EcoRI digested and CIAP treated lentiviral vector pLKO.1 puro (Section 
2.1.1.3; Table 2.1). The knockdown plasmids shKIBRA-A and shKIBRA-B correspond 
to different target sequences within the KIBRA ORF. To test the cloning effectiveness, 
minipreps of the two knockdown plasmid DNAs from independent bacterial colonies 
were digested with AgeI and SpeI, and analysed on 1% agarose gels. Specifically, 3 
miniprep plasmid DNA samples of shKIBRA-A and 7 miniprep plasmid DNA samples 
of shKIBRA-B were analysed (Figure 4.1). When visualized, loss of the expected 469 
bp fragment was observed upon cloning of the oligonucleotides known to destroy AgeI 
restriction site. This was the case for all the three minipreps containing the knockdown 
plasmid shKIBRA-A (Figure 4.1A). A fragment around 469 bp was still present in the 
empty lentiviral vector pLKO.1 puro, used as a positive control for the AgeI digestion 
(Figure A.1 and A.2, Appendix A). Since the knockdown plasmid shKIBRA-B has an 
oligonucleotide sequence with a starting sense 5’ CCGGT, the AgeI restriction site was 
not destroyed and the anticipated shift from 469 bp to 528 bp in agarose gel was 
observed in 3 out of the 7 miniprep plasmid DNA samples analysed (Figure 4.1B; 
Figure A.1 and A.2, Appendix A). 
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Figure 4.1 – Two constructs were successfully cloned as suggested by electrophoresis in 1% 
agarose gel. (A) The 5’ sense oligonucleotides sequence of shKIBRA-A destroyed the AgeI 
restriction site and the 469 bp fragment is lost. (B) The 5’ sense oligonucleotides sequence of 
shKIBRA-B started with CCGGT, preventing the destruction of the AgeI restriction site. A shift 
from 469 bp to 528 bp band was observed in three out of the seven miniprep plasmid DNA 
analysed. 1-7 refers to miniprep plasmid DNA from independent bacterial colonies tested to 
determine whether the plasmid insert was corect. Empty lentiviral vector pLKO.1 puro was used 
as a control (fragment shown by arrow and box). Arrows indicate the miniprep plasmid DNA 
samples which were sucessfully cloned as suggested by electrophoresis. 
The DNA sequencing of sample 2 (shKIBRA-A) and sample 5 (shKIBRA-B) (Figure 
4.1) confirmed the successful cloning of the two lentiviral shRNA constructs (Figure 
4.2). 
shKIBRA-A shKIBRA-B
1 2 3 pLKO.1
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A
528 bp
469 bp
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A B
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Figure 4.2 – DNA sequencing of shKIBRA-A (sample nb 2) and shKIBRA-B (sample nb 5). 
The 5’ sense oligonucleotide sequences composed by 59 bp, were identified confirming the 
cloning of the annealed short hairpin oligonucleotide sequences into the lentiviral vector, 
pLKO.1. 
Viral particles containing either shKIBRA-A or shKIBRA-B knockdown plasmids were 
made and transduced into MCF10A cells, as previously described (Section 2.2.3). To 
confirm that MCF10A cells were expressing shRNA-targeting KIBRA (MCF10A-
shKIBRA), stable pools of cells were seeded and harvested 48h after incubation. 
MCF10A cells expressing a non-targeting shRNA sequence were used as a control 
(MCF10A-shScr). Equal amounts of protein were separated in 10% SDS-PAGE. 
Western blotting analysis confirmed the knockdown of endogenous KIBRA (Figure 
4.3). 
AgeI EcoRI
AgeI EcoRI
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Figure 4.3 – shKIBRA-A and shKIBRA-B efficient knockdown in MCF10A cells. Cell lysates 
of MCF10A-shKIBRA-A and MCF10A-shKIBRA-B cells were harvested and equal amounts of 
protein were separated on a 10% SDS-PAGE. Immunoblots show knockdown of both KIBRA-
A and KIBRA-B compared with MCF10A-shScramble control cells. β-actin was used as a 
loading control. 
4.3.1. KIBRA knockdown inhibits activation of the Hippo signalling Pathway 
The deregulation of upstream components, such as Willin, inhibits the activation of the 
Hippo pathway (Angus et al., 2012); thus, the ability of KIBRA to activate the core 
kinase cascade was assayed by western blotting. MCF10A cells containing either 
shKIBRA-B or shScramble were seeded and 48h later harvested as described in Section 
2.3.2.2. Drug-selected pools of infected cells were used in the analysis to avoid clonal 
selection effects. Equal amounts of protein were separated by 10% SDS-PAGE and the 
subsequent PVDF membranes probed with antibodies against phosphorylated and total 
MST1/2, LATS1, and YAP. The knockdown of KIBRA resulted in decreased 
phosphorylation levels of the Hippo pathway kinase LATS1 and YAP, but not MST1/2 
in these cells (Figure 4.4. and Figure 4.5). Phosphorylation of the MST1/2 substrate 
MOBKL1A/B (Praskova et al., 2008) at Thr12 also did not decrease in MCF10A-
shKIBRA cells; rather interestingly phosphorylation increased at this phosphorylation 
site (Figure 4.6). The MOBKL1A/B Thr35 phosphorylation site was also probed, as 
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MST1/2 has been shown to phosphorylate MOBKL1A/B at both Thr12 and Thr35 
(Praskova et al., 2008). However, due to technical difficulties related with the available 
antibody (a kind gift from Dr. Avruch, Harvard Medical School, USA), the analysis of 
this phosphorylation site was not successful. Importantly, MCF10A-shKIBRA-B cells 
displayed a stronger inhibition in the core components phosphorylation levels compared 
with MCF10A-shKIBRA-A cells, and hence the former cells were analysed. 
 
Figure 4.4. – KIBRA knockdown in MCF10A cells causes a decrease of phosphorylated 
LATS1 and YAP but not MST1/2 or MOBKL1A/B. Total MST1/2, MOBKL1A/B, LATS1, and 
YAP were used as loading controls. Relative phosphorylation levels were determined compared 
to background phosphorylation (MCF10A-shScr set to 1). Means were calculated from three 
independent experiments conducted in triplicate using Image J software. Error bars represent 
±SD (n=9). MCF10A-shScr vs MCF10A-shKIBRA-B: *** p < 0.001, Student’s t-test. 
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Figure 4.5 – Immunoblot analysis of triplicate experiments used for images and quantification 
showed in Figure 4.4. Upon knockdown of endogenous KIBRA, no changes in MST1 
(Thr183)/MST2 (Thr180) phosphorylation levels were observed compared with shScramble 
control cells. 
 
Figure 4.6 – Immunoblot analysis of triplicate experiments used for images and quantification 
showed in Figure 4.4. Upon knockdown of endogenous KIBRA, an increase in MOBKL1A/B-
Thr12 phosphorylation levels was observed compared with shScramble control cells. 
To verify whether MST1/2- and MOBKL1A/B-independent regulation on YAP by 
KIBRA would be maintained in a different cell line, the same experiment was 
performed in HEK 293T cells. For this purpose, cells were seeded and transiently 
transfected with shKIBRA-B or with non-targeting shScramble (used as a control), as 
described in Section 2.2.4.2. Cells were harvested 48h post-transfection and protein 
samples separated by 10% SDS-PAGE. Western blotting analysis confirmed a decrease 
in the relative phosphorylation levels of the Hippo pathway kinase LATS1 and YAP, 
but not MST1/2 in these cells (Figure 4.7). Surprisingly, MOBKL1A/B did not increase 
phosphorylation at Thr12 as observed in MCF10A cells, suggesting cell type-dependent 
regulation (Figure 4.7). These findings further confirmed the results obtained with 
MCF10A cells. 
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Figure 4.7 – Immunoblot analysis of HEK 293T cells expressing either shScr or shKIBRA. 
KIBRA knockdown in HEK 293T cells results in a decrease of phosphorylated LATS1 and 
YAP but not MST1/2 or MOBKL1A/B. Total MST1/2, MOBKL1A/B, LATS1, and YAP were 
used as loading controls. 
4.3.2. KIBRA knockdown induces features of EMT in MCF10A cells 
4.3.2.1. Knockdown of KIBRA promotes morphological changes resembling 
YAP-induced mesenchymal-like phenotype 
Epistatic studies in Drosophila have placed Kibra upstream of Hippo, the ortholog of 
mammalian MST1/2 (Baumgartner et al., 2010; Genevet et al., 2010; Yu et al., 2010). 
KIBRA has also been shown to regulate the Hippo signalling in mammalian cells (Xiao 
et al., 2011). Furthermore, deregulation of core Hippo pathway components such as 
YAP (Overholtzer et al., 2006; Zhang et al., 2008a), as well as upstream components 
such as Willin (Angus et al., 2012; Chapter 3), was shown to induce EMT in MCF10A 
cells. However, the question whether KIBRA induces EMT in MCF10A cells has not 
yet been addressed. Aiming to investigate whether knockdown of endogenous KIBRA 
induces EMT in these cells, the occurrence of morphological changes was established. 
While MCF10A cells expressing a non-targeting control (shScr) grew in epithelial-type 
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islands on monolayer cultures, MCF10A cells expressing shRNA targeting KIBRA 
(MCF10A-shKIBRA) displayed abnormal features resembling YAP-induced EMT 
(Figure 4.8). The spindle-shaped morphology, suggests loss of close interaction and 
tight junctions among the cells. 
 
Figure 4.8 – KIBRA loss induces a morphology change in MCF10A cells that resembles YAP-
induced EMT. Representative phase-contrast images of cells growing in monolayer cultures and 
transfected with either non-targeting shRNA (shScr) or shRNA targeting KIBRA (shKIBRA), 
and MCF10A cells expressing an empty vector (MCF10A-vector) or YAP (MCF10A-YAP). 1 – 
MCF10A-shScr and MCF10A-vector cells grew in epithelial-type islands whereas 2 – 
MCF10A-shKIBRA-A, MCF10A-shKIBRA-B, and MCF10A-YAP cells exhibited a spindle-
shaped mesenchymal appearance and increased cell scattering. Scale bar = 20 µm. 
The morphological changes observed through the knockdown of KIBRA were further 
confirmed by phalloidin staining for F-actin, and then analysed by OMX three-
dimensional structured illumination microscopy (3D-SIM). Accordingly with the 
phenotype observed upon knockdown of Willin (Section 3.3.2), the loss of KIBRA 
resulted in the shift from internal cortical actin to stress fibers, and the emergence of 
projections (potentially filopodia), which suggests pro-migratory behaviour (Figure 
4.9). This phenotype was consistent for both MCF10A-shKIBRA-A and MCF10A-
shKIBRA-B (Figure 4.9B and C), and antagonistic to that observed in MCF10A-shScr 
control cells (Figure 4.9A). Moreover, this phenotype was enhanced by simultaneous 
knockdown of KIBRA and Merlin (Figure 4.9D and Section 4.3.2.3). 
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Figure 4.9 – 3D-SIM images of F-actin organization patterns in MCF10A expressing (A) 
shScramble (B) shKIBRA-A (C) shKIBRA-B or (D) shKIBRA-B/shMerlin. KIBRA 
knockdown promotes alterations in the cytoskeleton framework with 3 - increased 
disorganization of internal cortical actin, 4 - pronounced potential filopodia projections, and 
antagonizing the 1 - higher internal cortical actin arrangement with 2 - absence of potential 
filopodia extensions observed in MCF10A-shScr cells. Cells were stained with Alexa Fluor® 
568 phalloidin (grey channel). Scale bar = 5 µm. 
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4.3.2.2. KIBRA knockdown induces the expression of EMT markers 
The aim in the next analysis was to determine whether knockdown of KIBRA regulates 
the expression of EMT markers. Cell lysates of MCF10A-shScr, MCF10A-shKIBRA-
A, MCF10A-shKIBRA-B, MCF10A-YAP, and MCF10A-vector cells were harvested 
and equal amounts of protein separated on a 10% SDS-PAGE. The subsequent PVDF 
membranes were probed for epithelial and mesenchymal markers. The mesenchymal 
markers N-cadherin and vimentin were up-regulated by YAP overexpression or by 
KIBRA knockdown. On the other hand, the epithelial markers, E-cadherin and occludin, 
were down-regulated by both of these manipulations (Figure 4.10). This is consistent 
with the EMT-like phenotype observed upon knockdown of endogenous Willin (Section 
3.3.3; Angus et al., 2012) or LATS1 (Zhang et al., 2008a). The efficient knockdown of 
KIBRA was assayed by immunoblotting (Figure 4.10). 
 
Figure 4.10 – KIBRA knockdown results in features of EMT. Immunoblot analysis of E-
cadherin, occludin (epithelial markers), N-cadherin, and vimentin (mesenchymal markers) show 
loss of epithelial markers as well as gain of mesenchymal markers in MCF10A-shKIBRA cells. 
β-actin was used as a loading control. 
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4.3.2.3. KIBRA knockdown promotes anchorage-independent growth in soft 
agar 
The ability of KIBRA loss to induce anchorage-independent growth in soft agar was 
probed by counting the number of formed colonies; a colony being defined as a group 
of 5 or more cells. MCF10A-shKIBRA cells produced 4-fold more colonies in soft agar 
than MCF10A-shScr cells, after 21 days in culture (Figure 4.11 and 4.12). This finding 
is consistent with the results displayed in Section 3.3.4 and with Angus et al. (2012), 
where the loss of Willin promoted anchorage-independent growth in soft agar. 
Aiming to look at the co-stimulatory effects when silencing KIBRA and Merlin 
simultaneously, a KIBRA/Merlin double knockdown MCF10A cell line was generated, 
and the functional consequences in the soft agar assay were investigated. It was found 
that KIBRA and Merlin synergise in this assay, since simultaneous knockdown of 
KIBRA and Merlin resulted in more colony formation as compared with single 
knockdowns (Figure 4.11 and 4.12). Furthermore, the number of colonies formed by the 
KIBRA/Merlin double knockdown was very similar to those observed in MCF10A-
YAP cells. 
Other combinations of simultaneous knockdowns were attempted in MCF10A cells, 
namely, the knockdown of KIBRA and Willin, as well as that of Willin and Merlin. 
However, these were unsuccessful, which may be due not only with the technicality to 
generate double knockdowns by lentiviral infection, but also to the presence of a 
potential compensatory feedback in these cells (Section 4.6). 
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Figure 4.11 – KIBRA knockdown promotes anchorage-independent growth in soft agar. 
MCF10A-shScr, MCF10A-shKIBRA-A, MCF10A-shKIBRA-B, MCF10A-shMerlin, 
MCF10A-shKIBRA-B/shMerlin, MCF10A-YAP, and MCF10A-vector cells were cultured in 
soft agar for 21 days. Means were calculated from three independent experiments conducted in 
triplicate. Error bars represent ±s.e. (n=9). MCF10A-shScr vs MCF10A-shKIBRA-A, 
MCF10A-shKIBRA-B, MCF10A-shMerlin or MCF10A-shKIBRA-B/shMerlin: *** p < 0.001; 
One-way ANOVA and Bonferroni post-hoc test. MCF10A-YAP vs MCF10A-vector: *** p < 
0.001, Student’s t-test. 
 
Figure 4.12 – Simultaneous knockdown of KIBRA and Merlin (shK/M) results in features of 
EMT. Drug-selected pools of infected cells were used in the analyses to avoid clonal selection 
effects. (A) Representative phase-contrast image of cells growing in monolayer culture. Scale 
bar = 20 µm. Immunoblot analysis of efficient knockdown of KIBRA and Merlin. β-actin was 
used as a loading control. (B) Representative images of soft agar colonies (indicated by black 
arrows) from MCF10A-shScr, MCF10A-shKIBRA, and MCF10A-shK/M cells. 
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4.3.2.4. KIBRA knockdown induces cell migration 
Two different analyses were performed to determine the effects of knocking down 
endogenous KIBRA on cellular migration of MCF10A cells grown in 2D cultures. The 
hypothesis being investigated was whether KIBRA’s loss phenocopies the YAP-
induced cell migration pattern, consequently showing the negative regulation on YAP 
by KIBRA. Firstly, in the Boyden chamber assay, MCF10A-shScr, MCF10A-
shKIBRA-A, MCF10A-shKIBRA-B, MCF10A-YAP, and MCF10A-vector cells were 
cultured in 24-well Boyden chambers with 8.0 µm pores. 24h later, cells were stained 
and the cells that migrated through the 8.0 µm pores were counted. MCF10A-shKIBRA 
cells showed a 4-fold increased migration compared to MCF10A-shScr cells (Figure 
4.13A). This observation was consistent with the results observed upon knockdown of 
Willin (Section 3.3.5; Angus et al., 2012) as well as the knockdown of core Hippo 
pathway components such as LATS1 (Zhang et al., 2008a). 
Secondly, in the in vitro wound healing assay, a scratch (Section 2.4.4) on confluent 
monolayers of MCF10A cells expressing shScr, shKIBRA-A or shKIBRA-B was 
performed. The rate of scratch closure was observed over 16h. Representative 
brightfield images of wound healing assay at the different time points are shown in 
Figure 4.14. The percentage of scratch covered was measured by using Image J 
software. After 16h, MCF10A-shKIBRA-A and MCF10A-shKIBRA-B cells closed the 
scratch faster than MCF10A-shScr control cells (Figure 4.14). This data supports the 
previous observations from the Boyden chamber assay (as shown in Figure 4.13), where 
the loss of KIBRA enhanced cell migration in MCF10A cells. 
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Figure 4.13 – KIBRA knockdown promotes migration. (A) MCF10A-shScr, MCF10A-
shKIBRA-A, MCF10A-shKIBRA-B, MCF10A-YAP or MCF10A-vector cells were cultured in 
Boyden chambers, and migration was assessed after 24h. Error bars represent ±s.e. (n=9). 
MCF10A-shScr vs MCF10A-shKIBRA-A or MCF10A-shKIBRA-B: *** p < 0.001, One-way 
ANOVA and Bonferroni post-hoc test. MCF10A-YAP vs MCF10A-vector: *** p < 0.001, 
Student’s t-test. (B) Representative images of migration Boyden chambers from MCF10A-shScr 
and MCF10A-shKIBRA cells, as indicated by the black arrows.  
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Figure 4.14 – KIBRA knockdown promotes cell migration. The wound closure ability of 
MCF10A-shScr, MCF10A-shKIBRA-A or MCF10A-shKIBRA-B cells was assessed by wound 
healing scratch assay. Representative phase-contrast images show the wounded area (0h) and 
cell migration towards the wound after 12h, 14h, and 16h. The percentage of scratch covered 
was measured by quantifying the total distance of cells moved from the edge of the scratch 
towards the center (shown by red lines) using image J software, followed by conversion to the 
percentage of scratch covered. Data is presented as the mean percentage of scratch covered in 
three independent experiments. Error bars represent ±S.D. (n=3). MCF10A-shScr vs MCF10A-
shKIBRA-A or MCF10A-shKIBRA-B: ** p < 0.01; *** p < 0.001; One-way ANOVA and 
Bonferroni post-hoc test. 
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4.3.2.5. KIBRA knockdown suppresses cell adhesion to basement membrane 
To investigate whether knockdown of endogenous KIBRA suppressed cell adhesion to 
ECM - a hallmark of EMT (Zeisberg and Neilson, 2009), stable pools of MCF10A-
shScr, MCF10A-shKIBRA-A, and MCF10A-shKIBRA-B cells were seeded onto 
laminin coated 96-well plates. The plates were left incubating for 30 min and then fixed. 
The total number of cells adhered to the laminin plate was counted. As observed for the 
knockdown of Willin (Section 3.3.7), both MCF10A-shKIBRA-A and MCF10A-
shKIBRA-B cells displayed a significant reduction in the number of cells adherent to 
laminin. MCF10A-shKIBRA-A cells showed approximately 30% less cell adhesion 
whilst MCF10A-shKIBRA-B cells showed 40% less adherence when compared with 
MCF10A-shScr control cells (Figure 4.15). 
 
Figure 4.15 – KIBRA knockdown inhibits cell adhesion to the basement membrane. MCF10A-
shScramble, MCF10A-shKIBRA-A, and MCF10A-shKIBRA-B cells were seeded in laminin-
coated plates and the number of adherent cells was counted. Means were calculated from two 
independent experiments conducted in triplicate. Error bars represent ±s.e. (n=6). MCF10A-
shScr vs MCF10A-shKIBRA-A; MCF10A-shKIBRA-B: ** p < 0.01; *** p < 0.001; One-way 
ANOVA and Bonferroni post-hoc test.  
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4.3.2.6. KIBRA knockdown induces cell proliferation 
Since knockdown of KIBRA expression was shown to inhibit activation of the Hippo 
pathway (Section 4.3.1), its ability to influence cell proliferation was determined. With 
KIBRA being an upstream component of the Hippo pathway kinases, its deregulation 
could result in decreased contact inhibition; a phenomenon previously reported for other 
components of the signalling cascade (Camargo et al., 2007, Dong et al., 2007, Zhao et 
al., 2007). Cell proliferation was assessed by MTT assay as previously described 
(Section 2.4.8.1), every 24h for 6 days. Loss of KIBRA enhanced the rate of cell 
proliferation compared to that of MCF10A-shScr cells (Figure 4.16). A proliferation 
plateau in the MCF10A-shKIBRA cells was observed after 5 days, at approximately 1.3 
x 106 cells, whilst MCF10A-shScr cells continued to proliferate, over the analysed time 
course. These findings are contrary to the results observed with the Willin knockdown 
(Section 3.3.8). The Willin knockdown experiments did not induce cell proliferation. 
However, the MTT assay is not a direct quantifiable method for proliferation, and 
Willin ectopic expression in MCF10A cells has been reported to enhance contact 
inhibition and to reduce cell proliferation at high cell densities (Angus, 2011). As such, 
knockdown of the known upstream regulators of the Hippo signalling cascade, Willin, 
KIBRA, and Merlin (Section 3.3.8) could actually result in reduced contact inhibition 
and promotion of cell proliferation. 
CHAPTER 4 – KIBRA exhibits MST-independent functional regulation 
 145 
 
Figure 4.16 – Knockdown of KIBRA expression enhances cell proliferation and reduced 
contact inhibition over 5 days. Proliferation rates of MCF10A-shScramble, MCF10A-
shKIBRA-A or MCF10A-shKIBRA-B cells were measured by MTT assay every 24h for 6 
days. Means of absorbance at 570 nm were calculated from one experiment conducted in 
triplicate. Error bars represent ±SD (n=3). (MCF10A-shScr vs MCF10A-shKIBRA-A or 
MCF10A-shKIBRA-B) x Days: * p < 0.05; Repeated measures ANOVA.  
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4.4. KIBRA knockdown phenotype is dependent on LATS and YAP 
but not MST1/2 
Since it was determined that the activity of MST1/2 phosphorylation levels was not 
affected in MCF10A-shKIBRA cells (Section 4.3.1), KIBRA regulation of LATS1 and 
YAP independent of the MST1/2 kinases was further investigated. It was analysed if the 
functional consequences of KIBRA knockdown, shown by increased migration, were 
dependent on Hippo pathway activity. Small interfering RNAs (siRNAs) targeting 
MST1/2, LATS1, and YAP were introduced into MCF10A-shScr, MCF10A-shKIBRA-
B or MCF10A-YAPS127A cells. MCF10A-shScr cells as well as MCF10A cells 
expressing the constitutively active YAP, YAPS127A, were used as control cell lines. 
Since transient transfections with short-lived siRNA reagents were performed, longer 
time-course experiments were not feasible and the analysis was conducted by using the 
robust, short-term readout of migration.  
The reduction of MST1/2 in MCF10A-shScr and MCF10A-shKIBRA-B cells by two 
independent siRNA duplexes (siMST-A and siMST-B) did not abrogate the enhanced 
migratory phenotype, but rather showed enhanced migration (Figure 4.17A). 
Surprisingly, the reduction of MST1/2 expression in MCF10A-YAPS127A cells caused 
decreased migration (Figure 4.17A), which suggests the presence of a compensatory 
feedback mechanism in these cells to maintain the pathway function. The effective 
reduction of MST1/2 expression was confirmed by western blotting analysis (Figure 
4.17B). 
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Figure 4.17 – KIBRA knockdown phenotype is MST1/2-independent. (A) MCF10A-shScr, 
MCF10A-shKIBRA-B or MCF10A-YAPS127A cells with listed siRNA addition were cultured in 
Boyden chambers and migration assessed after 24h. Means were calculated from three 
independent experiments conducted in triplicate. Error bars represent ±s.e. (n=9). MCF10A-
shScr-Ctr vs MCF10A-shScr-siMST-A or MCF10A-shScr-siMST-B: * p < 0.05; *** p < 0.001; 
One-way ANOVA and Bonferroni post-hoc test. MCF10A-shKIBRA-Ctr vs MCF10A-
shKIBRA-siMST-A or MCF10A-shKIBRA-siMST-B: *** p < 0.001; One-way ANOVA and 
Bonferroni post-hoc test. MCF10A-YAPS127A-Ctr vs MCF10A-YAPS127A-siMST-A or 
MCF10A-YAPS127A-siMST-B: *** p < 0.001; One-way ANOVA and Bonferroni post-hoc test. 
(B) Immunoblot analysis of efficient knockdown of MST1/2 using two independent siRNA 
duplexes (siMST-A and siMST-B). siControl refers to a non-targeting siRNA duplex. β-actin 
was used as a loading control. 
To analyse whether KIBRA knockdown phenotype is dependent on LATS1, LATS1 
was reduced by siRNAs (siLATS1-A and siLATS-B) in MCF10A-shScr, MCF10A-
shKIBRA-B, and MCF10A-YAPS127A cells. LATS2 knockdown was not tested since 
LATS2 does not functionally antagonize YAP in MCF10A cells (Zhang et al., 2008a). 
As expected, reduced LATS1 expression caused an increase in migration of MCF10A-
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shScr cells (Figure 4.18A) (Zhang et al., 2008a). Surprisingly, both siRNA duplexes 
targeting LATS1 caused decreased migration in MCF10A-shKIBRA and MCF10A-
YAPS127A cells (Figure 4.18A). This remarkable finding shows that silencing YAP and 
LATS1 causes the same phenotypic effect, although it is reported that YAP and LATS1 
have the reverse effect (Zhang et al., 2008a). To dissect this controversial result, 
western blot analysis for YAP phosphorylation levels in all three cellular backgrounds 
was conducted (Figure 4.18B). It was found that reduction in migration of MCF10A-
shKIBRA-siLATS1 and MCF10A-YAPS127A-siLATS1 cells correlates with an increase 
of anti-migratory phosphorylated YAP at S127 phosphorylation site, suggesting once 
more (Figure 4.17A) the presence of a compensatory feedback system in these cells. 
Importantly, although MCF10A-shScr-siLATS1 cells displayed increased migration, no 
increase in the YAP phosphorylation levels was observed. 
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Figure 4.18 – KIBRA knockdown phenotype is LATS1-dependent. (A) MCF10A-shScr, 
MCF10A-shKIBRA-B or MCF10A-YAPS127A cells with listed siRNA addition were cultured in 
Boyden chambers and migration assessed after 24h. Means were calculated from three 
independent experiments conducted in triplicate. Error bars represent ±s.e. (n=9). MCF10A-
shScr-Ctr vs MCF10A-shScr-siLATS1-A or MCF10A-shScr-siLATS1-B: * p < 0.05; ** p < 
0.01; One-way ANOVA and Bonferroni post-hoc test. MCF10A-shKIBRA-Ctr vs MCF10A-
shKIBRA-siLATS1-A or MCF10A-shKIBRA-siLATS1-B: *** p < 0.001; One-way ANOVA 
and Bonferroni post-hoc test. MCF10A-YAPS127A-Ctr vs MCF10A-YAPS127A-siLATS1-A or 
MCF10A-YAPS127A-siLATS1-B: *** p < 0.001; One-way ANOVA and Bonferroni post-hoc 
test. (B) Immunoblot analysis of efficient knockdown of LATS1 using two independent siRNA 
duplexes (siLATS1-A and siLATS1-B). siControl refers to a non-targeting siRNA duplex. β-
actin was used as a loading control. Immunoblot analysis of phosphorylated YAP levels are 
shown from MCF10A-shKIBRA cells treated with siLATS and MCF10A-YAPS127A cells treated 
with siLATS. Total YAP was used as loading control. 
The following step in this analysis was to determine whether the KIBRA knockdown 
phenotype is dependent on YAP. MCF10A-shScr, MCF10A-shKIBRA-B, and 
MCF10A-YAPS127A cells were transfected with siRNAs (siYAP-1 and siYAP-2) to 
reduce YAP expression. Reduced YAP expression caused decreased migration of all the 
three cell lines (Figure 4.19A). The effective reduction of YAP expression was 
confirmed by western blotting analysis (Figure 4.19B). 
Strikingly, the reduced migration due to the presence of siControl occurred in 
MCF10A-shKIBRA cells (compare number of migrated cells shown in Figure 4.13A 
and Figure 4.17A, 4.18A and 4.19A), but not in MCF10A-shScr or MCF10A-YAPS127A 
(Figure 4.17A, 4.18A and 4.19A). This shows that, although siRNAs do give some 
pleotropic effects such as decreased migration when adding siControl to MCF10A-
shKIBRA cells, the number of migrated cells did not change in MCF10A-shScr or 
MCF10A-YAPS127A. These results, together with the remaining data presented in this 
chapter, suggest that the effects of KIBRA knockdown are MST1/2-independent. 
 
CHAPTER 4 – KIBRA exhibits MST-independent functional regulation 
 150 
 
Figure 4.19 – KIBRA knockdown phenotype is YAP-dependent. (A) MCF10A-shScr, 
MCF10A-shKIBRA-B or MCF10A-YAPS127A cells with listed siRNA addition were cultured in 
Boyden chambers and migration assessed after 24h. Means were calculated from three 
independent experiments conducted in triplicate. Error bars represent ±s.e. (n=9). MCF10A-
shScr-Ctr vs MCF10A-shScr-siYAP-1 or MCF10A-shScr-siYAP-2: * p < 0.05; *** p < 0.001; 
One-way ANOVA and Bonferroni post-hoc test. MCF10A-shKIBRA-Ctr vs MCF10A-
shKIBRA-siYAP-1 or MCF10A-shKIBRA-siYAP-2: *** p < 0.001; One-way ANOVA and 
Bonferroni post-hoc test. MCF10A-YAPS127A-Ctr vs MCF10A-YAPS127A-siYAP-1 or MCF10A-
YAPS127A-siYAP-2: *** p < 0.001; One-way ANOVA and Bonferroni post-hoc test. (B) 
Immunoblot analysis of efficient knockdown of YAP using two independent siRNA duplexes 
(siYAP-1 and siYAP-2). siControl refers to a non-targeting siRNA duplex. β-actin was used as 
a loading control. 
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4.5. KIBRA knockdown activates the AKT pathway 
The PI3K/AKT pathway is a main cell survival pathway, suppressing apoptosis through 
regulation of a number of molecules including the negative regulation of FOXO activity 
(Greer and Brunet, 2005). Previous studies have shown that AKT is a target 
downstream of YAP (Overholtzer et al., 2006; Zhang et al., 2008a). It has been 
determined that YAP overexpression not only results in the activation of the AKT 
pathway (Overholtzer et al., 2006), but also its abrogation in MCF10A-shLATS1 cells 
suppressed activation of the pathway (Zhang et al., 2008a). Furthermore, AKT was 
shown to be a major regulator of MST1 activity by phosphorylating MST1 at Thr120 
both in vitro and in vivo (Yuan et al., 2010). This causes inhibition of MST1 
conformational change, avoiding caspase-mediated cleavage and autophosphorylation at 
Thr183 (Yuan et al., 2010). Both events are pivotal for the full activation of the MST1 
kinase (de Souza and Lindsay, 2004). Thus, AKT was shown to play a critical role in 
regulating the core components of the mammalian Hippo pathway. 
To probe whether an upstream component of the signalling kinase cascade, such as 
KIBRA, could also modulate activation of the AKT pathway, MCF10A-shScr, 
MCF10A-shKIBRA-B, and MCF10A-YAP cells were seeded in medium without serum 
or EGF, for 36 h. Cell lysates were harvested as described in Section 2.3.2.2. Equal 
amounts of protein were separated by 10% SDS-PAGE, and the subsequent PVDF 
membranes probed with antibodies against phosphorylated (AKTSer473) and total AKT. 
The AKTSer473 phosphorylation site was analysed, since previously it was shown that 
AKT maximum activity is dependent on the phosphorylation of both Thr308 and 
Ser473 residues (Alessi et al., 1996). 
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Interestingly, KIBRA knockdown activated the AKT pathway, with approximately a 
20% increase in the levels of phosphorylated AKT at Ser473 compared to MCF10A-
shScr cells (Figure 4.20). Therefore, KIBRA showed a similar activation pattern to YAP 
overexpression. Since KIBRA is upstream of the core kinase, activation of the AKT 
pathway was not so robust as the one observed upon knockdown of LATS1 (Zhang et 
al., 2008a), suggesting that KIBRA has a weaker effect on AKT than LATS. 
 
Figure 4.20 – Immunoblot analysis of the increased phosphorylated AKTSer473 levels in 
MCF10A-shKIBRA cells cultured for 36 hours in the absence of serum and EGF. Total AKT 
and β-actin were used as loading controls. Relative phosphorylation levels were determined 
compared to background phosphorylation (MCF10A-YAP cells set to 1). Means were 
calculated from three independent experiments using Image J software. Error bars represent 
±SD (n=3). MCF10A-YAP vs MCF10A-shScr or MCF10A-shKIBRA-B: *** p < 0.001, One-
way ANOVA and Bonferroni post-hoc test. MCF10A-shScr vs MCF10A-shKIBRA-B: ** p < 
0.01, Student’s t-test. 
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4.6. Compensatory feedback upstream of the core kinase cassette 
During the course of these experiments, it was noted that knocking down Willin caused 
an increase in the expression of Merlin (Figure 3.9). Taking together this observation 
and the fact that attempts to simultaneously knockdown diverse combinations of 
upstream components were mostly unsuccessful, led to an investigation into the 
presence of potential compensatory feedback, acting upstream of the core kinase 
cassette. Only simultaneous knockdown of KIBRA and Merlin was observed (Figure 
4.12). Although one cannot rule out mistakes in the technical aspects, the presence of 
compensation leading to maintenance of the pathway function is more likely to occur. 
To uncover this issue, it was investigated how the expression of KIBRA, Willin, and 
Merlin changed upon knockdown of one of the upstream counterparts. Additionally, 
their expression was also probed in MCF10A-shMST1 cells since MST1 is a central 
component of the core kinase cascade. 
Knockdown of KIBRA endogenous expression caused down-regulation of Willin and 
up-regulation of Merlin (Figure 4.21A). Although this might suggest that KIBRA acts 
upstream of both Willin and Merlin, knockdown of Willin caused the up-regulation of 
both KIBRA and Merlin (Figure 4.21B). Knockdown of Merlin did not result in 
variations of KIBRA and Willin expression (Figure 4.21C). Taken together, these 
results suggest that both KIBRA and Willin act upstream of Merlin. Since the loss of 
Willin caused increased expression of its upstream counterparts, this might suggest that 
Willin is a stronger regulator than KIBRA, as KIBRA caused the opposite expression of 
Willin and Merlin. This line of thought is further supported by the successful generation 
of a KIBRA and Merlin double knockdown. This was not possible with Willin and 
Merlin. Furthermore, knockdown of MST1 caused no variations in Willin and KIBRA, 
but did cause significant down-regulation of Merlin expression (Figure 4.21D). 
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Collectively, these results suggest that MST1 is downstream of both Willin and KIBRA, 
but upstream of Merlin. This is not in agreement with the results presented in Section 
4.3.2.4 (Figure 4.13), and Section 4.4 (Figure 4.17). Specifically, migration of 
MCF10A-shKIBRA cells was not effectively changed by MST1/2 depletion (it is 
increased compared with shKIBRA/siControl, but not compared with shKIBRA only). 
This means that MST1/2 is, in fact, upstream of KIBRA. Importantly, previous studies 
have shown that MST needs to be both phosphorylated and cleaved to result in an 
apoptotic downstream effect (Graves et al., 2001). However, potential variations in 
MST activity were not determined in the present scenario. Also variations in 
phosphorylation levels of upstream components, following the knockdown of one of 
their counterparts, were not determined. Nevertheless, this study suggests the presence 
of compensatory feedback in MCF10A cells, with Merlin playing a central role, towards 
the fine tuned maintenance by the Hippo signalling pathway of its downstream effectors 
(Table 4.1). 
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Figure 4.21 – Upstream components of the Hippo pathway display compensatory feedback. (A) 
Loss of KIBRA causes down-regulation of Willin expression and up-regulation of Merlin. 
mRNA expression of Willin was assessed by quantitative real-time PCR in MCF10A-shKIBRA 
cells. mRNA levels were compared with the MCF10A-shScr control cells (set to 1). β-actin was 
used to normalize for variances in input cDNA. Error bars represent ±SD (n=3). MCF10A-shScr 
vs MCF10A-shKIBRA: *** p < 0.001, Student’s t-test. Immunoblot analysis of Merlin 
expression in MCF10A-shKIBRA cells. β-actin was used as a loading control. (B) Loss of 
Willin causes up-regulation of both KIBRA and Merlin expression. Cell lysates were harvested 
and equal amounts of protein separated on a 10% SDS-PAGE. β-actin was used as a loading 
control. (C) Loss of Merlin causes no variations in Willin or KIBRA expression. Cell lysates 
were harvested and equal amounts of protein separated on a 10% SDS-PAGE. β-actin was used 
as a loading control. (D) Loss of MST1 causes down-regulation of Merlin but not Willin or 
KIBRA expression levels. mRNA expression of Willin was assessed by quantitative real-time 
PCR in MCF10A-shMST1 cells. mRNA levels were compared with the MCF10A-shScr control 
cells (set to 1). β-actin was used to normalize for variances in input cDNA. Immunoblot analysis 
of KIBRA and Merlin expression in MCF10A-shMST1 cells. β-actin was used as a loading 
control. 
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Table 4.1 – Overall view of the potential compensatory feedback in upstream 
components of the Hippo signalling pathway. 
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4.7. KIBRA activates the Hippo signalling pathway and its expression 
antagonizes a YAP-induced EMT phenotype in MCF10A cells 
4.7.1. KIBRA expression activates the Hippo signalling pathway 
After analysing the effects of KIBRA knockdown, it was investigated whether KIBRA 
overexpression promotes activation of the Hippo signalling pathway. Therefore, 
MCF10A cells overexpressing YAP (MCF10A-YAP) were infected with a retrovirus 
expressing KIBRA or an empty vector (Section 2.2.2). Drug-selected pools of infected 
cells were used in the analyses to avoid clonal selection effects. MCF10A-YAP-KIBRA 
or MCF10A-YAP-vector cells were seeded and 48h later harvested (Section 2.3.2.2). 
Equal amounts of protein were separated on a 10% SDS-PAGE, and the subsequent 
PVDF membranes probed with antibodies against phosphorylated and total MST1/2, 
LATS1, and YAP. Increases in LATS1 and YAP relative phosphorylation levels were 
observed when MCF10A-YAP cells over-expressed KIBRA (Figure 4.22). While over-
expression of Willin in MCF10A-YAP cells increased levels of phosphorylated MST1/2 
and MOBKL1A/B (Praskova et al., 2008), KIBRA over-expression caused no 
significant changes in the levels observed for phosphorylated MST1/2 or MOBKL1A/B 
at Thr12 (Figure 4.22, 4.23 and 4.24). 
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Figure 4.22 – KIBRA overexpression in MCF10A-YAP cells results in an increase of 
phosphorylated LATS1 and YAP but not MST1/2 or MOBKL1A/B. Relative phosphorylation 
to total protein levels (MST1/2, MOBKL1A/B, LATS1 or YAP), and background 
phosphorylation (in MCF10A-YAP-vector) is set to 1. Means were calculated from three 
independent experiments conducted in triplicate using Image J software. Error bars represent 
±SD (n=9). MCF10A-YAP-vector vs MCF10A- YAP-KIBRA: *** p < 0.001, Student’s t-test. 
 
Figure 4.23 – Immunoblot analysis of triplicate experiments used for images and quantification 
showed in Figure 4.22. Upon over-expression of KIBRA, no changes in MST1 (Thr183)/MST2 
(Thr180) phosphorylation levels were observed compared with MCF10A-YAP-vector control 
cells. Note the increase in MCF10A-YAP-Willin cells. 
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Figure 4.24 – Immunoblot analysis of triplicate experiments used for images and quantification 
showed in Figure 4.22. Upon over-expression of KIBRA, no changes in MOBKL1A/B-Thr12 
phosphorylation levels were observed compared with MCF10A-YAP-vector control cells. Note 
the increase in MCF10A-YAP-Willin cells. 
To verify whether MST1/2- and MOBKL1A/B-independent regulation on YAP by 
KIBRA would be observed in a different cell line, the same experiment was performed 
in HEK 293T cells. For this purpose, cells were seeded and transiently transfected with 
KIBRA or with an empty vector, as described in Section 2.2.4.2. Cells were harvested 
48h post-transfection and protein samples separated on a 10% SDS-PAGE. Western 
blotting analysis confirmed an increase in the relative phosphorylation levels of the 
Hippo pathway kinases LATS1 and YAP, but not MST1/2 in these cells (Figure 4.25). 
Surprisingly, MOBKL1A/B phosphorylation levels at Thr12 were strongly down-
regulated (Figure 4.25). This was not observed in MCF10A cells, suggesting cell type-
dependent regulation (Figure 4.22). 
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Figure 4.25 – Immunoblot analysis of HEK 293T cells expressing either KIBRA or an empty 
vector. KIBRA expression in HEK 293T cells results in an increase of phosphorylated LATS1 
and YAP but not MST1/2 or MOBKL1A/B. Total MST1/2, MOBKL1A/B, LATS1 and YAP 
were used as loading controls.  
4.7.2. KIBRA expression antagonizes a YAP-induced EMT phenotype in 
MCF10A cells 
Next, it was explored if KIBRA expression could antagonize a YAP-induced EMT 
phenotype. Ectopic expression of YAP and KIBRA in MCF10A-YAP-KIBRA, 
MCF10A-YAP-vector, and MCF10A cells expressing the constitutively active YAP, 
YAPS127A, was confirmed by immunoblotting analysis (Figure 4.26). 
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Figure 4.26 – Immunoblot analysis of efficient FLAG-YAP and KIBRA expression in 
MCF10A-YAP-KIBRA, MCF10A-YAP-vector, MCF10A-YAPS127A–KIBRA or MCF10A-
YAPS127A–vector cells. β-actin was used as a loading control. KIBRA relative band intensity to 
MCF10A-YAP or MCF10A-YAPS127A control cells, display an approximately 1.6-fold increase 
in expression of KIBRA. Means were calculated from three independent experiments using 
Image J software. Error bars represent ±SD (n=3). MCF10A-YAP-vector vs MCF10A-YAP-
KIBRA: *** p < 0.001, Student’s t-test. MCF10A-YAPS127A-vector vs MCF10A-YAPS127A–
KIBRA: *** p < 0.001, Student’s t-test. 
4.7.2.1. KIBRA expression inhibits anchorage-independent growth in MCF10A 
cells 
Firstly, it was analysed if the ectopic expression of KIBRA resulted in the inhibition of 
anchorage-independent growth by MCF10A-YAP cells, and therefore antagonizing a 
YAP-induced EMT phenotype. The number of formed colonies was counted; a colony 
being defined as a group of 5 or more cells. MCF10A-YAP cells expressing KIBRA 
produced 70% fewer colonies in soft agar than MCF10A-YAP cells containing an 
empty vector, after 21 days in culture (Figure 4.27A and 4.27B). Notably, KIBRA 
exhibited a stronger ability to antagonize YAP-induced anchorage-independent growth 
than Willin (Section 3.4.3), as the latter suppressed formation of colonies by 50%, 
whereas KIBRA displayed 70% inhibition. Moreover, KIBRA was unable to antagonize 
a YAPS127A mutant under the same conditions (Figure 4.27A and 4.27B). 
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Figure 4.27 – KIBRA expression antagonizes YAP-induced anchorage-independent growth in 
soft agar. MCF10A-YAP-KIBRA, MCF10A-YAP-vector, MCF10A-YAPS127A-KIBRA or 
MCF10A-YAPS127A-vector cells were cultured in soft agar for 21 days. One colony was scored 
if it was ≥ 5 cells. Means were calculated from three independent experiments conducted in 
triplicate. Error bars represent ±s.e. (n=9). MCF10A-YAP-vector vs MCF10A-YAP-KIBRA: 
*** p < 0.001; Student’s t-test. MCF10A-YAPS127A-vector vs MCF10A- YAPS127A-Willin: p = 
0.284; Student’s t-test. (B) Representative images of soft agar colonies (indicated by black 
arrows)  from MCF10A-YAP-KIBRA, MCF10A-YAP-vector, MCF10A-YAPS127A-KIBRA, 
and MCF10A-YAPS127A-vector cells. 
4.7.2.2. KIBRA expression suppresses YAP-induced cell migration in MCF10A 
cells 
Next, it was analysed if overexpression of KIBRA suppressed YAP-induced cell 
migration. MCF10A-YAP or MCF10A-YAPS127A cells expressing either KIBRA or an 
empty vector were cultured in 24-well Boyden chambers with 8.0 µm pores. 24h later, 
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cells were stained and the number of cells that migrated through the 8.0 µm pores was 
counted. MCF10A-YAP cells expressing KIBRA showed attenuated migration by 50% 
as compared to MCF10A-YAP cells containing empty vector (Figure 4.28A and 4.28B). 
Strikingly, MCF10A-YAPS127A cells were refractory to the effects of KIBRA expression 
(Figure 4.28A and 4.28C). Collectively, these results show that KIBRA antagonizes 
YAP via Ser127 phosphorylation. Furthermore, KIBRA antagonistic effect on YAP-
induced cell migration is consistent with the effect observed upon ectopic expression of 
Willin, as both upstream components inhibited cell migration by 50% (Section 3.4.4). 
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Figure 4.28 – KIBRA expression antagonizes YAP-induced cell migration in MCF10A cells. 
(A) MCF10A-YAP-KIBRA, MCF10A-YAP-vector, MCF10A-YAPS127A-KIBRA or MCF10A- 
YAPS127A-vector cells were cultured in Boyden chambers and migration assessed after 24h. 
Means were calculated from three independent experiments conducted in triplicate. Error bars 
represent ±s.e. (n=9). MCF10A-YAP-vector vs MCF10A-YAP-KIBRA: *** p < 0.001; 
Student’s t-test. MCF10A-YAPS127A-vector vs MCF10A-YAPS127A-KIBRA: p = 0.281; 
Student’s t-test. (B) (C) Representative images of migration Boyden chambers from MCF10A-
YAP-KIBRA, MCF10A-YAP-vector, MCF10A- YAPS127A-KIBRA, and MCF10A- YAPS127A-
vector cells as indicated by the black arrows. 
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4.8. The effect of Willin, Merlin and KIBRA antagonism on a YAP-
induced EMT phenotype in MCF10A cells 
Previously, Hao et al. (2008), by using a whole human genome oligonucleotide 
microarray, determined the expression profile of genes regulated by YAP. These genes 
were found to be involved in the regulation of diverse biological functions such as cell 
proliferation, cell death, cytoskeletal organization, cell migration, and cell adhesion 
(Hao et al., 2008). Furthermore, it was reported that LATS1 together with MST2 
inhibited YAP-induced transcription regulation (Hao et al., 2008). The data displayed in 
this chapter together with the results presented by Angus et al. (2012), led to an 
investigation as to whether phosphorylation of YAP by KIBRA may suppress YAP’s 
nuclear transcriptional regulation. The analysis of KIBRA-induced variations in the 
expression of genes regulated by YAP was extended to Willin and Merlin; and therefore 
gaining insight if the three upstream components of the Hippo pathway differentially 
regulate genes controlled by YAP. 
While the experiments presented in this chapter were being conducted, a functional 
Willin antibody was kindly provided by Dr. Takeichi (RIKEN Center for 
Developmental Biology, Kobe, Japan; Ishiuchi and Takeichi, 2011). Thus, ectopic 
expression of KIBRA, Willin, and Merlin in MCF10A-YAP cells was confirmed by 
immunoblotting analysis (Figure 4.29). Quantification of KIBRA, Willin, and Merlin 
over-expression levels in MCF10A-YAP cells, showed 2.7, 1.8, and 8.6-fold increases 
compared to MCF10A-YAP-vector control cells (Figure 4.29). 
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Figure 4.29 – Immunoblot analysis of KIBRA, Willin or Merlin over-expression in MCF10A-
YAP cells, showing 2.7, 1.8, and 8.6-fold increases compared to MCF10A-YAP-vector control 
cells. β-actin was used as a loading control. MCF10A-YAP-vector vs MCF10A-YAP-KIBRA 
or MCF10A-YAP-Merlin: *** p < 0.001, One-way ANOVA and Bonferroni post-hoc test. 
MCF10A-YAP-vector vs MCF10A-YAP-Willin: ** p < 0.01, One-way ANOVA and 
Bonferroni post-hoc test.  
Quantitative real-time PCR analysis showed that both KIBRA and Willin could 
antagonize the mRNA levels of genes known to be regulated by YAP, by up-regulating 
BMP2 and RASSF4, and down-regulating CTGF, FGF1, PDGFβ, and IGFBP3 (Figure 
4.30). Importantly, CTGF provided a robust readout of KIBRA and Willin’s ability to 
suppress YAP-induced transcriptional regulation. From all of the examined genes, 
CTGF is the only gene known to be a YAP and TEAD1 direct target, with both YAP 
and TEAD binding to the CTGF promoter (Zhao et al., 2008a). Moreover, RASSF8 
mRNA expression levels were up-regulated by Willin but not by KIBRA (Figure 4.30). 
RASSF8 was the only gene that showed differential regulation by these two upstream 
components of the Hippo pathway. RASSF8 has been shown to be a potential binding 
partner of Willin (Rual et al., 2005), and its up-regulation upon Willin overexpression is 
in agreement with the findings reported by Angus et al. (2012). Interestingly, Merlin 
overexpression did not significantly influence the YAP-induced expression of the 
analysed genes, even with an 8-fold overexpression of Merlin (Figure 4.29). This 
regulatory pattern had two exceptions (Figure 4.30). Whilst FGF1 expression, 
mimicking the regulation of its upstream counterparts, was down-regulated; integrin β2 
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(ITGB2) was up-regulated by Merlin, with KIBRA or Willin showing no significantly 
influence in its expression. Taken together, these results suggest that these three 
upstream components of the Hippo pathway differentially regulate YAP-induced 
transcriptional regulation. 
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Figure 4.30 – KIBRA expression antagonizes YAP-induced transcriptional regulation. mRNA 
expression of the YAP-regulated genes CTGF, BMP2, FGF1, RASSF4, PDGFβ, IGFBP3, 
RASSF8, and ITGB2 was assessed by quantitative real-time PCR in MCF10A-YAP cells 
overexpressing KIBRA, Willin or Merlin. mRNA levels were compared with the empty vector 
control MCF10A-YAP cells. KIBRA and Willin overexpression increased BMP2 and RASSF4 
mRNA levels and decreased CTGF, FGF1, PDGFβ, and IGFBP3 mRNA levels. Merlin 
overexpression increased ITGB2 mRNA levels. Means were calculated from Ct values from 
two analyse conducted in triplicate. Error bars represent ±s.e. (n=6). MCF10A-YAP-vector vs 
MCF10A-YAP-KIBRA or MCF10A-YAP-Willin for all the analysed genes: *p < 0.05, **p < 
0.01, ***p < 0.001; One-way ANOVA and Bonferroni post-hoc test. MCF10A-YAP-vector vs 
MCF10A- YAP-Merlin: CTGF (p = 0.129), FGF1 (p = 0.005), BMP2 (p = 0.585), RASSF4 (p = 
0.307), PDGFβ (p = 0.06), IGFBP3 (p = 0.278), RASSF8 (p = 0.073), ITGB2 (p = 2.3 x 10-4); 
Student’s t-test. 
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4.9. Discussion  
During the last decade, pivotal advances have been made in the understanding of the 
mammalian Hippo signalling pathway, but less is known about the proteins upstream of 
the core kinase cassette.  In D. melanogaster, previous studies identified Kibra as an 
upstream regulator of the Salvador/Warts/Hippo kinases cascade network (Baumgartner 
et al., 2010; Genevet et al., 2010; Yu et al., 2010). Furthermore, human KIBRA, 
encoded by the WWC1 gene, has been shown to be involved in diverse biological 
functions (Schneider et al., 2010), and to regulate the Hippo signalling activity via 
interactions with LATS kinases (Xiao et al., 2011). 
The data presented in this chapter provides clear evidence that reducing endogenous 
KIBRA expression decreases phosphorylation of LATS1 and YAP, but not MST1/2 or 
MOBKL1A/B in both MCF10A and HEK 293T cells. Since MOBKL1A/B is a MST1/2 
substrate, it provided a sensitive readout of MST1/2 activity. MOBKL1A/B were 
identified as MST1/2 kinases physiological substrates, with MST phosphorylating 
MOBKL1A/B at both Thr12 and Thr35, which then leads to LATS phosphorylation by 
promoting MOBKL1A/B binding to LATS (Praskova et al., 2008). Moreover, KIBRA 
over-expression increased LATS1 and YAP, but not MST1/2 or MOBKL1A/B 
phosphorylation. These findings are in agreement with Xiao et al. (2011), supporting a 
model whereby LATS1 phosphorylation occurs independently of MST1/2 or via Merlin 
in a WW45 dependent manner (Zhang et al., 2010). These observations contrast with 
the regulatory system of Willin, that acts via MST1/2 (Chapter 3, Angus et al., 2012). A 
MST-independent regulatory pattern has been previously described (Zhou et al., 2009). 
In fact, embryonic fibroblasts from mice lacking MST1/2 show phosphorylation of 
LATS1/2 and YAP (Zhou et al., 2009), further supporting the notion of MST-
independent pathway activation. Interestingly, it was observed that in MCF10A cells, 
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KIBRA knockdown up-regulated phosphorylation of MOBKL1A/B at Thr12 (Figure 
4.4). This negative regulation on MOBKL1A/B by KIBRA may suggest the occurrence 
of MST-independent MOBKL1A/B phosphorylation. This regulatory mechanism may 
therefore inhibit phosphorylation of LATS1 activation loop (Ser909 residue), and the 
hydrophobic motif (T1079 residue) (Chan et al., 2005), as well as YAP 
phosphorylation; thus promoting cell proliferation and tissue growth. However, these 
findings were found to be cell-type specific. 
While the phosphorylation of YAP upon interaction of KIBRA WW domain with LATS 
hydrophobic sites has been reported (Xiao et al., 2011), the results displayed in this 
chapter show that decreased expression of endogenous KIBRA promotes EMT. In fact, 
KIBRA knockdown resulted in morphological changes towards a spindle-like 
mesenchymal phenotype, down-regulation of epithelial markers with the concomitant 
up-regulation of mesenchymal markers, anchorage-independent growth, cell migration, 
cell proliferation, and loss of cell adhesion to the ECM. Moreover, the ectopic 
expression of KIBRA in MCF10A-YAP cells antagonizes the YAP-induced phenotypes 
of anchorage-independent growth and migration, but not when YAP is mutant at S127A 
phosphorylation site. This is consistent with the evidence that YAP Ser127 
phosphorylation mediates the tumour suppressive activity of the Hippo pathway in 
mammals (Dong et al., 2007). Furthermore, these findings phenocopy the action of 
Willin, which also functions through Ser127 phosphorylation of YAP (Chapter 3; 
Angus, 2011; Angus et al., 2012), and with the core kinase cassette component, LATS1 
(Zhang et al., 2008a). Importantly, previous data has described an interaction between 
KIBRA, DDR1 and aPKC, which occurs in a collagen-regulated manner (Hilton et al., 
2008), suggesting a role for KIBRA in the collagen- stimulated activation of the MAPK 
cascade. Collagen in the extracellular environment inhibits the KIBRA-DDR1 
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interaction, but is required for KIBRA-induced ERK phosphorylation (Hilton et al., 
2008). In normal mammary epithelium when context is essential, for example the 
organization of the mammary gland, then KIBRA expression would promote collagen 
sensing and Hippo pathway activation to maintain tissue architecture. Conversely, 
decreased KIBRA expression would allow cells to disconnect from sensing the 
extracellular environment and to turn on EMT/migration phenotypes. Moreover, 
KIBRA was shown to associate with Merlin but not with Willin, MST2 or RASSF6 
(Genevet et al., 2010). In Drosophila, Kibra’s first WW domain associates with 
Expanded (Ex) RXPPXY motif and in mammals Willin (the human orthologue of Ex) 
lacks the C-terminal domain, which is where Ex harbors the RXPPPXY motif. Thus, the 
missing C-terminus in Willin could explain the lack of interaction between the two 
proteins. It will be interesting to probe functional readouts resulting from the interaction 
between Willin N-terminal FERM-domain, the functional domain of Willin, and 
KIBRA. In fact, interactions amongst the two proteins have been described with both 
KIBRA and Willin shown to interact and regulate the polarity complex PAR3-aPKC-
PAR6 (Ishiuchi and Takeichi, 2011, Yoshihama et al., 2011). The ability of KIBRA to 
regulate EMT highlights the concept that in mammals, the Hippo pathway is an 
endogenous EMT regulatory pathway. 
The observation that migration in shKIBRA cells is not effectively changed by MST1/2 
depletion (it is increased compared to shKIBRA-siControl, but not compared to 
shKIBRA only) further support the notion that KIBRA is independent of MST1/2. This 
suggests that MST1/2 is upstream of KIBRA. Importantly, the decreased migration of 
shKIBRA cells treated with siYAP reagents suggests YAP is downstream of KIBRA 
and thus, KIBRA is a physiological regulator of YAP. Surprisingly, a reduction in 
migration of shKIBRA cells treated with siLATS reagents compared with shKIBRA-
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siControl cells was observed. However, this reduction in migration of shKIBRA-
siLATS cells correlates with an increase in anti-migratory phospho-YAPS127. This 
strongly suggests the presence of compensatory feedback or off-target effects in these 
cells aiming to maintain the fine-tuned pathway activity. The use of proper controls 
validates this view. In fact, shScr cells treated with siLATS showed increased 
migration, agreeing with previous reports (Zhang et al., 2008a). Also, in this increased 
migration scenario, there was no increase in phospho-YAPS127 levels compared to 
siControl cells. The upstream compensation study displayed in Section 4.6, further 
suggests the existence of a compensatory feedback in the Hippo pathway. In fact, 
previous reports have shown the feedback loop regulation of signalling pathway 
components by the pathway itself (Niehrs and Meinhardt, 2002). Merlin expression was 
up-regulated upon knockdown of Willin and KIBRA. However, no changes in Willin or 
KIBRA expression were observed in MCF10A-shMerlin cells. From all the attempted 
combinations to generate upstream double knockdown components, only KIBRA and 
Merlin knockdown succeeded. This partial redundancy was confirmed by the KIBRA 
and Merlin double knockdown ability to generate more colonies in soft agar than each 
component alone. One could expect that Willin and Merlin positively regulate each 
other expression levels. Specifically, in Drosophila, Ex and Mer were shown to function 
as a semi-redundant upstream branch (McCartney et al., 2000; Hamaratoglu et al., 2006; 
Pellock et al., 2006). Yet, this was not observed as knockdown of Merlin did not induce 
Willin’s up-regulation, highlighting that the Hippo pathway mode of regulation is not 
entirely evolutionarily conserved between Drosophila and mammals. 
Next, it was investigated whether downstream YAP targets are differentially expressed 
by KIBRA, Willin, and Merlin. Surprisingly, it was found that KIBRA and Willin 
regulate the YAP targets CTGF, FGF1, PDGFβ, RASSF4, BMP2, and IGFBP3 but 
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Merlin only regulates FGF1 and ITGB2. CTGF, IGFBP3, PDGFβ, and FGF1 were 
previously shown to be up-regulated by YAP (Hao et al., 2008, Zhao et al., 2008a), and 
to be associated with transformed phenotypes, including EMT (Grimberg, 2000, Board 
and Jayson, 2005, Eswarakumar et al., 2005, Zhao et al., 2008a). Furthermore, KIBRA 
and Willin inhibited YAP-induced transcriptional activation of BMP2 and RASSF4, 
which is consistent with the data presented by Angus et al., (2012) and Hao et al., 
(2008). RASSF8 was up-regulated by Willin but not by KIBRA. RASSF8 acts as a 
tumour suppressor (Falvella et al., 2006, Lock et al., 2010) and does not contain 
SARAH motifs (Falvella et al., 2006, Donninger et al., 2007). Whilst its up-regulation 
by Willin may depict RASSF8 as a potential binding partner of Willin (Rual et al., 
2005), why KIBRA inhibits its expression needs further investigation. Moreover, YAP 
was found to strongly induce ITGB2 expression in MCF10A cells (Zhao et al., 2008a). 
Whereas KIBRA and Willin did not change ITGB2 expression levels, Merlin induced 
its significant up-regulation. These observations suggest that KIBRA and Willin 
regulate the Hippo pathway in MCF10A cells, but Merlin does not act in the same 
manner. As such, the present findings support a model whereby KIBRA regulates 
LATS1 phosphorylation not by association with Merlin in a WW45-dependent manner, 
but through a MST1/2-independent mechanism (Figure 4.31). These results highlight 
the upstream complexity and ability of the pathway to fine-tune output. This is further 
supported by the fact that KIBRA and Willin, but not Merlin abrogation, resulted in the 
significant down-regulation of occludin (Figure 4.10; Chapter 3, Figure 3.10; Angus et 
al., 2012), which together with the claudins (Furuse et al., 1998a, Furuse et al., 1998b), 
are components of tight junctions. 
Finally, in primary breast tumours, low KIBRA expression and high CTGF expression 
correlated with the claudin-low subtype, characterized by low expression of claudin-3, -
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4, -7, a lack of luminal differentiation markers, immune response gene enrichment, 
cancer stem cell-like features and high enrichment for EMT markers such as E-
cadherin, vimentin and SNAI2 (Moleirinho et al., 2013a). Consistent with in vitro 
findings shown in this chapter, down-regulation of E-cadherin and the up-regulation of 
the mesenchymal markers vimentin as well as N-cadherin, were described as occurring 
almost exclusively in this triple-negative subtype of tumour (Sarrio et al., 2008). 
Importantly, claudin-low tumours have been linked to stem cells tumour initiating cells 
(Creighton et al., 2009) and EMT development (Mani et al., 2008). Interestingly, 
increasing evidence has shown the involvement of the Hippo pathway in the regulation 
of stem cell self-renewal and expansion (Hong et al., 2005, Lian et al., 2010) however, 
the regulatory role of KIBRA in this scenario needs further investigation. Correlation of 
the Hippo pathway with histological grade supports recent findings of a “gene signature 
for the Hippo signalling pathway” associated with grade (Cordenonsi et al., 2011). In 
this study, the researchers found up-regulated TAZ in high-grade breast tumours 
(Cordenonsi et al., 2011). It was therefore determined whether TAZ expression is high 
in claudin-low breast cancer, where KIBRA is expressed at lower levels (Moleirinho et 
al., 2013a). However, a discrepant TAZ expression was found between both studies and 
this may be due to probe set issues arising in the Affymetrix GeneChip data, and/or 
differences in the tumour samples analysed in the two studies. Yet, the YAP/TAZ direct 
target gene CTGF was highly expressed in claudin-low tumours (p=0.005), suggesting 
Hippo pathway inactivation in these tumours (Moleirinho et al., 2013a). 
To conclude, the data provided in this chapter has shown that Willin and KIBRA have 
similar effects on YAP activity. However, in the proposed system, KIBRA activity is 
MST1/2-independent, while Willin is MST1/2-dependent. In addition, loss of KIBRA 
expression displays epithelial-to-mesenchymal transition features, whilst KIBRA 
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ectopic expression antagonizes YAP functional output by acting on YAP serine 127 
phosphorylation site. Moreover, it was also found that the acknowledged upstream 
components of the core signalling cascade, KIBRA, Willin, and Merlin differently 
regulate YAP downstream targets, highlighting the complexity and fine-tune of this 
pathway. An understanding of how these Hippo pathway upstream components 
influence activation of the pathway in physiological settings represents important 
questions to be addressed. Figure 4.31 depicts the schematic representation of the 
proposed model for the action of KIBRA on Hippo signalling. 
 
Figure 4.31 – KIBRA exhibits MST-independent functional regulation of the mammalian 
Hippo signalling pathway. Schematic representation of a model for the action of KIBRA on 
Hippo signalling (Moleirinho et al., 2013a). 
Contents of this chapter were published in the following article: Moleirinho S, Chang 
N, Sims AH, Tilston-Lünel AM, Angus L, Steele A, Boswell V, Barnett SC, Ormandy 
C, Faratian D, Gunn-Moore FJ & Reynolds PA. 2013. KIBRA exhibits MST-
independent functional regulation of the Hippo signalling pathway in mammals. 
Oncogene Apr 4; 32(14):1821-30.  
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5.1. Introduction 
Regeneration of the peripheral nerve is a dynamic process initiated by Schwann cells 
and the extracellular matrix, which confer a growth-promoting environment to 
peripheral axons. Damaged axons transmit a signal to Schwann cells informing them of 
their intention to degenerate. This signal is mediated by the Raf/MEK/ERK signalling 
pathway, and triggers myelinated Schwann cells to dedifferentiate to a progenitor-like 
cell state (Harrisingh et al., 2004, Napoli et al., 2012). Regrowing axons and Schwann 
cells migrate towards the nerve gap to promote reinnervation of the distal stump, and 
rely on signals mediated by both the ephrin/Eph pathway and fibroblasts (Parrinello et 
al., 2010). Tissue repair, after a major injury, relies on the expansion and/or 
dedifferentiation of an existing population of progenitor cells, such as primary satellite 
cells (Judson et al., 2012), which may recapitulate the developmental process involving 
the reprogramming of diverse molecular pathways (Charge and Rudnicki, 2004).  Here, 
repression of pathways involved in developmental tissue growth, such as the Hippo 
kinase cascade, induces YAP stemness properties by promoting a controlled cell 
proliferation, which aims to restore of organ function (Cai et al., 2010, Lian et al., 2010). 
The Hippo pathway has been extensively studied in the fibroblast cell line NIH-3T3, and 
the core signalling cascade components were found to be expressed in primary mouse 
embryonic fibroblasts (MEF’s) (Guo et al., 2007, Zhou et al., 2009). However, less is 
known about the presence and regulation of the Hippo signalling in Schwann cells. So 
far, Merlin, encoded by the neurofibromatosis-2 (NF2) gene located on chromosome 22 
(Rouleau et al., 1993, Trofatter et al., 1993), is the only acknowledged upstream 
component known to regulate these cells. In fact, Merlin functions as a tumour 
suppressor in mice and humans, for example mutations in the NF2 gene have been well 
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characterized as hallmarks of neurofibromatosis type 2 (NF2) disease, which confers a 
predisposition to the appearance of schwannomas and meningiomas (McClatchey et al., 
1998, Giovannini et al., 2000). Schwannomas exist as benign nerve sheath tumours 
composed of Schwann cells. Its development is associated with compression of the 
nervous system structures, a condition that leads to a high morbidity, significantly 
decreasing the average lifespan to less than 40 years (Gusella et al., 1999). 
Willin (FRMD6) was first identified in the rat sciatic nerve (Gunn-Moore et al., 2005) 
which is composed of neurons, Schwann cells, and fibroblasts. Willin is the nearest 
human sequence homologue to the Drosophila protein Expanded (Ex) sharing 60% of 
homology with the Ex FERM domain. In Drosophila, the lack of Ex expression has been 
shown to be associated with overgrowth of certain structures such as the wing and 
imaginal discs (Boedigheimer and Laughon, 1993) reflecting a direct role in controlling 
cell growth in these tissues. In mammals, the FERM domain of Willin was recently 
shown to be sufficient to activate the Hippo pathway via MST1/2 and to antagonize 
YAP-induced phenotypes in mammalian cells (Angus, 2011; Angus et al., 2012). Willin 
activated the Hippo pathway, inducing the phosphorylation of MST1/2, LATS1, and 
YAP in MCF10A and HEK 293T cells. Knockdown of Willin expression mimicked 
YAP overexpression with respect to inducing an Epithelial-Mesenchymal transition 
(EMT) phenotype in MCF10A cells (Chapter 3, Angus et al., 2012). 
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5.2. Aims of the Chapter 
Since Willin was first identified within the mammalian sciatic nerve, I sought to 
determine its function within this tissue structure, and whether it acts in the same 
manner as in epithelial cells. Therefore, I aimed to determine whether in mammalian 
peripheral nerve fibroblasts, Willin expression controls the phosphorylation of MST1/2, 
LATS1, and YAP, and thereby YAP’s translocation from the nucleus to the cytoplasm. 
Secondly, I analysed whether activation of the Hippo pathway is an upstream regulator 
of ephrinB/EphB signalling and EGFR, which are known factors to be involved in nerve 
regeneration, and if Willin expression controls the rate at which wounds close. Finally, I 
investigated whether Willin and YAP differently regulate genes known to be regulated 
by YAP in the context of primary fibroblasts isolated from the sciatic nerve. 
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5.3. Willin is expressed in fibroblasts within the sciatic nerve 
Willin was first identified by a yeast two-hybrid screen of a rat sciatic nerve cDNA 
library using the neuronal transmembrane protein, neurofascin, as bait (Gunn-Moore et 
al., 2005). From this yeast two hybrid screen, the C-terminal domain of neurofascin was 
found to bind Willin, and northern blot analysis had confirmed Willin’s expression in 
this structure (Gunn-Moore et al., 2005). 
To establish where Willin is located within the sciatic nerve, Prof. Frank Gunn-Moore 
compared the mRNA expression pattern of Willin with the Schwann cell expressing 
isoform of the transmembrane receptor neurofascin (Gunn-Moore et al., 2006) by in situ 
hybridization. The Willin transcript appeared to be predominately located at the 
perineurium (the periphery) of the sciatic nerve (Figure 5.1A), but also within discrete 
cells within the endoneurium. However, from their morphology these cells appeared to 
be different from those in which the glial neurofascin isoform transcript was expressed 
(Figure 5.1A). 
The sciatic nerve is composed of cell bodies of Schwann cells and fibroblasts; therefore, 
to determine the expression of Willin in either of these cells, both Schwann cells and 
fibroblasts were cultured from rat sciatic nerve (Figure 5.1B). These cells were a kind 
gift from the third supervisor of this PhD project, Prof. Susan Barnett (Institute of 
Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK). 
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Figure 5.1 – Willin is mainly expressed in primary fibroblasts within the sciatic nerve. (A) 
Differential expression of Neurofascin 155 and Willin transcripts in rat peripheral nervous 
system (PNS). Rat sciatic nerve sections were hybridized with riboprobes specific for NF155 or 
Willin and viewed by dark-field microscope. NF155 transcripts were dispersed around the 
sciatic nerve, consistent with Schwann cells location at the endoneurium. A robust expression of 
Willin mRNA was observed at the perineurium (red arrows) suggesting that Willin is expressed 
in a different population of cells within the sciatic nerve. Work done by Prof. Frank Gunn-
Moore. (B) Representative phase-contrast images of Schwann cell and fibroblast cultures 
isolated from the sciatic nerve growing in monolayers cultures. Schwann cells and fibroblasts 
populations display distinct morphologies. Scale bars = 50 µm. 
Quantitative real-time PCR was performed to investigate the level of expression of 
Willin in primary Schwann cell and fibroblast cultures. Interestingly, the Willin 
transcript was expressed 10-fold more in the fibroblasts than in the Schwann cells 
(Figure 5.2). Furthermore, since Willin is an upstream component of the Hippo pathway 
(Chapter 3, Chapter 4, Angus et al., 2012; Moleirinho et al, 2013a), components of this 
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newly emerging signalling cascade were analyzed to determine whether they were also 
expressed within the sciatic nerve. All components were expressed in both cell lines. 
Interestingly, MST2, LATS1, and LATS2 were more strongly expressed within the 
fibroblasts than Schwann cells, KIBRA and YAP less expressed, whilst Merlin, Ezrin, 
and MST1 were present in both cell types at the same level as assessed by quantitative 
RT-PCR (Figure 5.2). 
 
Figure 5.2 – The Hippo signalling pathway is present in the sciatic nerve. mRNA expression of 
the Hippo pathway components Willin, KIBRA, Merlin, Ezrin, MST1/2, LATS1/2, and YAP 
was determined by quantitative real-time PCR in fibroblasts and Schwann cells. mRNA levels 
were compared with Schwann cells (SC set to 1). Willin, MST2, LATS1, and LATS2 mRNA 
levels are increased in the fibroblasts whereas YAP and KIBRA mRNA expression decreases in 
these cells. Means were calculated from Ct values in three independent experiments. β-actin was 
used to normalize for variances in input cDNA. Error bars represent ±s.e. (n=3). Schwann cells 
vs fibroblasts for all the analyzed genes: * p < 0.05; ** p < 0.01; *** p < 0.001, Student’s t-test. 
Schwann cells vs fibroblasts: Merlin (p = 0.784); Ezrin (p = 0.07); MST1 (p = 0.75); Student’s 
t-test. 
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5.4. Willin expression influences the activation of the Hippo pathway in 
fibroblasts 
Previously, it was shown that Willin expression in epithelial MCF10A cells induces 
YAP phosphorylation at Ser127, by a MST1/2 and MOBKL1A/B-dependent 
mechanism (Chapter 3, Chapter 4, Angus et al., 2012; Moleirinho et al, 2013a). 
Phosphorylation of YAP at Ser127 by LATS1/2 results in YAP translocation to the 
cytoplasm, and then its subsequent ubiquitination and concomitant degradation (Zhao et 
al., 2007, Zhao et al., 2010b). Since YAP regulation could be context-dependent, Willin 
was investigated to determine whether it could activate the Hippo pathway in primary 
fibroblasts derived from the rat sciatic nerve. 
Firstly, the minimal inhibitory concentration of puromycin and hygromycin selection 
agents required to eliminate primary fibroblasts was determined. This was accomplished 
by performing both puromycin and hygromycin “kill assays”, as described in Section 
2.4.8.4. Puromycin selection was conducted since Willin-HA ORF was cloned into 
pBabe puromycin-resistant vector, whilst hygromycin selection was made since Flag-
YAP1 ORF was cloned into pBabe hygromycin-resistant vector (Section 2.1.2.6). 
Fibroblasts were seeded and the antibiotic selections started. After 24h, no changes in 
the fibroblast viabilities were observed (Figure 5.3A and Figure 5.4A). As shown in 
Figure 5.3B, after 5 days in the presence of 2.5 µg/mL puromycin, all the fibroblasts 
were killed. In addition, after 10 days in the presence of 300 µg/mL hygromycin, all the 
fibroblasts were eliminated (Figure 5.4B). 
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Figure 5.3 – Primary fibroblasts puromycin kill assay. Fibroblasts were seeded and puromycin 
(stock solution 10 mg/mL) was added to the concentrations of 0, 1.5, 2, 2.5, 3, and 3.5 µg/mL. 
For each condition, a triplicate of wells was analysed. (A) Representative phase-contrast image 
shows that after 24h under puromycin selection, fibroblasts were still alive in all the probed 
conditions. (B) Representative phase-contrast images showing that after 5 days under 
puromycin selection, a puromycin concentration of 2.5 µg/mL induced fibroblasts death. Scale 
bars = 50 µm. 
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Figure 5.4 – Primary fibroblasts hygromycin kill assay. Fibroblasts were seeded and 
hygromycin (stock solution 50 mg/mL) was added to the concentrations of 0, 100, 150, 200, 
250, 300, 350, 400, 450, 500, 600, and 700 µg/mL. For each condition, a triplicate of wells was 
analysed. (A) Representative phase-contrast image shows that after 24h under hygromycin 
selection, fibroblasts were still alive in all the probed conditions. Scale bar = 50 µm. (B) 
Representative phase-contrast images showing that after 10 days under hygromycin selection, a 
hygromycin concentration of 300 µg/mL induced fibroblasts death. Scale bars = 20 µm. 
After determining the concentrations of puromycin and hygromycin needed for the 
selection of untransduced fibroblasts, these cells were infected with retroviruses 
expressing either Willin, YAP or an empty vector. The transduced cells were selected 
with 2.5 µg/mL puromycin or with 300 µg/mL hygromycin. These selections continued 
for 5 days (puromycin) or 10 days (hygromycin), after which cells were harvested for 
further experiments. To confirm the ectopic expression of Willin and YAP, cell lysates 
were harvested and equal amounts of protein separated on a 10% SDS-PAGE. The 
subsequent PVDF membranes were probed for Willin and YAP (Figure 5.5). The 
antibody against Willin that was used was different from the one described in Chapter 4. 
In this chapter, a commercial custom Willin rabbit polyclonal antibody was generated 
against the unique sequence KEASKGIDQFGPPMIIHC of Willin (residues 86–102) 
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which was also used to affinity purify the antibody from the resulting serum (Dundee 
Cell Products, Dundee, UK). Immunoblotting analysis confirmed the ectopic expression 
of Willin and YAP (Figure 5.5). 
 
Figure 5.5 – Immunoblot analysis of YAP and Willin overexpression in primary fibroblasts. β-
actin was used as a loading control. 
Stable pools of drug-selected fibroblasts expressing either Willin or an empty vector 
were investigated by western blotting for their ability to influence the activation of the 
Hippo pathway. Cells were seeded and 48h later harvested, as described in Section 
2.3.2.2. Equal amounts of protein were separated on a 10% SDS-PAGE and the 
subsequent PVDF membranes probed with antibodies against phosphorylated and total 
MST1/2, LATS1, and YAP. Upon ectopic Willin expression (Fibro-Willin cells), as 
predicted, there was a significant increase in MST1/2, LATS1, and YAP 
phosphorylation when compared to the empty-vector control (Fibro-Vector) cells 
(Figure 5.6A). These findings were further supported by knocking down endogenous 
Willin using small interfering RNAs (siRNAs). Down-regulation of Willin using siRNA 
(Fibro-siWillin cells) caused a significant reduction in MST1/2, LATS1, and YAP 
phosphorylation (Figure 5.6B), when compared with control cells (Fibro-siCtr). 
Knockdown of Willin was confirmed by immunoblotting analysis (Figure 5.6B). 
Vector Willin YAP
Fibroblasts
YAP
β-actin
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Figure 5.6 – Willin activates the Hippo signalling pathway in fibroblasts of the sciatic nerve. 
Drug-selected pools of infected cells were used in the analyses to avoid clonal selection effects. 
Immunoblot analysis of the retroviral infected fibroblasts with either Willin or empty vector 
shows (A) Willin increases MST1/2, LATS1, and YAP phosphorylation. Relative 
phosphorylation to total proteins levels (MST1/2, LATS1 or YAP) are shown and background 
phosphorylation (in Fibro-Vector) is set to 1. Error bars represent ±s.e. (n=3). Fibro-Vector vs 
Fibro-Willin: * p < 0.05; ** p < 0.01; *** p < 0.001; Student’s t-test. (B) Willin knockdown 
induces YAP, LATS1, and MST1/2 dephosphorylation. Primary fibroblasts were transfected 
with either non-targeting siRNA (siCtr) or siRNA targeting Willin (siWillin) for two 
consecutive days. Cell lysates for western blotting analysis were prepared 48h post-transfection. 
The ratios between relative YAP, LATS1, and MST1/2 phosphorylation levels to total proteins 
(YAP, LATS1, and MST1/2) are shown and background phosphorylation of Fibro-siCtr was 
arbitrarily set to 1. Immunoblot analysis of efficient Willin knockdown is also presented. β-actin 
was used as a loading control. Means were calculated from three independent experiments. 
Error bars represent ± s.e. (n=3). Fibro-siCtr vs Fibro-siWillin: * p < 0.05; ** p < 0.01; *** p < 
0.001; Student’s t-test. 
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5.4.1. Willin induces YAP, but not TAZ, cytoplasmic retention in fibroblasts 
The efficient phosphorylation of YAP at Ser127 induces cytoplasmic retention through 
binding to 14-3-3 proteins (Zhao et al., 2007). Since Willin was shown to influence the 
activation of the Hippo pathway, it was analysed whether Willin induced YAP and TAZ 
(the paralogue of YAP; (Lei et al., 2008)) nuclear-to-cytoplasmic translocation. Lysates 
from Fibro-Willin or Fibro-Vector cells were separated into cytoplasmic and nuclear 
fractions, as described in Section 2.4.3. Equal protein concentrations of the cytoplasmic 
and nuclear fractions were separated on a 10% SDS-PAGE. The subsequent PVDF 
membranes were probed with antibodies against YAP or TAZ. As expected, Willin 
expression promoted YAP sequestration in the cytoplasm. Surprisingly, the localization 
of TAZ was unaffected by Willin expression (Figure 5.7A). Moreover, investigations 
were also carried out to determine whether YAP dephosphorylation was accompanied by 
YAP sequestration in the nucleus upon Willin knockdown. In fact, YAP nuclear 
retention was observed upon Willin knockdown (Fibro-siWillin cells) when compared 
with control cells (Fibro-siCtr). However, TAZ consistently did not translocate from the 
cytoplasm to the nucleus in this scenario (Figure 5.7B). Taken together, the data suggest 
that within sciatic nerve fibroblasts, Willin is an upstream regulator of YAP but not 
TAZ. 
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Figure 5.7 – (A) Willin expression results in YAP, but not TAZ, translocation from the nucleus 
to the cytoplasm. Cytoplasmic and nuclear fractions were separated for western blot analysis as 
indicated. The blots shown are representative of three independent experiments (n=3). (B) 
Willin knockdown in primary fibroblasts sequesters YAP, but not TAZ, in the nucleus. YAP 
and TAZ subcellular location was determined by immunoblotting analysis of cytoplasmic and 
nuclear fractions. β-actin and Lamin-β were used as loading controls for the cytoplasmic and 
nuclear fractions, respectively. The blots shown are representative of three independent 
experiments (n=3). 
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5.5. Willin suppresses cellular proliferation 
During the process of tissue culture maintenance, it was noted that Fibro-Willin cells 
displayed unique morphological traits compared with either Fibro-vector or Fibro-YAP 
cells. At low cell density, while elongated cell processes characterized Fibro-vector and 
Fibro-YAP cells, these processes were absent in Fibro-Willin cells and the cells had a 
more a smooth muscle-like morphology (Figure 5.8A). However, in this scenario, the 
Fibro-Willin cells were not quiescent, but continued to grow. In addition, it was noted 
that Fibro-Willin cells, at high cell density, displayed lower coverage of the plate 
(Figure 5.8A) suggesting slower cell proliferation compared to fibroblasts expressing 
either YAP (Fibro-YAP) or an empty vector. Therefore the effect of Willin and YAP 
expression on cell proliferation was explored. Stable pools of cells were selected and 
equal numbers of cells were cultured and counted every day for 6 days (Figure 5.8B). 
Fibro-Willin cells showed a significant delay in proliferation when compared to Fibro-
YAP or Fibro-Vector cells. Interestingly, ectopic YAP expression resulted in an 
increased cellular proliferation, when compared with Fibro-Vector cells (Figure 5.8B). 
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Figure 5.8 – Ectopic expression of Willin, but not YAP, suppresses cell proliferation in the 
sciatic nerve. Primary fibroblasts were retroviral infected with Willin, YAP or an empty vector. 
Stable pools were selected and maintained in normal fibroblasts medium.  (A) Representative 
phase-contrast images of fibroblasts growing in monolayer cultures. Images were taken at high 
and low density. Scale bar at low density = 20 µm. Scale bar at high density = 50 µm. (B) 
Proliferation curves of fibroblasts stably expressing Willin, YAP or an empty vector, over a 6-
day time course, show that Willin suppresses cellular proliferation whereas YAP induces it. 
The morphology of fibroblasts upon knockdown of Willin expression was notably 
different: at low density, the Fibro-siWillin cells had elongated cell processes and a 
more pronounced flat spindle shape compared to Fibro-siCtr cells; after three days, 
Fibro-siWillin cells organized into a dense and close network of multiple interconnected 
processes protruding from the body of each cell (Figure 5.9A). This effect was 
accompanied by a 3.5 fold increase in cellular proliferation compared to Fibro-siCtr 
cells (Figure 5.9B). Collectively, these results indicate that the knockdown of Willin, 
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results in a substantial increase in cellular proliferation which resembles YAP 
overexpression in fibroblasts. Such a strong proliferation phenotype was not observed in 
MCF10A epithelial cells (Chapter 3; Angus et al., 2012). 
 
Figure 5.9 – Knockdown of the Willin expression promotes cell proliferation in the sciatic 
nerve. (A) Representative phase-contrast images of fibroblasts growing in monolayer cultures 
transfected with either non-targeting siRNA (siCtr) or siRNA targeting Willin (siWillin) for two 
consecutive days. Images were taken at low and high density. At low density, siWillin 
fibroblasts present a large and flat spindle-shape with multiple oval nucleoli with extended and 
interconnected cell processes protruding from the body of each cell. At high density, the cells 
are confluent and arranged in parallel arrays with the interconnected processes organized in a 
dense and close network. This effect is not observed in Fibro-siCtr cells. Scale bars = 20 µm. 
(B) Proliferation curve of control fibroblasts (siCtr) or knockdown Willin (siWillin) cells. Cells 
were transiently transfected with the respective siRNAs and the growth curve monitored over 4 
days. 48h after the second transfection Fibro-siWillin cells show a 3.46 fold increase in cell 
proliferation when compared with the Fibro-siCtr cells. Red arrow – experimental time point 
indicating when cells were harvested for downstream analyses. Each data point is the mean of 
three independent experiments. Error bars represent ±s.d. (n=3). Fibro-siCtr vs Fibro-siWillin: * 
p < 0.05; *** p < 0.001; Student’s t-test. 
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5.6. Willin suppresses cellular proliferation in a cell-cycle independent 
manner 
To determine if the slower proliferation rate of Fibro-Willin cells was associated with 
cell cycle changes, these cells were analyzed by flow cytometry. Fibro-Willin, Fibro-
YAP or Fibro-Vector cells were seeded at 1x106 cells (corresponding to day 2 of Figure 
5.8B), and 24h later they were pulse-labeled with BrdU for 1h and probed by flow 
cytometry (Section 2.4.2.1). Strikingly, there was no statistically significant difference 
in the number of cells residing in G0/G1, S or G2/M phases (Figure 5.10A) in any of the 
cell-types tested, suggesting that there was no cell cycle arrest in Fibro-Willin cells.  
Complementing the results observed in the overexpression scenario (Figure 5.10A), 
cells with decreased Willin expression (Fibro-siWillin), displayed no statistically 
significant difference in the number of cells observed in G0/G1, S or G2/M phases 
compared to Fibro-siCtr cells (Figure 5.10B). These observations suggest that in 
fibroblasts, as with epithelial cells, Willin suppresses cellular proliferation whilst YAP 
promotes it; however, in a cell cycle independent manner. 
CHAPTER 5 - Willin orchestrates peripheral nerve fibroblasts  
 195 
 
Figure 5.10 – Willin and YAP cell proliferation patterns are cell cycle independent. (A) Willin, 
YAP and vector-overexpressing fibroblasts were cultured to confluence. Cells at a similar 
density were pulse-labeled with 10 µM BrdU for 1h, followed by staining with anti-BrdU and 
propidium iodide (20 µg/mL for 30 min) for flow cytometry. FL2-H in the X-axis displays red 
fluorescence intensity. No statistical significant arrest of cells residing in G0/G1, S or G2/M 
phases was observed. The mean percentage of cells in the different cell cycle phases was 
determined. Error bars represent ±S.D. (n=6). (B) Willin knockdown induces cellular 
proliferation in a cell-cycle independent manner. Cells at a similar density were fixed in 70% 
ethanol and stained with propidium iodide (4 µg/mL for 30 min) for FACScan analysis. No 
statistical significant arrest of cells residing in G0/G1, S or G2/M phases was observed. The 
mean percentage of cells in the different cell cycle phases was determined. Error bars represent 
±S.D. (n=6). 
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5.7. Willin expression promotes fibroblasts migration 
Fibroblasts have an important role in wound healing, since these cells are the first to 
bridge the physical gap between the proximal and distal stumps following sciatic nerve 
transection (Scaravilli, 1984, Schroder et al., 1993). To assess the effect of Willin and 
YAP expression in promoting fibroblast wound closure, scratch assays were performed 
on confluent fibroblast monolayers and the rate of scratch closure was observed over 
16h. Representative phase-contrast images of the wound healing (scratch) assay at the 
different time points are shown in Figure 5.11A. The percentage of scratch covered was 
measured by using Image J software. Fibro-Willin cells demonstrated a faster scratch 
closure rate compared to Fibro-Vector cells (Figure 5.11A). Cell numbers were counted 
to determine whether the faster scratch closure by Fibro-Willin cells was due to 
increased cellular proliferation and/or increased directional cell migration towards the 
wound. Interestingly, there was no change in the number of Fibro-Willin cells over the 
time course of the experiment. In contrast, Fibro-YAP cells showed increased cellular 
proliferation after 16h compared to Fibro-Vector cells (Figure 5.11B). The impact of 
Willin expression on fibroblasts migration was further confirmed using Fibro-siWillin 
cells. Representative phase-contrast images of the wound healing assay at the different 
time points are shown in Figure 5.11C. The percentage of scratch covered was measured 
by using Image J software. As predicted, Fibro-siWillin cells displayed an inhibition of 
migration when compared to Fibro-siCtr cells (Figure 5.11C). Taken together, the results 
suggest that Willin expression promotes the migration of sciatic nerve derived 
fibroblasts. This migration was accomplished by the directional movement of cells at the 
border of the scratch and not due to increased cell proliferation, unlike Fibro-YAP cells. 
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Figure 5.11 – Willin expression promotes fibroblasts migration. Primary fibroblasts were 
retroviral infected with Willin, YAP or an empty vector. Stable pools were selected and 
maintained in normal fibroblasts medium. (A) Willin overexpression promotes faster cellular 
migration than YAP. Wound closure ability of fibroblasts stable cells was assessed by a wound-
healing assay. Representative phase contrast images show the wounded area (0h) and cell 
migration towards the wound after 14h and 16h. The percentage of scratch covered was 
measured by quantifying the total distance the cells moved from the edge of the scratch towards 
the center of the scratch (shown by red lines), using Image J software, followed by conversion 
to a percentage of scratch covered. Data is presented as the mean percentage of scratch covered 
in three independent experiments. Error bars represent ±S.D. (n=3). Fibro-vector vs Fibro-
Willin or Fibro-YAP: * p < 0.05; ** p < 0.01; *** p < 0.001;  One-way ANOVA and 
Bonferroni post-hoc test. (B) Willin promotion of wound closure is caused by directional cell 
migration and not by increased cell proliferation. The number of total cells in each one of the 
indicated time points was determined by cell count and the percentage of fibroblasts expressing 
vector, Willin or YAP relative to 0h assessed. Means were calculated from three independent 
experiments. Error bars represent ±S.D. (n=3). (C) Willin knockdown inhibits fibroblasts 
migration. Representative phase-contrast images of wound healing assay performed in Fibro-
siCtr or Fibro-siWillin fibroblasts show the wounded area (0h) and cell migration towards the 
wound after 16h, 20h and 40h (shown by red lines). Motility was quantified as described. Data 
is presented as the mean percentage of scratch covered in three independent experiments. Error 
bars represent ±S.D. (n=3). Fibro-sivector vs Fibro-siWillin: * p < 0.05; ** p < 0.01; *** p < 
0.001, Student’s t-test. 
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5.8. Willin is an upstream regulator of EphrinB2 and EGFR 
expression 
Previously, Parrinello and colleagues described the ephrin/Eph signalling from 
fibroblasts as being responsible for the directional axonal outgrowth of Schwann cells 
(Parrinello et al., 2010). In order to establish whether the Hippo pathway plays a role in 
ephrin/Eph signalling, the expression of ephrinB2 was analyzed in Fibro-Willin, Fibro-
YAP, and Fibro-Vector cells. Quantitative RT-PCR (Figure 5.12A) and immunoblotting 
analysis (Figure 5.12B) showed that ectopic Willin expression resulted in ephrinB2 
down-regulation whereas YAP induced ephrinB2 up-regulation, as compared to Fibro-
Vector cells. However, the decrease observed in ephrinB2 protein in Fibro-Willin cells 
was not accompanied by a statistical significant decrease in the ephrinB2 mRNA levels 
(p = 0.055; Student’s t-test), suggesting that the down-regulation resulted from post-
transcriptional changes.  
This finding was complemented by determining whether endogenous Willin regulates 
ephrinB2 expression. As predicted, knockdown of Willin in Fibro-siWillin cells resulted 
in an increase in ephrinB2 levels, both at the mRNA (Figure 5.12C) and protein levels 
(Figure 5.12D), as compared to Fibro-siCtr cells. Importantly, this expression pattern 
mimics the one observed upon YAP ectopic expression. Furthermore, the increase in 
ephrinB2 protein levels was not accompanied by a statistically significant rise in the 
ephrinB2 mRNA levels (p = 0.555; Student’s t-test). This is in agreement with the 
ephrinB2 expression observed in Fibro-Willin cells (Figure 5.12A and 5.12B). 
Previous studies have shown that activated epidermal growth factor receptor (EGFR) 
leads to increased cell migration in wound repair mediated by fibroblasts (Brown et al., 
1989, Carpenter and Cohen, 1990, Cao et al., 2006). Thus, the expression of EGFR was 
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analyzed in Fibro-Willin, Fibro-YAP, and Fibro-Vector cells by both quantitative RT-
PCR and western blotting analysis (using pre-cast polyacrylamide NuPAGE® Novex® 
4-12% Bis-Tris Gels). The observed results closely mirrored the ones observed with the 
analysis of ephrinB2 expression. Specifically, there was a down-regulation of EGFR in 
Fibro-Willin cells compared to Fibro-Vector cells, both at the mRNA (Figure 5.12A) 
and protein levels (Figure 5.12B). Conversely, comparing the Fibro-YAP cells to the 
control Fibro-Vector cells resulted in a significant increase in EGFR mRNA levels 
(Figure 5.12A), but not at the protein level (Figure 5.12B). 
Confirming the role of Willin on EGFR expression, Fibro-siWillin cells displayed a 
predicted up-regulation of EGFR as compared to Fibro-siCtr cells, both at the mRNA 
(Figure 5.12C) and protein level (Figure 5.12D). Collectively, these results show that 
Willin and YAP are upstream regulators of ephrinB2 expression. In addition, it suggests 
that the Willin-mediated directional migration may be due to EGFR down-regulation, 
whilst the increased YAP-induced cell migration might be due to EGFR up-regulation. 
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Figure 5.12 – Willin is an upstream regulator of EphrinB2 and EGFR (A) Willin expression is 
antagonistic to YAP EphrinB2 and EGFR transcriptional regulation. mRNA levels of Ephrin B2 
and EGFR were probed by quantitative real-time PCR. mRNA levels were compared with the 
empty vector control fibroblast cells (set to 1). At the transcriptional level, Willin 
overexpression decreases EGFR and to a less extend EphrinB2 whereas YAP results in an 
increase in both EphrinB2 and EGFR mRNA levels. Means were calculated from Ct values in 
six independent experiments. β-actin was used to normalize for variances in input cDNA. Error 
bars represent ±s.e. (n=6). Fibro-vector vs Fibro-Willin or Fibro-YAP for the analysed genes: * 
p < 0.05; ** p < 0.01; *** p < 0.001; Student’s t-test. Fibroblasts-vector vs Fibroblasts-Willin: 
EphrinB2 (p = 0.055); Student’s t-test. (B) Immunoblots analysis of EphrinB2 and EGFR show 
loss of expression upon ectopic Willin expression and gain of EphrinB2 expression upon YAP 
overexpression when compared to empty vector control (set to 1). β-actin was used as a loading 
control. Means were calculated from six independent experiments. Error bars represent ±s.e. 
(n=6). Fibro-vector vs Fibro-Willin or Fibro-YAP: * p < 0.05; ** p < 0.01; Student’s t-test. 
Fibroblasts-vector vs Fibroblasts-YAP: EGFR (p = 0.40); Student’s t-test. (C) EGFR mRNA 
levels are upregulated upon Willin knockdown but EphrinB2 does not show statistical 
significant change at the transcriptional level. mRNA levels of Ephrin B2 and EGFR were 
probed by quantitative real-time PCR and mRNA levels compared with the Fibro-siCtr cells (set 
to 1). Means were calculated from Ct values in six independent experiments. β-actin was used to 
normalize for variances in input cDNA. Error bars represent ±s.e. (n=6). Fibro-siCtr vs Fibro-
siWillin cells: * p < 0.05; Student’s t-test. Fibro-siCtr vs Fibro-siWillin cells: EphrinB2 (p = 
0.555); Student’s t-test. (D) Immunoblots analysis of EphrinB2 and EGFR show upregulated 
expression when Willin is knockdown. Relative expression was determined compared to 
background expression (Fibro-siCtr cells set to 1). β-actin was used as a loading control. Means 
were calculated from three independent experiments. Error bars represent ±s.e. (n=3). Fibro-
siCtr vs Fibro-siWillin cells: ** p < 0.01; *** p < 0.001; Student’s t-test. 
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5.9. Willin influences expression of some but not all genes regulated by 
YAP in sciatic nerve fibroblasts 
Previously, the Willin FERM domain was shown to be sufficient to influence the 
activity of genes regulated by YAP (Angus et al., 2012). Since the Hippo kinase cascade 
has cell-specific regulatory functions in different tissues (Zhao et al., 2011b, Ramos and 
Camargo, 2012, Zhao et al., 2012, Lin et al., 2013), some of these genes were analyzed 
to establish whether they are influenced by Willin and YAP expression in sciatic nerve 
fibroblasts. To test this hypothesis, quantitative RT-PCR analysis of CTGF, BMP2, 
FGF1, RASSF8, IGFBP3, PRL, and PDGFβ mRNA levels was conducted on Fibro-
Willin, Fibro-YAP, and Fibro-Vector cells (Figure 5.13). PRL (prolactin), among all the 
analyzed genes was the most up-regulated (by 5-fold) in Fibro-Willin cells when 
compared to Fibro-Vector cells, but down-regulated in Fibro-YAP cells. Intriguingly, 
CTGF, a direct YAP target gene in NIH-3T3 and MCF10A cells (Zhao et al., 2008a), 
was down-regulated in Fibro-YAP cells as compared to Fibro-Vector cells. Loss of 
CTGF expression was also observed in Fibro-Willin cells as compared to Fibro-Vector 
cells. Notably, FGF1 and IGFBP3 mRNA levels were significantly up-regulated in 
Fibro-Willin cells, and down-regulated in Fibro-YAP cells, when compared to Fibro-
Vector cells. Furthermore, BMP2 and RASSF8 were up-regulated in Fibro-Willin cells 
when compared to Fibro-Vector cells. Finally, PDGFβ expression mRNA levels were 
significantly down-regulated in Fibro-YAP cells compared with Fibro-Vector cells, with 
no changes in its expression levels in Fibro-Willin cells. These data demonstrate that in 
fibroblasts isolated from the sciatic nerve, Willin and YAP have antagonistic regulatory 
functions upon FGF1, RASSF8, IGBP3, and PRL genes, but other genes show context-
dependent regulation. Specifically, BMP2 expression was influenced by Willin and not 
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by YAP, while PDGFβ is influenced by YAP and not by Willin. Surprisingly, CTGF 
expression is inhibited by both Willin and YAP. 
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Figure 5.13 – Willin antagonizes some of the genes regulated by YAP in sciatic nerve 
fibroblasts. mRNA expression of the YAP target genes CTGF, BMP2, FGF1, RASSF8, 
IGFBP3, PRL, and PDGFβ was probed in fibroblasts expressing Willin or YAP by quantitative 
real-time PCR. mRNA levels were compared with the empty vector control (set to 1). Willin 
overexpression increased BMP2, FGF1, RASSF8, IGFBP3, and PRL mRNA levels and, 
together with YAP, decreased CTGF mRNA expression in these cells. Means were calculated 
from Ct values in three independent experiments. β-actin was used to normalize for variances in 
input cDNA. Error bars represent ±s.e. (n=3). Fibroblasts-vector vs Fibroblasts-Willin or 
Fibroblasts-YAP for all the analysed genes: * p < 0.05; ** p < 0.01; *** p < 0.001; One-way 
ANOVA and Bonferroni post-hoc test. Fibroblasts-vector vs Fibroblasts-YAP: BMP2 (p = 
0.217); Student’s t-test. Fibroblasts-vector vs Fibroblasts-Willin: PDGFβ (p = 0.098); Student’s 
t-test. 
The characterization of some of the genes known to be regulated by YAP and Willin in 
the context of fibroblasts isolated from the sciatic nerve highlights the concept that the 
Hippo pathway has cell-specific regulatory functions in different tissues. The induction 
or repression of Hippo pathway target genes depending on cellular context has been 
previously reported (Dong et al., 2007; Zhao et al., 2007; Hao et al., 2008; Angus et al., 
2012; Moleirinho et al., 2013a). Specifically, some of the analysed genes shown in 
Figure 5.13, display different transcriptional regulation by YAP and Willin in 
fibroblasts compared with MCF10A-YAP cells (Chapter 4). Table 5.1 summarizes these 
differences. 
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Table 5.1 – Analysis of the transcriptional regulation of some of the Hippo pathway target 
genes by Willin and YAP in Fibroblasts, and by Willin and KIBRA in MCF10A cells 
 
Legend – Green arrows represent the up-regulation of the correspondent gene whereas red 
arrows represent down-regulation of the correspondent gene. Fibroblasts-vector vs Fibroblasts-
Willin or Fibroblasts-YAP for all the analysed genes: * p < 0.05; ** p < 0.01; *** p < 0.001; 
One-way ANOVA and Bonferroni post-hoc test. MCF10A-YAP-vector vs MCF10A-YAP-
Willin or MCF10A-YAP-KIBRA for all the analysed genes: * p < 0.05; ** p < 0.01; *** p < 
0.001; One-way ANOVA and Bonferroni post-hoc test. Student’s t-test. 
 
Vector Willin YAP Vector Willin KIBRA
CTGF 1       **       ** 1       ***       **
BMP2 1
      **
No variation 1
      *       *
FGF1 1
      *       *
1
      ***       ***
RASSF8 1
      **       *
1
      **       ***
RASSF4 1 1
      *       *
IGFBP3 1
      **       **
1
      **       *
PRL 1
      ***       ***
1
ITGB2 1 1 No variation No variation
PDGFβ 1 No variation
      **
1
      ***       ***
Fibroblasts MCF10-YAP
This gene was not 
analysed in this scenario
This gene was not 
analysed in this scenario
This gene was not 
analysed in this scenario
CHAPTER 5 - Willin orchestrates peripheral nerve fibroblasts  
 207 
5.10. Discussion 
Although several advances have been made in the understanding of the emerging 
mammalian Hippo signalling pathway in its regulation of organ size control, tissue 
regeneration and stem-cell renewal (Zhao et al., 2011b; Ramos et al., 2012), little is 
known about the involvement of this pathway in the peripheral nervous system where 
Willin/FRMD6 was first identified (Gunn-Moore et al., 2005). This study establishes a 
role for Willin in mammalian peripheral nerve fibroblasts based on four findings. Firstly, 
it was found that Willin as well as other components of the Hippo signalling pathway are 
expressed in these fibroblasts. Secondly, Willin has previously been shown to activate 
the Hippo pathway in epithelial cells (Chapter 3; Chapter 4; Angus et al., 2012; 
(Moleirinho et al., 2013a) and this was extended to fibroblasts, where Willin expression 
increases MST1/2, LATS1, and YAP phosphorylation, and consequently a shift of YAP 
from the nucleus to the cytoplasm. These findings were further confirmed by 
knockdown of Willin. Thirdly, it is shown that Willin expression promotes fibroblast 
wound closure by directional migration in the absence of proliferation. Finally, it was 
found that Willin expression down-regulates ephrinB2 and EGFR (Figure 5.14). 
Initially, primary fibroblasts and Schwann cells were analysed to determine in which cell 
type, within the sciatic nerve, Willin is endogenously expressed. Willin together with the 
core Hippo pathway components MST2 and LATS1/2, were predominantly expressed in 
the rat fibroblast cells. This is in agreement with previous reports showing the 
expression of core Hippo pathway components in primary mouse fibroblasts (MEF’s) 
(Guo et al., 2007; Zhou et al. 2009). Importantly, around 40% of the fibroblasts arise 
from epithelial-to-mesenchymal transition (Iwano M, 2002, Kalluri and Zeisberg, 2006), 
and Willin was found to regulate EMT (Chapter 3; Angus et al., 2012). YAP and 
KIBRA were mainly expressed in Schwann cells. However, it should be noted that 
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fibroblasts are quite diverse in their functions in a tissue-context dependent manner, and 
YAP expression could therefore be up-regulated in fibroblasts isolated from different 
tissues. Also, the expression of different isoforms of Willin could be cell-type specific 
and future studies should address this possibility. 
Ectopic expression of Willin increased MST1/2, LATS1, and YAP Ser127 
phosphorylation levels with a subsequent shift of YAP from the nucleus to the 
cytoplasm, results further confirmed by knockdown of Willin. Accordingly, Willin has 
been shown to activate the Hippo pathway in epithelial cells (Chapter3; Chapter 4; 
Angus et al., 2012; Moleirinho et al., 2013a). Intriguingly, TAZ cytoplasmic 
translocation upon Willin overexpression was not observed. This could possibly be due 
to different roles of YAP and TAZ in rat sciatic nerve fibroblasts. Previously, species-
dependent expression of YAP or TAZ has been shown to be related to the different 
signalling pathways involved for example, in the control of the stem-like cells. 
Specifically, TAZ, but not YAP regulates human embryonic stem cells (hESC) self-
renewal, and generation of human induced pluripotent stem cells (iPSCs), but has no role 
in mouse ES cells (Varelas et al., 2008, Cordenonsi et al., 2011). On the contrary, YAP 
regulates mouse ESC self-renewal with no role in human ES cells or iPS cell generation 
(Qin et al., 2012). In fibroblasts isolated from the sciatic nerve, YAP and TAZ 
expression could therefore be regulated by different signal inputs that might change 
depending on the tissue’s needs for a fine-tuned homeostasis. 
Fibroblasts are the main mediators of the dynamic and well-organized process of wound 
healing. They accumulate at nerve injury sites (Parrinello et al., 2010), synthesize ECM 
components forming granulation tissue, and promote mechanical forces within the 
wound to initiate tissue contraction, a mechanism that leads to scar formation (Gabbiani 
et al., 1972). Several studies have shown that the change of fibroblastic cells towards the 
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myofibroblastic phenotype is essential in the physiological reconstruction of connective 
tissue, during both normal and pathological wound healing (Tomasek et al., 2002, Hinz, 
2007). Fibroblasts are also involved in angiogenesis, promoting wound vascularization 
and inflammation by secreting proinflammatory cytokines (Sorrell and Caplan, 2009). If 
extensive invasion and proliferation of scar-forming fibroblasts occurs, 
pathophysiological conditions may arise such as neuromas or hypertrophic scars 
(Burnett and Zager, 2004). During the process of tissue repair, the extracellular matrix 
goes through physical changes in terms of elasticity and cell shape. Recently YAP has 
been described as a crucial mediator of physical and mechanical cues in the cellular 
microenvironment, such that a “stiff” microenvironment activates YAP (Dupont et al., 
2011, Halder et al., 2012). Therefore, these modifications may exert mechanical signals 
that activate YAP, which would be antagonized by signals from the Hippo pathway. 
Willin expression induces wound closure in the absence of proliferation and this might 
be associated with an initial injury event. When the microenvironment becomes more 
“stiff” upon the accumulation of fibroblasts, then YAP activation would predominate, 
increasing fibroblast proliferation, inhibiting fibroblast migration, and causing increased 
Ephrin B2 and EGFR expression in the fibroblasts. Parrinello and colleagues (2010) 
(Parrinello et al., 2010) recently described that ephrinB2 ligand expression on fibroblasts 
induces activation of the EphB2 receptors located on Schwann cells. The 
ephrinB2/EphB2 signal results in an organized directional cell migration by the 
Schwann cells as it mediates their sorting in the form of multicellular cords to guide 
axons regrowth across the wound. Activation of EphB2 receptor on Schwann cells was 
found to be Sox2 dependent (Parrinello et al., 2010). Sox2 is pivotal for the maintenance 
of pluripotency and regulation of stem cell self-renewal and differentiation (Takahashi 
and Yamanaka, 2006, Chambers and Tomlinson, 2009). Interestingly, YAP has been 
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shown to regulate Sox2 in mES cells (Lian et al., 2010), and higher YAP expression in 
Schwann cells as compared to fibroblasts was observed in my analysis. Without an 
antagonizing signal, this process would continue resulting in an excess of fibroblasts. In 
fact, ephrinB2 has been found overexpressed in different fibroproliferative diseases 
(Umeda et al., 2004, Wynn, 2007). My data suggests a role for the Hippo pathway in the 
negative regulation of ephrinB2/EphB2 receptor signalling in fibroblasts, limiting 
excessive fibroblast proliferation and inappropriate Schwann cell activation by 
fibroblasts. 
Several studies have shown that EGF, by activating EGFR, leads to increased cell 
migration, a feature of tumour progression, metastasis and wound healing (Matthay et 
al., 1993, Fujii et al., 1995) but in other cell-types leads to increased cell proliferation 
(Traverse et al., 1992, Xie et al., 2012). High EGFR expression has been shown in 
wound repair of both epithelial and human skin fibroblasts by promoting cell migration 
and wound epithelialization (Carpenter and Cohen, 1990, Cao et al., 2006, Block and 
Klarlund, 2008). In these experiments, an increase in ectopic Willin expression induced 
down-regulation of EGFR, with an increase in cell migration but inhibition/delay of 
cellular proliferation, whilst a decrease in Willin expression resulted in an increase in 
EGFR expression with a inhibition/delay of cell migration but an increase in cell 
proliferation. This suggests that Willin expression can influence the level of EGFR in 
sciatic nerve fibroblasts, and that this in turn regulates the potential of over-proliferation, 
highlighting the fact that fibroblasts have different functions in a tissue-context 
dependent manner. In agreement with my observations, Merlin in mammalian cells also 
inhibits EGFR in mouse embryonic fibroblasts (MEFs) and cells undergo contact-
dependent inhibition of proliferation (Curto et al., 2007). Furthermore, in Drosophila, 
Mer and Ex mutant cells show an up-regulation of the EGFR signalling pathway (Maitra 
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et al., 2006). It is also possible to hypothesise that there may also be an element of 
feedback control, as EGF itself has been shown to influence the cellular distribution of 
Willin (Gunn-Moore et al., 2005); and recently the EGFR ligand, amphiregulin, has 
been identified as a transcriptional YAP target (Zhang et al., 2009). 
Willin induced transcriptional activation of BMP2, FGF1, IGFBP3, PRL, and RASSF8. 
Importantly, it was observed that Willin and YAP displayed opposite effects on FGF1, 
IGFBP3, RASSF8, and PRL expression. Willin increased expression, while YAP 
decreased expression of these genes. While, BMP2 and RASSF8 displayed a similar 
trend in Willin-induced up-regulation with the data presented by Moleirinho et al. (2013) 
and Angus et al. (2012) (Chapter 4, Moleirinho et al., 2013a; Angus et al., 2012), in 
epithelial MCF10A cells, FGF1, IGFBP3, and PRL were regulated by Willin expression 
but displayed the opposite trend. BMP2 has been shown to induce cell migration in 
different cell types, including MEF (Gamell et al., 2011) and its involvement in the liver 
and peripheral nerve healing response has been previously described (Tsujii et al., 2009, 
Oumi et al., 2012). The pronounced Willin-induced up-regulation of BMP2 could also 
explain the migratory pattern observed in the wound-healing assay. Expression of 
CTGF, a YAP direct target (Leask and Abraham, 2006, Zhao et al., 2008a), in tissue 
wound repair has been reported to be a major player in the pathogenesis of fibrotic 
processes (Brigstock, 1999). Its expression was found to be down regulated upon Willin 
expression. Further characterization of these and other downstream genes of Willin and 
YAP will have great impact on our understanding of the signal transduction pathway of 
the Hippo pathway in the context of wound healing analysis. 
The data shown in this chapter suggests that the Hippo signalling pathway might have a 
significant role in both the development and maintenance of the mammalian peripheral 
nervous system. Specifically it would be of great interest to explore this further in both 
CHAPTER 5 - Willin orchestrates peripheral nerve fibroblasts  
 212 
fibroblasts and Schwann cells to verify how the signalling cascade regulates ephrin/Eph 
signalling, and its ability to control wound repair and, ultimately, regeneration of the 
PNS. Figure 5.14 depicts a schematic representation of the proposed model for the 
action of Willin in primary fibroblasts isolated from the sciatic nerve. 
 
 
Figure 5.14 – Willin orchestrates sciatic nerve fibroblasts. Ectopic expression of Willin 
activates the Hippo signalling pathway and YAP translocation from the nucleus to the 
cytoplasm. It also promotes wound closure by directional migration without increased cellular 
proliferation and induces down-regulation of ephrinB2 and EGFR expression. Knockdown of 
Willin expression further supports the aforementioned findings. Image adopted from Moleirinho 
et al., 2013b. 
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J. Gunn-Moore. 2013. Willin, an upstream component of the Hippo signalling pathway, 
orchestrates mammalian peripheral nerve fibroblasts. PLoSOne. Apr 8;8(4):e60028. doi: 
10.1371/journal.pone.0060028. 
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During the last decade several studies have started to uncover the answer to a 
fundamental biological question: how is organ size controlled? Initially delineated in 
Drosophila, the Hippo signalling pathway, which is highly conserved in mammals, has 
been shown as a key player in the regulation of organ size and cell contact inhibition. 
Although the downstream components of this signalling cascade have been increasingly 
uncovered, the intricacies of the regulatory mechanisms acting upstream of the core 
kinase remain largely unknown. My study has presented strong evidence suggesting that 
both Willin and KIBRA act upstream of the mammalian Hippo pathway.  
FERM domains are found in a wide variety of proteins, but in particular they constitute 
the major, and in some cases the only, recognized functional domain present in the 
FRMDs. The general three-dimensional structure of the FERM domain is consistent 
with its proposed role as a scaffold for numerous protein-protein and protein-
phospholipid interactions. Although only partial crystal structures have been determined 
for the FERM domains of Ezrin, Radixin, and Moesin, computer aided molecular 
modelling of other FERM domains shows that high structural homology exists and three 
dimensional configurations are maintained in the FERM domains of FRMDs despite 
rather low primary sequence homology. FERM domains are unusual biochemical motifs 
in that they are able to bind a diverse range of molecules. Interestingly, while 
FRMD6/Willin has been shown to bind phospholipids, specifically to PtdIns(3)P, 
PtdIns(4)P and PtdIns(5)P, KIBRA a two N-terminus WW domains and an internal C2-
like domain was also shown to interact with this class of lipids (Kremerskothen et al., 
2003, Gunn-Moore et al., 2005). Whether binding of these upstream components to 
phospholipids is essential for modulation of their activities is currently unknown and 
future studies should explore this possibility. 
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Willin is the closest human sequence homologue of Ex, sharing 60% homology with the 
Expanded FERM domain (Chapter 1, Section 1.2.6.1). While FRMD6/Willin shares 
similar subcellular localization with Expanded, it was not able to compensate for the 
loss of Ex in Drosophila (Angus et al., 2012). The C-terminal region of Expanded 
possesses three PPXY motifs that are essential for its interaction with the WW domains 
of Yorkie (Yki) (Badouel et al., 2009). Notably, Angiomotin (AMOT) has three 
(L/P)PXY motifs (two PPXY and one LPXY), which bind to the WW domains found in 
Yes-Associated protein (YAP) (Chen et al., 1997, Kasanov et al., 2001, Pires et al., 
2001, Zhao et al., 2011a). Therefore, it is possible that the role of Ex has been split over 
evolutionary time into the combined actions of FRMD6/Willin and AMOT (Chapter 1 - 
Figure 1.9; (Yin and Zhang, 2011, Angus et al., 2012). To determine whether this 
hypothesis is a valid one, their co-expression followed by the use of functional assays 
could be performed. For example, the creation of a Willin-AMOT fusion protein would 
be useful to establish if the chimeric protein could rescue the Ex mutant phenotype in 
Drosophila. 
Even though Willin and KIBRA were shown to act upstream of the Hippo pathway, 
their action is on different downstream components of the core kinase cassette. Whilst 
Willin induces LATS1/2 phosphorylation in a MST1/2 and MOBKL1A/B dependent 
manner, KIBRA acts independently of these two core components but does induce 
LATS1/2 phosphorylation. Though both proteins localize at the plasma membrane, 
whether they regulate downstream signals in mammals by forming a complex together 
with Merlin (as in Drosophila) remains unknown. Importantly, although they both 
interact with phospholipids, several studies suggest differences in how they regulate the 
Par3-aPKC-Par6 complex. Whereas Willin regulates epithelial apical constriction 
through aPKC-mediated ROCK phosphorylation, KIBRA mediates this regulation by 
suppressing the activity of the aPKC kinase. Together with the findings showing 
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differences in the manner they induce LATS1/2 and YAP phosphorylation, an attractive 
model that can be suggested is that Willin and KIBRA are regulated by different 
membrane receptors. The bridge between the extracellular environment and the 
intracellular world has just recently begun to be elucidated. Several membrane receptors 
have been elegantly described as negative or positive regulators of the Hippo signalling 
cascade. For example, whilst CD44 attenuates activation of the Hippo pathway rather 
than promoting it, LIFR induces YAZ/TAZ phosphorylation (Stamenkovic and Yu, 
2010, Xu et al., 2010, Chen et al., 2012, Piccolo, 2012). The G-protein-coupled 
receptors (GPCRs) have been shown to signal the downstream signalling cascade 
through heterotrimetric G proteins (Yu et al., 2012; Lin et al., 2013). Gαs-coupled 
signals inhibits YAP/TAZ phosphorylation whereas Gα12/13-, Gαq/11--, or Gαi/o-
coupled signals promotes it (Yu et al., 2012; Lin et al., 2013). Since this regulatory 
mechanism in mammalian cells was shown to bypass MST1/2 kinase activity, it is 
tempting to speculate that one or several GPCRs signal through KIBRA, which also 
regulates YAP activity in a MST1/2 independent manner, to orchestrate LATS1/2 
kinase activity.  Future studies should address this crucial question. 
Concerning Willin, preliminary co-immunoprecipitation studies conducted in our lab 
have shown the potential binding between CRB3 and Willin. Both Drosophila Crumbs 
and Willin were shown to interact with the kinase aPKC. Whilst aPKC is recruited to 
the adherens junctions by the juxta-FERM domain region (JFR) of Willin, aPKC was 
shown to induce Crumbs phosphorylation. This raises the possibility that upon an 
external environmental signal, Crumbs mammalian orthologue is activated by aPKC-
mediated phosphorylation, strategically placed at the adherens junctions by Willin JFR. 
Formation of this potential complex may thus activate Willin and its concomitant 
growth regulatory effects. To test this hypothesis, it would be interesting to knockdown 
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CRB3 in cells overexpressing Willin, and to determine whether MST1/2, LATS1, and 
YAP/TAZ phosphorylation outcomes would differ from the ones reported by Angus et 
al., (2012) and Moleirinho et al. (2013a). Alternatively, since CRB3 polarity complex 
has been shown to directly bind YAP/TAZ bypassing the core kinase cassette (Varelas 
et al., 2010), it may be that CRB3 upon activation by aPKC, signals through Willin 
independently of the core cassette. This could occur as a safety feedback mechanism 
triggered in scenarios when one of the core cassette components is mutated, and thus 
preventing overgrowth. Additionally, Willin may also be involved downstream of 
GPCRs via the Hippo pathway. Since GPCRs integrate a number of diverse 
extracellular signals, cross talk with these receptors would affect many cellular 
signalling networks, including the polarity machinery. Importantly, the compensation 
study presented in Chapter 4, strongly suggests the occurrence of a potential 
compensatory feedback mechanism rather than a competitive upstream regulation 
between Willin and KIBRA. In MCF10A-shKIBRA cells, Willin endogenous 
expression was down-regulated whereas in MCF10A-shWillin cells, KIBRA expression 
levels were up-regulated. It is therefore unlikely that these two upstream components 
compete for the same upstream receptor, and that actually different membrane receptors 
signal through Willin and KIBRA to activate the core Hippo branch. Furthermore, ERM 
proteins can compensate for each other’s loss (Fehon et al., 2010). In the compensation 
study (Chapter 4), Merlin expression levels varied upon knockdown of either KIBRA or 
Willin. Although this study was not fully uncovered as variations in the phosphorylation 
levels upon knockdown of one of the upstream components were not determined, this 
finding brings a new level of complexity to this already intricate pathway. 
Willin expression was determined in two different cell-type contexts: in the epithelial 
cell line MCF10A (Chapter 3 and 4), and in primary fibroblasts isolated from rat’s 
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sciatic nerve (Chapter 5). Interestingly, although Willin promoted activation of the 
Hippo pathway in both scenarios, it induced different migratory behaviours in the 
migration assays conducted. In MCF10A epithelial cells, overexpression of Willin 
inhibited cellular migration, a hallmark of EMT, whereas in fibroblasts it promoted 
directional migration in the absence of proliferation. This highlights the view that 
proteins can exert different functions depending on both cellular and stimuli-dependent 
contexts. Altered migratory ability is observed in diverse physiological settings such as 
wound healing and tissue repair, embryonic development or immune responses. 
However, in the context of tumourigenesis and EMT, increased cellular motility has a 
different meaning. In fact, cells that acquire tumourigenic traits such as enhanced 
migratory ability are able to induce EMT resulting in epithelial cells to invade, to 
proliferate, to promote metastasis development, and potential progression into 
carcinomas. Furthermore, Willin’s transcriptional regulation of some of the Hippo 
pathway target genes further suggests cell-type dependent modulation (Chapter 5 - 
Table 5.1). Although Willin seems to have different roles depending of the cell type into 
which is being expressed, in both MCF10A cells and in sciatic nerve fibroblasts, it 
negatively regulates YAP acting as an upstream component of the Hippo core kinases. 
An important finding was the observation that Willin negatively regulates ephrinB2 
protein levels (Chapter 5). Aiming at a clear understanding of the role of Willin as well 
as the pertaining components of the Hippo pathway in the maintenance of the 
mammalian peripheral nervous system, it would be of great interest to knockdown YAP 
in Fibro-Willin cells to verify whether ephrinB2 expression levels vary. This would give 
useful insights to whether the regulation on ephrinB2 by Willin is YAP dependent or if 
it is due to off target effects. Furthermore, it would be pertinent to determine potential 
variations in the ephrinB2/Eph signalling when co-culturing primary fibroblasts and 
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Schwann cells as this scenario better mimics the physiological setting. Alternatively, it 
would be useful to analyse how Willin orchestrates other components of the ephrin 
family, as Willin may potentiate the up-regulation of other ephrins rather than ephrinB2. 
Future studies should explore these exciting avenues. 
Another important question is to what extent the three known isoforms of Willin or the 
two human isoforms of KIBRA differently regulate the Hippo pathway. This question is 
central for a clear understanding of the function of these upstream components. Taking 
human YAP1 as an example, its two major isoforms YAP1-1 and YAP1-2 have been 
shown to differently regulate some of the components of the Hippo pathway. Whereas 
YAP1-1 does not interact with angiomotin-like-1 (AMOTL1) protein, YAP1-2 does and 
it is negatively regulated by this protein (Oka et al., 2012). The intricacies of the 
regulatory mechanisms displayed by the Hippo components multiple isoforms add 
further complexity to this signalling cascade. 
In addition to the acknowledged roles of Willin and KIBRA in polarity, the question 
also still remains of whether Willin and KIBRA play a role in other signalling 
pathways. It may be possible that these upstream Hippo components cross talk with and 
integrate signals from other pathways to coordinate the processes of tissue growth and 
organ size. As an example, MST, LATS, TAZ or YAP, core components of the kinase 
cassette, have been implicated in the regulation of the Wnt and PI(3)K-mTOR pathways 
(Varelas et al., 2010, Csibi and Blenis, 2012, Tumaneng et al., 2012a, Tumaneng et al., 
2012b). 
Finally, it should be noted that modulation of the Hippo pathway has been shown to be 
cell-type specific, a concept further supported by the analysis of Willin expression in 
MCF10A cells and in primary fibroblasts (Chapter 3, 4 and 5). For example, as 
mentioned in the introduction of this thesis (Chapter 1), it has been reported that Willin 
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acts independently of the Hippo pathway in MDA-MB-231 cells overexpressing Willin, 
with no observed phosphorylation of the core kinase cassette (Visser-Grieve et al., 
2012). This is in contradiction with my findings (Chapter 3, 5 and Angus et al., 2012). 
Furthermore, YAP has been shown to have tumour suppressive functions in MCF-7 and 
MDA-MB-231 cell lines (Yuan et al., 2008). This highlights the fact that although cell 
culture analysis is of unquestionable value, histopathological and immunohistochemical 
methods applied to human primary tissue would bring pivotal information concerning 
Willin and KIBRA behaviour in the in vivo physiological setting. These methodologies 
also present limitations as for example, they do not exactly recapitulate the cellular 
microenvironment. Following this line of thought, the best model to accurately 
determine the functions of these two upstream components would be by generating 
transgenic Willin and KIBRA knock-out mice, and future studies should address these 
possibilities. In addition, Genome Wide Analysis Studies (GWAS) studies are 
beginning to link the activities of Hippo components including FERM proteins to 
diverse disease settings, including diabetes, cancer, and Alzheimer’s (Stein et al., 2010, 
Hong et al., 2012, Moleirinho et al., 2013a). Future studies should elucidate both the 
biochemistry and the pathophysiology of these proteins in order to link their functional 
roles to defects in disease. 
The Hippo signalling pathway is currently acknowledged as one of the central players in 
the orchestration of normal and pathological physiology in mammals. Although many 
pieces are still missing, in the next few years one could expect important advances not 
only in solving the conundrum of organ size control, but also in the discovery of new 
therapeutics targets for treatment of diseases such as cancer and atrophy. 
Figure 6.1 displays a detailed and updated representation of the mammalian Hippo 
pathway, including the findings presented in this thesis. 
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Figure 6.1 – The mammalian Hippo signalling pathway. Putative oncoproteins are shown in 
brown and putative tumour suppressors are shown in light green. Cell membrane receptors are 
shown in light brown. Black arrows represent described regulations whilst dashed arrows 
represent potential but not yet fully described interactions. The two major findings of this thesis 
concerning Willin and KIBRA upstream regulation of YAP are shown by red arrows. 
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A.1. – Human Willin Sequences 
Amino acid Sequence 
Full-length cDNA clone Image: 3941276 (Accession No.: BC020521). Open Reading 
Frame 31 Chromosome 14 from the human genome. 
NCBI Reference Sequence: NP_001035946.1 
MNKLNFHNNRVMQDRRSVCIFLPNDESLNIIINVKILCHQLLVQVCDLLRLKDCHLFGLSVIQNNEHVYMELSQKLYK
YCPKEWKKEASKGIDQFGPPMIIHFRVQYYVENGRLISDRAARYYYYWHLRKQVLHSQCVLREEAYFLLAAFALQADL
GNFKRNKHYGKYFEPEAYFPSWVVSKRGKDYILKHIPNMHKDQFALTASEAHLKYIKEAVRLDDVAVHYYRLYKDKRE
IEASLTLGLTMRGIQIFQNLDEEKQLLYDFPWTNVGKLVFVGKKFEILPDGLPSARKLIYYTGCPMRSRHLLQLLSNS
HRLYMNLQPVLRHIRKLEENEEKKQYRESYISDNLDLDMDQLEKRSRASGSSAGSMKHKRLSRHSTASHSSSHTSGIE
ADTKPRDTGPEDSYSSSAIHRKLKTCSSMTSHGSSHTSGVESGGKDRLEEDLQDDEIEMLVDDPRDLEQMNEESLEVS
PDMCIYITEDMLMSRKLNGHSGLIVKEIGSSTSSSSETVVKLRGQSTDSLPQTICRKPKTSTDRHSLSLDDIRLYQKD
FLRIAGLCQDTAQSYTFGCGHELDEEGLYCNSCLAQQCINIQDAFPVKRTSKYFSLDLTHDEVPEFVV 
 
Nucleotide Sequence 
NCBI Reference Sequence: NM_001042481.2 (5066 bp; coding sequence: bp 510-
2354) 
ATGAACAAATTGAATTTTCATAACAACAGAGTCATGCAAGACCGCCGCAGTGTGTGCATTTTCCTTCCCAACGATGAA
TCTCTGAACATCATCATAAATGTTAAGATTCTGTGTCACCAGTTGCTGGTCCAGGTTTGTGACCTGCTCAGGCTAAAG
GACTGCCACCTCTTTGGACTCAGTGTTATACAAAATAATGAACATGTGTATATGGAGTTGTCACAAAAGCTTTACAAA
TATTGTCCAAAAGAATGGAAGAAAGAGGCCAGCAAGGGTATCGACCAATTTGGGCCTCCTATGATCATCCACTTCCGT
GTGCAGTACTATGTGGAAAATGGCAGATTGATCAGTGACAGAGCAGCAAGATACTATTATTACTGGCACCTGAGAAAA
CAAGTTCTTCATTCTCAGTGTGTGCTCCGAGAGGAGGCCTACTTCCTGCTGGCAGCCTTTGCCCTGCAGGCTGATCTT
GGGAACTTCAAAAGGAATAAGCACTATGGAAAATACTTCGAGCCAGAGGCTTACTTCCCATCTTGGGTTGTTTCCAAG
AGGGGGAAGGACTACATCCTGAAGCACATTCCAAACATGCACAAAGATCAGTTTGCACTAACAGCTTCCGAAGCTCAT
CTTAAATATATCAAAGAGGCTGTCCGACTGGATGACGTCGCTGTTCATTACTACAGATTGTATAAGGATAAAAGGGAA
ATTGAAGCATCGCTGACTCTTGGATTGACCATGAGGGGAATACAGATTTTTCAGAATTTAGATGAAGAGAAACAATTA
CTTTATGATTTCCCCTGGACAAATGTTGGAAAATTGGTGTTTGTGGGTAAGAAATTTGAGATTTTGCCAGATGGCTTG
CCTTCTGCCCGGAAGCTCATATACTACACGGGGTGCCCCATGCGCTCCAGACACCTCCTGCAACTTCTGAGCAACAGC
CACCGCCTCTATATGAATCTGCAGCCTGTCCTGCGCCATATCCGGAAGCTGGAGGAAAACGAAGAGAAGAAGCAGTAC
CGGGAATCTTACATCAGTGACAACCTGGACCTCGACATGGACCAGCTGGAAAAACGGTCGCGGGCCAGCGGGAGCAGT
GCGGGCAGCATGAAACACAAGCGCCTGTCCCGTCATTCCACCGCCAGCCACAGCAGTTCCCACACCTCGGGCATTGAG
GCAGACACCAAGCCCCGGGACACGGGGCCAGAAGACAGCTACTCCAGCAGTGCCATCCACCGCAAGCTGAAAACCTGC
AGCTCAATGACCAGTCATGGCAGCTCCCACACCTCAGGGGTGGAGAGTGGCGGCAAAGACCGGCTGGAAGAGGACTTA
CAGGACGATGAAATAGAGATGTTGGTTGATGACCCCCGGGATCTGGAGCAGATGAATGAAGAGTCTCTGGAAGTCAGC
CCAGACATGTGCATCTACATCACAGAGGACATGCTCATGTCGCGGAAGCTGAATGGACACTCTGGGTTGATTGTGAAA
GAAATTGGGTCTTCCACCTCGAGCTCTTCAGAAACAGTTGTTAAGCTTCGTGGCCAGAGTACTGATTCTCTTCCACAG
ACTATATGTCGGAAACCAAAGACCTCCACTGATCGACACAGCTTGAGCCTCGATGACATCAGACTTTACCAGAAAGAC
TTCCTGCGCATTGCAGGTCTGTGTCAGGACACTGCTCAGAGTTACACCTTTGGATGTGGCCATGAACTGGATGAGGAA
GGCCTCTATTGCAACAGTTGCTTGGCCCAGCAGTGCATCAACATCCAAGATGCTTTTCCAGTCAAAAGAACCAGCAAA
TACTTTTCTCTGGATCTCACTCATGATGAAGTTCCAGAGTTTGTTGTGTAA 
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A.2. – Human KIBRA Sequences 
Amino acid Sequence 
Full-length cDNA clone Image: 100063148 (Accession No.: BC156527.1). 
Chromosome 5q34 from the human genome. 
NCBI Reference Sequence: NP_056053.1 
MPRPELPLPEGWEEARDFDGKVYYIDHTNRTTSWIDPRDRYTKPLTFADCISDELPLGWEEAYDPQVGDYFIDHNTKT
TQIEDPRVQWRREQEHMLKDYLVVAQEALSAQKEIYQVKQQRLELAQQEYQQLHAVWEHKLGSQVSLVSGSSSSSKYD
PEILKAEIATAKSRVNKLKREMVHLQHELQFKERGFQTLKKIDKKMSDAQGSYKLDEAQAVLRETKAIKKAITCGEKE
KQDLIKSLAMLKDGFRTDRGSHSDLWSSSSSLESSSFPLPKQYLDVSSQTDISGSFGINSNNQLAEKVRLRLRYEEAK
RRIANLKIQLAKLDSEAWPGVLDSERDRLILINEKEELLKEMRFISPRKWTQGEVEQLEMARKRLEKDLQAARDTQSK
ALTERLKLNSKRNQLVRELEEATRQVATLHSQLKSLSSSMQSLSSGSSPGSLTSSRGSLVASSLDSSTSASFTDLYYD
PFEQLDSELQSKVEFLLLEGATGFRPSGCITTIHEDEVAKTQKAEGGGRLQALRSLSGTPKSMTSLSPRSSLSSPSPP
CSPLMADPLLAGDAFLNSLEFEDPELSATLCELSLGNSAQERYRLEEPGTEGKQLGQAVNTAQGCGLKVACVSAAVSD
ESVAGDSGVYEASVQRLGASEAAAFDSDESEAVGATRIQIALKYDEKNKQFAILIIQLSNLSALLQQQDQKVNIRVAV
LPCSESTTCLFRTRPLDASDTLVFNEVFWVSMSYPALHQKTLRVDVCTTDRSHLEECLGGAQISLAEVCRSGERSTRW
YNLLSYKYLKKQSRELKPVGVMAPASGPASTDAVSALLEQTAVELEKRQEGRSSTQTLEDSWRYEETSENEAVAEEEE
EEVEEEEGEEDVFTEKASPDMDGYPALKVDKETNTETPAPSPTVVRPKDRRVGTPSQGPFLRGSTIIRSKTFSPGPQS
QYVCRLNRSDSDSSTLSKKPPFVRNSLERRSVRMKRPSPPPQPSSVKSLRSERLIRTSLDLELDLQATRTWHSQLTQE
ISVLKELKEQLEQAKSHGEKELPQWLREDERFRLLLRMLEKRQMDRAEHKGELQTDKMMRAAAKDVHRLRGQSCKEPP
EVQSFREKMAFFTRPRMNIPALSADDV 
 
Nucleotide Sequence 
NCBI Reference Sequence:  NM_015238.2 (6735 bp; coding sequence: bp 94-3445) 
ATGCCCCGGCCGGAGCTGCCCCTGCCGGAGGGCTGGGAGGAGGCGCGCGACTTCGACGGCAAGGTCTACTACATAGAC
CACACGAACCGCACCACCAGCTGGATCGACCCGCGGGACAGGTACACCAAACCGCTCACCTTTGCTGACTGCATTAGT
GATGAGTTGCCGCTAGGATGGGAAGAGGCATATGACCCACAGGTTGGAGATTACTTCATAGACCACAACACCAAAACC
ACTCAGATTGAGGATCCTCGAGTACAATGGCGGCGGGAGCAGGAACATATGCTGAAGGATTACCTGGTGGTGGCCCAG
GAGGCTCTGAGTGCACAAAAGGAGATCTACCAGGTGAAGCAGCAGCGCCTGGAGCTTGCACAGCAGGAGTACCAGCAA
CTGCATGCCGTCTGGGAGCATAAGCTGGGCTCCCAGGTCAGCTTGGTCTCTGGTTCATCATCCAGCTCCAAGTATGAC
CCTGAGATCCTGAAAGCTGAAATTGCCACTGCAAAATCCCGGGTCAACAAGCTGAAGAGAGAGATGGTTCACCTCCAG
CACGAGCTGCAGTTCAAAGAGCGTGGCTTTCAGACCCTGAAGAAAATCGATAAGAAAATGTCTGATGCTCAGGGCAGC
TACAAACTGGATGAAGCTCAGGCTGTCTTGAGAGAAACAAAAGCCATCAAAAAGGCTATTACCTGTGGGGAAAAGGAA
AAGCAAGATCTCATTAAGAGCCTTGCCATGTTGAAGGACGGCTTCCGCACTGACAGGGGGTCTCACTCAGACCTGTGG
TCCAGCAGCAGCTCTCTGGAGAGTTCGAGTTTCCCGCTACCGAAACAGTACCTGGATGTGAGCTCCCAGACAGACATC
TCGGGAAGCTTCGGCATCAACAGCAACAATCAGTTGGCAGAGAAGGTCAGATTGCGCCTTCGATATGAAGAGGCTAAG
AGAAGGATCGCCAACCTGAAGATCCAGCTGGCCAAGCTTGACAGTGAGGCCTGGCCTGGGGTGCTGGACTCAGAGAGG
GACCGGCTGATCCTTATCAACGAGAAGGAGGAGCTGCTGAAGGAGATGCGCTTCATCAGCCCCCGCAAGTGGACCCAG
GGGGAGGTGGAGCAGCTGGAGATGGCCCGGAAGCGGCTGGAAAAGGACCTGCAGGCAGCCCGGGACACCCAGAGCAAG
GCGCTGACGGAGAGGTTAAAGTTAAACAGTAAGAGGAACCAGCTTGTGAGAGAACTGGAGGAAGCCACCCGGCAGGTG
GCAACTCTGCACTCCCAGCTGAAAAGTCTCTCAAGCAGCATGCAGTCCCTGTCCTCAGGCAGCAGCCCCGGATCCCTC
ACGTCCAGCCGGGGCTCCCTGGTTGCATCCAGCCTGGACTCCTCCACTTCAGCCAGCTTCACTGACCTCTACTATGAC
CCCTTTGAGCAGCTGGACTCAGAGCTGCAGAGCAAGGTGGAGTTCCTGCTCCTGGAGGGGGCCACCGGCTTCCGGCCC
TCAGGCTGCATCACCACCATCCACGAGGATGAGGTGGCCAAGACCCAGAAGGCAGAGGGAGGTGGCCGCCTGCAGGCT
CTGCGTTCCCTGTCTGGCACCCCAAAGTCCATGACCTCCCTATCCCCACGTTCCTCTCTCTCCTCCCCCTCCCCACCC
TGTTCCCCTCTCATGGCTGACCCCCTCCTGGCTGGTGATGCCTTCCTCAACTCCTTGGAGTTTGAAGACCCGGAGCTG
AGTGCCACTCTTTGTGAACTGAGCCTTGGTAACAGCGCCCAGGAAAGATACCGGCTGGAGGAACCAGGAACGGAGGGC
AAGCAGCTGGGCCAAGCTGTGAATACGGCCCAGGGGTGTGGCCTGAAAGTGGCCTGTGTCTCAGCCGCCGTATCGGAC
GAGTCAGTGGCTGGAGACAGTGGTGTGTACGAGGCTTCCGTGCAGAGACTGGGTGCTTCAGAAGCTGCTGCATTTGAC
AGTGACGAATCGGAAGCAGTGGGTGCGACCCGAATTCAGATTGCCCTGAAGTATGATGAGAAGAATAAGCAATTTGCA
ATATTAATCATCCAGCTGAGTAACCTTTCTGCTCTGTTGCAGCAACAAGACCAGAAAGTGAATATCCGCGTGGCTGTC
CTTCCTTGCTCTGAAAGCACAACCTGCCTGTTCCGGACCCGGCCTCTGGACGCCTCAGACACTCTAGTGTTCAATGAG
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GTGTTCTGGGTATCCATGTCCTATCCAGCCCTTCACCAGAAGACCTTAAGAGTCGATGTCTGTACCACCGACAGGAGC
CATCTGGAAGAGTGCCTGGGAGGCGCCCAGATCAGCCTGGCGGAGGTCTGCCGGTCTGGGGAGAGGTCGACTCGCTGG
TACAACCTTCTCAGCTACAAATACTTGAAGAAACAGAGCAGGGAGCTCAAGCCAGTGGGAGTCATGGCCCCTGCCTCA
GGGCCTGCCAGCACGGACGCTGTGTCTGCTCTGTTGGAACAGACAGCAGTGGAGCTGGAGAAGAGGCAGGAGGGCAGG
AGCAGCACACAGACACTGGAAGACAGCTGGAGGTATGAGGAGACCAGTGAGAATGAGGCAGTAGCCGAGGAAGAGGAG
GAGGAGGTGGAGGAGGAGGAGGGAGAAGAGGATGTTTTCACCGAGAAAGCCTCACCTGATATGGATGGGTACCCAGCA
TTAAAGGTGGACAAAGAGACCAACACGGAGACCCCGGCCCCATCCCCCACAGTGGTGCGACCTAAGGACCGGAGAGTG
GGCACCCCGTCCCAGGGGCCATTTCTTCGAGGGAGCACCATCATCCGCTCTAAGACCTTCTCCCCAGGACCCCAGAGC
CAGTACGTGTGCCGGCTGAATCGGAGTGATAGTGACAGCTCCACTCTGTCCAAAAAGCCACCTTTTGTTCGAAACTCC
CTGGAGCGACGCAGCGTCCGGATGAAGCGGCCGTCCCCACCCCCACAGCCTTCCTCGGTCAAGTCGCTGCGCTCCGAG
CGTCTGATCCGTACCTCGCTGGACCTGGAGTTAGACCTGCAGGCGACAAGAACCTGGCACAGCCAATTGACCCAGGAG
ATCTCGGTGCTGAAGGAGCTCAAGGAGCAGCTGGAACAAGCCAAGAGCCACGGGGAGAAGGAGCTGCCACAGTGGTTG
CGTGAGGACGAGCGTTTCCGCCTGCTGCTGAGGATGCTGGAGAAGCGGCAGATGGACCGAGCGGAGCACAAGGGTGAG
CTTCAGACAGACAAGATGATGAGGGCAGCTGCCAAGGATGTGCACAGGCTCCGAGGCCAGAGCTGTAAGGAACCCCCA
GAAGTTCAGTCTTTCAGGGAGAAGATGGCATTTTTCACCCGGCCTCGGATGAATATCCCAGCTCTCTCTGCAGATGAC
GTCTAA 
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A.3. - Plasmids 
	  
Figure A.1 – Plasmid map of pLKO.1puro empty backbone vector. An AgeI/EcoRI restriction 
digest reaction was performed on 1µg of CIAP treated lentiviral vector pLKO.1puro generating 
a two site digested plasmid with sticky-ends compatible with target short-hairpin RNA 
oligonucleotides. 
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Figure A.2 – Map of pLKO.1 containing an shRNA insert. (A) The original pLKO.1-TRC 
cloning vector (Plasmid 10878, Addgene) has a 1.9kb stuffer that is released by digestion with 
AgeI and EcoRI. shRNA oligos were cloned into the AgeI and EcoRI sites in place of the 
stuffer. The AgeI site is destroyed in most cases (depending on the target sequence), while the 
EcoRI site is preserved. The oligos of interest contain the shRNA sequence flanked by 
sequences that are compatible with the sticky ends of AgeI and EcoRI. (B) Suitable 21-mer 
targets in Willin, KIBRA, Merlin, and MST1 genes were generate for cloning into pLKO.1puro. 
Forward and reverse oligos were designed as follows: FW-5’CCGG—21bp sense—
CTCGAG—21bp antisense—TTTTTG 3’; RV-5’ AATTCAAAAA—21bp sense—
CTCGAG—21bp antisense 3’. (C) Forward and reverse oligos were annealed and ligated into 
the pLKO.1puro vector, producing a final plasmid that expresses the shRNA of interest. The 
figure displays the main knockdown plasmids produced during the PhD course: pLKO.1puro-
shWillin-A, pLKO.1puro-shWillin-B, pLKO.1puro-shKIBRA-A, and pLKO.1puro-shKIBRA-
B. 
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Table B.1 – Sequences of the Primers used in qRT-PCR 
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C.1. Primary Antibodies for Western Blotting 
Table C.1 – Primary Antibodies: dilutions, conditions, hosts, and suppliers for Western 
Blotting. 
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* SignalBoost Immunoreaction Enhancer Kit (Calbiochem, #407207). 
** Willin rabbit polyclonal antibody was generated against the unique sequence 
KEASKGIDQFGPPMIIHC of Willin (residues 86–102) which was also used to affinity purify 
the antibody from the resulting serum. 
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C.2. Primary Antibodies for Flow Cytometry and Immunofluorescence 
Table C.2 – Primary Antibodies: concentrations, conditions, hosts, and suppliers for 
Flow Cytometry (FC) and Immunofluorescence (IF). 
 
N/A – Not-Applicable. 
Antibody Host Supplier
FC IF
E-Cadherin
3%
(v/v) N/A Mouse BD Biosciences
N-Cadherin
3%
(v/v) N/A Mouse BD Biosciences
Vimentin
3%
(v/v) N/A Mouse BD Biosciences
Occludin
3.5%
(v/v) N/A Mouse Invitrogen
Alexa Fluor® 568 
Phalloidin N/A 1:100 N/A Invitrogen
BrdU
3%
(v/v) N/A N/A BD Biosciences
Propidium iodide 4µg/mL N/A N/A Sigma-Aldrich
Concentration
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C.3. Secondary Antibodies 
Table C.3 – Secondary Antibodies: concentrations, hosts and suppliers for Western 
Blotting (WB) and Flow Cytometry (FC). 
	  
N/A – Not-Applicable. 
 
Antibody Target Supplier
WB FC
Affinipure HRP 
goat 1:10 000 N/A Mouse IgG
Jackson 
ImmunoResearch
Affinipure HRP 
goat 1:10 000 N/A Rabbit IgG
Jackson 
ImmunoResearch
Goat Dylight 488 N/A
3% 
(v/v) Mouse IgG
Jackson 
ImmunoResearch
(#115-485-062)
Goat-FITC N/A 2 µg/mL Mouse IgG Sigma-Aldrich
Concentration
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Abstract
Willin/FRMD6 was first identified in the rat sciatic nerve, which is composed of neurons, Schwann cells, and fibroblasts. Willin
is an upstream component of the Hippo signaling pathway, which results in the inactivation of the transcriptional co-
activator YAP through Ser127 phosphorylation. This in turn suppresses the expression of genes involved in cell growth,
proliferation and cancer development ensuring the control of organ size, cell contact inhibition and apoptosis. Here we
show that in the mammalian sciatic nerve, Willin is predominantly expressed in fibroblasts and that Willin expression
activates the Hippo signaling cascade and induces YAP translocation from the nucleus to the cytoplasm. In addition within
these cells, although it inhibits cellular proliferation, Willin expression induces a quicker directional migration towards
scratch closure and an increased expression of factors linked to nerve regeneration. These results show that Willin
modulates sciatic nerve fibroblast activity indicating that Willin may have a potential role in the regeneration of the
peripheral nervous system.
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Introduction
The Salvador/Warts/Hippo (Hippo) signaling pathway controls
tissue growth and organ size by promoting a normal fine tuned
homeostasis. Originally characterized in Drosophila melanogaster, this
pathway limits overgrowth, which may lead to cancer develop-
ment by inhibiting cell proliferation and promoting apoptosis [1–
4]. Highly conserved, the Drosophila Hippo pathway core
components and downstream effectors have direct orthologues in
mammals. This functional conservation is confirmed by the ability
of mammal orthologues to rescue Drosophila mutants in vivo; the
core components Hpo, Sav, Wts and Mats have respective
vertebrate homologues MST1 and MST2, WW45 (also known as
Sav1), the kinases LATS1 and LATS2 and MOB1 (MOBKL1A/
B). The main targets of the mammalian Hippo signaling cascade
are the two Drosophila Yki orthologues, Yes-associated protein
(YAP) and the transcriptional coactivator with PDZ binding motifs
(TAZ). Mimicking the regulation process observed in Drosophila
Yki when in the presence of high cell densities, LATS
phosphorylates YAP at Ser127 and TAZ at Ser89 creating
a protein 14-3-3 binding site, which in turn leads to YAP/TAZ
cytoplasmic localization. Defects in the Hippo pathway lead to
a lack of YAP/TAZ cytoplasmic sequestration which results in
YAP/TAZ nuclear accumulation and, eventually, in tumour
development [5–8] Indeed, we and others have previously
described that deregulation of the Hippo signaling cascade
components results in YAP dephosphorylation, nuclear sequestra-
tion and overgrowth [4,9–15]. Less is known about the upstream
components of the core kinase cassette. Merlin, KIBRA (WWC1)
and Willin (FRMD6) have been shown to be upstream of MST1/2
and to be able to induce LATS and YAP phosphorylation
[9,11,16–19]. Yet, so far only Merlin is functionally validated
in vivo, although recently we showed that reduced KIBRA
expression in primary breast cancer specimens correlates with
the claudin-low subtype [11].
Several lines of research have established a new role for the
Hippo signaling pathway in tissue regeneration. Tissue repair,
after a major injury, relies on the expansion and/or dedifferen-
tiation of an existing population of progenitor cells, such as
primary satellite cells [20] which may recapitulate the develop-
mental process involving the reprogramming of diverse molecular
mechanisms [21]. Here, repression of pathways involved in
developmental tissue growth, such as the Hippo kinase cascade,
induces YAP stemness properties by promoting a controlled cell
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proliferation aiming restore of organ function [22,23]. Regener-
ation of the peripheral nerve is a dynamic process initiated by
Schwann cells and the extracellular matrix, which confers a growth
promoting environment to peripheral axons. The signal trans-
mitted by damaged axons to Schwann cells informing them of
their intention to degenerate is mediated by Raf/MEK/ERK
signaling pathway and triggers myelinated Schwann cells to
dedifferentiate to a progenitor-like cell [24,25]. Regrowing axons
and Schwann cells migrate towards the nerve gap to promote
reinnervation of the distal stump, and relies on signals mediated by
both the ephrin/Eph pathway and fibroblasts [26].
Willin (FRMD6) was first identified in the rat sciatic nerve [27]
which is composed of neurons, Schwann cells and fibroblasts, and
is the nearest human sequence homologue to the Drosophila protein
Expanded (Ex) sharing 60% of homology with the Ex FERM
domain. In Drosophila, the lack of Ex expression has been shown to
be associated with overgrowth of certain structures such as the
wing and imaginal discs [28] reflecting a direct role in controlling
cell growth in these tissues. In mammals, recently the FERM
domain of Willin was shown to be sufficient to activate the Hippo
pathway via MST1/2 and to antagonize YAP-induced phenotypes
in mammalian cells [9]. Willin activated the Hippo pathway,
inducing the phosphorylation of MST1/2, LATS1 and YAP in
MCF10A and 293T cells. Knockdown of Willin expression
mimicked YAP overexpression with respect to inducing an
Epithelial-Mesenchymal transition (EMT) phenotype in MCF10A
cells [9]. As Willin was first identified within the mammalian
sciatic nerve, we sought what its functions could be within this
structure and whether it shares the same functionalities as in
epithelial cells. We show that in mammalian peripheral nerve
fibroblasts Willin expression can control the phosphorylation of
MST1/2, LATS1 and YAP and thereby YAP’s translocation from
the nucleus to the cytoplasm. We also demonstrate that activation
of the Hippo pathway is an upstream regulator of ephrinB/EphB
signaling and EGFR, which are known factors to be involved in
nerve regeneration, and in addition we show that Willin
expression can control the rate at which wounds may close.
Therefore our results demonstrate that Willin and the Hippo
kinase cassette play a role in the maintenance of peripheral nerve
system homeostasis.
Materials and Methods
Schwann Cells and Fibroblasts Purification
Schwann Cells (SC) were purified using a modification of the
method described by Brockes and colleagues [29]. All procedures
were carried out in accordance with the guidelines, set forth by the
Animals Scientific Procedures Act under schedule 1 procedures.
Mice had access to food and water, ad libitum. Furthermore, all
procedures were carried out in accordance with the guidelines, set
forth by the Animals Scientific Procedures Act, under a project
license (No. 6003895) granted by the UK Home Office and with
the approval of the University of Glasgow Ethical Review Process
Applications Panel. Briefly, sciatic nerve was dissected from
neonatal P7 Sprague-Dawley pups. The tissue was minced finely
and enzymatically digested with trypsin (100 ml of 2.5%,
Invitrogen) and collagenase 500 ml collagenase (1.33%; ICN
Pharmaceuticals). The mixed cell population was cultured in
10% FBS without specific SC mitogens for approximately 48 hrs
before the addition of cytosine arabinoside (AraC, 1025 M, Sigma,
Dorset, UK) for a further 48 hrs to eliminate rapidly dividing
fibroblasts. Further purification was then carried out by trypsinis-
ing the cells and resuspending them in a small volume of serum
free media with anti-Thy1.1 antibody at room temperature for
15 min (1:50 supernatant, Sigma, Dorset, UK), followed by the
addition of rabbit complement (1:4, Harlan Laboratories Ltd.,
UK) for 45 min at 37uC [30]. All cell cultures were grown in PLL
coated tissue culture flasks. To isolate fibroblast from sciatic nerve
a culture was set up as described above but the fibroblasts were not
removed by the Thy1.1 complement-mediated kill. The cultures
were fed with 10% FBS and the fibroblast over grew the Schwann
cells.
Cell Culture
Purified Schwann cells were grown in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% foetal bovine
serum, 2 mM L-glutamine, 100 mg/ml streptomycin, 100 units
penicillin/ml, 10 mM forskolin and 20 ng/ml heregulin b1 (R&D
Systems, Europe, Oxon, UK). Purified fibroblasts were grown in
DMEM supplemented with 20% foetal bovine serum, 2 mM L-
glutamine, 100 mg/ml streptomycin, 100 units penicillin/ml. Both
cell types were grow in a humidified incubator at 37uC with 5%
CO2. All experiments were carried out between passage 4 and 18.
Plasmid Construction
The human Willin-HA ORF was cloned into the pBABEpuro
vector (pBabe-puro, Addgene, Cambridge, MA, USA) as an
BamHI-EcoRI fragment. The human pBABE-YAP1-Flag (Ad-
dgene plasmid 15682) expression clone was described previously
(Overholtzer et al., 2006; Angus et al., 2012). pBABE constructs
were packaged in PhoenixA cells for viral production. Retroviral
infection of primary fibroblasts was performed accordingly
standard protocols. The transduced cells were selected, after
24hours, with 2.5 mg/mL puromycin or with 300 mg/mL
hygromycin. The selections continued for 5 days (puromycin) or
10 days (hygromycin) after which cells were harvested for
downstream experiments. siRNA targeting Willin/FRMD6 (ID
#s141256) and a non-targeting siRNA control (ID #4390844
(Ambion, Warrington, UK) were transfected at a concentration of
20 nM, using Lipofectamine 2000 (Invitrogen, Paisley, UK),
according to the manufacturer’s instructions and as described
previously ([7,9,11] Moleirinho et al., 2012; Angus et al., 2012;
Zhang et al., 2008).
In situ Hybridization
In situ hybridization was performed with cRNA probes on sciatic
nerves of 21 day old mice as previously described [31]. Briefly,
RNA was prepared by TRIZOL extraction (Life Technologies) for
RT-PCR. Reverse transcription was performed with 1 mg of RNA
using SuperScriptTMII reverse transcriptase (400 U; Life Tech-
nologies) in the presence of random hexamers (Life Technologies).
After incubation at 42uC for 45 min, reactions were terminated by
heating at 80uC. DNA in 1 ml of the first strand reaction was
amplified by PCR with Dynazyme (Flowgen). Primer sequences
were selected from the published neurofascin (ankyrin-binding
protein) sequence (available from Gen- Bank/EMBL/DDBJ
under accession No. L11002) [32], that would specifically amplify
product from the 155- splice variant of neurofascin. A probe
specific for NF155 was amplified from within the third FNIII
domain of neurofascin with a forward primer, 59-CCTGAACAG-
CACAGCCATCAG-39 (nucleotides 3,550–3,570) and a reverse
primer 59-GACCACAACCATCTCCTGCTTG-39 (nucleotides
3,775–3,754). The products were cloned into the pGEM-T vector
(Promega) and sequenced. The cDNA templates were linearized
with either NotI or NcoI and transcribed with either T7 (antisense
probes) or SP6 RNA (sense probes) polymerases (Boehringer
Mannheim), respectively. Probes specific for Willin were made
using the plasmid pSPORT-Willin using the T7 promoter for
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Figure 1. Willin is mainly expressed in primary fibroblasts within the sciatic nerve. (A) Differential expression of Neurofascin 155 and Willin
transcripts in rat PNS. Rat sciatic nerve sections were hybridized with riboprobes specific for NF155 or Willin and viewed by dark-field microscope.
NF155 transcripts were dispersed around the sciatic nerve, consistent with Schwann cells location at the endoneurium. A robust expression of Willin
mRNA was observed at the perineurium suggesting that Willin is expressed in a different population of cells within the sciatic nerve. (B) Pure
Schwann cells and fibroblasts cultures isolated from the sciatic nerve present distinct morphologies. Representative phase-contrast images of cells
growing in monolayers cultures further confirmed the successful isolation of pure Schwann cells and fibroblasts populations. (C) The hippo signaling
pathway is present in the sciatic nerve. mRNA expression of the Hippo pathway components Willin, MST1/2, LATS1 and YAP was determined by
quantitative real-time PCR in fibroblasts cells. mRNA levels were compared with Schwann cells (SC set to 1). Willin, MST2, LATS1 mRNA levels are
increased in the fibroblasts whereas YAP mRNA expression decreases in these cells. Means were calculated from Ct values in three independent
experiments. b-actin was used to normalize for variances in input cDNA. Error bars represent 6s.e. (n=3). Schwann cells vs fibroblasts for all the
analyzed genes: *p,0.05; **p,0.01; ***p,0.001, Student’s t-test. Schwann cells vs fibroblasts: MST1 (p = 0.75); Student’s t-test.
doi:10.1371/journal.pone.0060028.g001
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sense and the SP6 promoter for antisense probes. For cloning into
pSPORT: sense 59-ATAAGAATGCGGCCGCTTTCAG-
GATGTAGTCCTTCC-39 and anti-sense 59-TTACGCGTC-
GACATGCAGGACCGCCGCAGAGTG-39 were used for
PCR using the 163SciII clone (Accession Number: AF441249)
(pSPORT-Willin). All constructs were sequenced prior to use.
RNA Extraction and Quantitative Real-time PCR Detection
Extraction of RNA from cell lysates was performed using
peqGold MicroSpin Total RNA kit (peqLab, Sarisbury Green,
UK) followed by cDNA synthesis of 1 mg DNase-digested RNA
using First Strand cDNA Synthesis kit for RT-PCR (AMV)
(Roche, Lewes, UK). Quantitative PCR of the synthesized cDNA
was conducted using SYBR Green 2x Master Mix (Agilent,
Wokingham, UK), Mx3005P machine (Agilent) and the following
primers: Willin, Merlin, ezrin, MST1/2, LATS1/2, KIBRA,
YAP, EphrinB2, EGFR, CTGF, BMP2, FGF1, RASSF8, IGFBP3
and PRL. All measurements were conducted in triplicate unless
otherwise indicated and standardized to the levels of b-actin.
Sequence of the qPCR primer pairs were as follows (59 to 39
direction):
Willin – FW: CAGCCCACAACACAATGAAC RV: AGTG-
CAGCACCTGTTTCCTT
Ezrin – FW: CCCGGCCGATCCCAATTTGTGAA RV:
GGCGGAGACACGTCGGGAC
Merlin - FW: TTTGCCATAGGCAGCCCGCC RV:GTTA-
CACCCACCACTCCTCAAATACC
KIBRA – FW: GTGGAGGGGCGAGCAGGAGA RV:
TGGCGTTCTGCTTCCAGGCG
MST1 - FW: TGCTTACTTGGTAACCCAGCCTCAG RV:
TGGGACTCGGTCCTCAGGGGA
MST2– FW: AGCAGGACTTCAAGAACAAGAGTCATG
RV: GGCGGCTTCAGTCGCAGGTT
LATS1– FW: TGCCGCAAAGGCCGAGCATA RV:
TGGCATTGATAGGTCTGGCAGCT
LATS2– FW: TGAGCGCAGAGACGGTGGGT RV:
ACGTCCAATGTTTTGGCATAGCTGATT
YAP – FW: AGCCCAAGTCCCACTCGCGA RV: AC-
GAGGGTCAAGCCTTGGGTC
EphrinB2– FW: TCCCTTTGTGAAGCCAAATC RV:
GTCTCCTGCGGTACTTGAGC
EGFR – FW: AACCAGTGTGCCGCAGGGTG RV:
GTTCAGGCCGACAACCGCCA
CTGF – FW: CTTGCCTGGATGGGGCCGTG RV:
TCCCGGGCAGCTTGACCCTT
BMP2– FW: CCCCTTATCCCGGCCTTCGGA RV:
TTTGAGCTGGCTGTGGCAGGC
FGF1– FW: GCCATGGACACCGAAGGGCT RV:
GCGCAGCCAATGGTCAAGGGAAC
RASSF8– FW: GGCTGCAGACGGGGAAGCTG RV:
GCCGGCAGCACAGTGACCTT
IGFBP3– FW: CCAGCACACACCGCGTGACT RV:
GTGGACGCCCCTGGGACTCA
PRL – FW: CAGCCAAGTGTCAGCCCGGA RV:
GTGTCTGGCAGTCGCCACCA
Immunoblot Analysis
Cells were lysed in a lysis buffer composed by 10 mM Tris at
pH 8.0, 150 mM NaCl, 1% Na Deoxycholate, 1% Nonidet P-40,
1% Sodium Dodecyl Sulfate, 1 mM EDTA, 1:25 protease
inhibitor cocktail and phosphatase inhibitors. Protein lysates
(30 mg) were run on an SDS polyacrylamide gel and transferred
onto PVDF transfer membrane (GE Healthcare, Amersham, UK).
Primary antibodies used as follows: MST1/2, Phospho-MST1
(Thr183)/MST2(Thr180), LATS1, Phospho-LATS1(Ser909),
YAP, Phospho-YAP (Ser127), (1:1000; Rabbit) (Cell Signaling
Technology, Hitchin, UK), TAZ/WWTR1 (LS-B94; 1:200;
Rabbit) (LifeSpan Biosciences, Nottingham, UK), EphrinB2
(ab75868; 1:1000; Rabbit) (Abcam, Cambridge, UK), EGFR (sc-
03; 1:500; Rabbit) (Santa Cruz Biotechnology, CA, USA), Lamin-
b (1:200; Rabbit) (Insight Biotechnology, Middlesex, UK), b-actin
(A1978; 1:10 000; Mouse) (Sigma-Aldrich, Dorset, UK). Willin
rabbit polyclonal antibody was generated against the unique
sequence KEASKGIDQFGPPMIIHC of Willin (residues 86–102)
which was also used to affinity purify the antibody from the
resulting serum (1:1000; Rabbit) (Dundee Cell Products, Dundee,
UK). Secondary antibodies used as follows: horseradish peroxidase
(HRP)-conjugate goat anti-mouse (#115-035-062) or anti-rabbit
(#111-035-045) (1:10 000) (Stratech, Newmarket, UK). Levels of
protein expression were quantified using Image J software and
student’s unpaired t-test used to test statistical significance.
Nuclear/Cytoplasmic Fractionation
Primary fibroblasts subcellular fractionation was performed
using a modification of the method described by Angus and
colleagues [9]. Briefly, after reached the desired confluence cells
were harvested, pelleted at 228 g rpm for 4 min, washed with PBS
and pelleted again at 228 g for 4 min. Pellet was resuspended in
0.5 ml of ice-cold cytoplasmic extraction buffer (10 mM HEPES
pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and cocktail
of protease inhibitors) and kept on ice for 5 min. Cells were lysed
with 20 strokes using a pre-chilled Dounce homogenizer and the
lysate was centrifuged at 228 g for 5 min at 4uC. The pellet
(nuclear fraction) was resuspended in 1 ml of ice-cold nuclear
extraction buffer (0.25 mM sucrose, 10 mMMgCl2 and cocktail of
protease inhibitors), layered over a sucrose bed (0.88 mM sucrose,
0.5 mM MgCl2 and cocktail of protease inhibitors) and centri-
fuged for 10 min at 4uC. Pellet was resuspended in 500 ml of 1x
Figure 2. Willin activates the Hippo signaling pathway in fibroblasts of the sciatic nerve. Immunoblot analysis of the retroviral infected
fibroblasts with either Willin or empty vector shows (A) Willin increases MST1/2, LATS1 and YAP phosphorylation. Relative phosphorylation to total
proteins levels (MST1/2, LATS1 or YAP) are shown and background phosphorylation (in Fibro-vector) is set to 1. Error bars represent 6s.e. (n=3).
Fibro-vector vs Fibro-Willin: *p,0.05; **p,0.01; ***p,0.001; Student’s t-test. (B) Willin knockdown induces YAP, LATS1 and MST1/2
dephosphorylation. Primary fibroblasts were transfected with either non-targeting siRNA (siCtr) or siRNA targeting Willin (siWillin) for two
consecutive days. Cell lysates for western blotting analysis were prepared 48 h post-transfection. The ratios between relative YAP, LATS1 and MST1/2
phosphorylation levels to total proteins (YAP, LATS1 and MST1/2) are shown and background phosphorylation of Fibro-siCtr was arbitrarily set to 1.
Immunoblot analysis of efficient Willin knockdown is also presented. b-actin was used as a loading control. Means were calculated from three
independent experiments. Error bars represent 6 s.e. (n=3). Fibro-siCtr vs Fibro-siWillin: *p,0.05; **p,0.01; ***p,0.001; Student’s t-test. (C) Willin
expression results in YAP, but not TAZ, translocation from the nucleus to the cytoplasm. Cytoplasmic and nuclear fractions were separated for
western blot analysis as indicated. The blots shown are representative of three independent experiments (n= 3). (D) Willin knockdown in primary
fibroblasts sequesters YAP, but not TAZ, in the nucleus. YAP and TAZ subcellular location was determined by immunoblotting analysis of cytoplasmic
and nuclear fractions. b-actin and Lamin-b were used as loading controls for the cytoplasmic and nuclear fractions, respectively. The blots shown are
representative of three independent experiments (n=3).
doi:10.1371/journal.pone.0060028.g002
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Figure 3. Ectopic expression of Willin, but not YAP, suppresses cell proliferation in the sciatic nerve. Primary fibroblasts were retroviral
infected with Willin, YAP or an empty vector. Stable pools were selected and maintained in normal fibroblasts medium. (A) Proliferation curves of
fibroblasts stably expressing Willin, YAP or an empty vector, over a 6-day time course, show that Willin suppresses cellular proliferation whereas YAP
induces it. (B) Immunoblot analysis of YAP and Willin overexpression in primary fibroblasts. b-actin was used as a loading control. (C) Willin and YAP
cell proliferation patterns are cell cycle independent. Willin, YAP and vector-overexpressing fibroblasts were cultured to confluence. Cells at a similar
density were pulse-labeled with 10 mM BrdU for 1hour, followed by staining with anti-BrdU and propidium iodide (20 mg/ml for 30 min) for flow
cytometry. No statistical significant arrest of cells residing in G0/G1, S or G2/M phases was observed. The mean percentage of cells in the different cell
cycle phases was determined. Error bars represent 6s.d. (n=6). (D) Willin knockdown induces cellular proliferation in a cell-cycle independent
manner. Cells at a similar density were fixed in 70% ethanol and stained with propidium iodide (4 mg/ml for 30 min) for FACScan analysis. No
statistical significant arrest of cells residing in G0/G1, S or G2/M phases was observed. The mean percentage of cells in the different cell cycle phases
was determined. Error bars represent 6s.d. (n=6). (E) Representative phase-contrast images of fibroblasts growing in monolayer cultures transfected
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RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40,
0,5% sodium deoxycholate and cocktail of protease inhibitors),
briefly sonicated on ice and centrifuged at 2800 g for 5 min at
4uC. The supernatant (cytoplasmic fraction) was transferred to
a new 1.5 ml tube, 300 ml of 1x RIPA buffer was added and the
lysate centrifuged at 2800 g for 10 min at 4uC to pellet any solids.
The supernatant was transferred to a new tube. Protein sample
buffer was added to both nuclear and cytoplasmic fractions and
30 mg of protein lysates run on an SDS/10% polyacrylamide gel.
In vitro Wound Healing Assay
For both overexpression and knockdown analysis the same
number of cells were plated in each well of a 6-well culture plate
(86105 and 36105, respectively). For the knockdown experiments,
cells at 60% confluence were transfected on two consecutive days
with siFRMD6 or siCtr and allowed to grow until reaching
confluence (3 days after the initial transfection). Monolayers of
confluent cultures were gently scratched with a sterile micropipette
tip and the migration towards the wound was monitored for up to
16 h (overexpression) or 40 h (knockdown). Phase-contrast images
were captured after the scratch for each one of the time points.
The percentage of scratch covered by cells was measured as the
percentage of the invaded area with respect to the initial wound
area and calculated using Image J software.
BrdU/PI labeling and Flow Cytometry
For cell cycle progression analysis, cells were cultured until
desired confluence and pulse-labeled with 10 mM BrdU (Sigma-
Aldrich, Dorset, UK) for 1hour at 37uC. After trypsinization and
two PBS/1% BSA washes cells were fixed in 70% ethanol at 4uC
for at least 30 min, centrifuged at 500 g for 10 min at 10uC and
the pellet was resuspended in 2 N HCl for 30 min on ice for DNA
denaturation. Cells were centrifuged at 500 g for 10 min at 10uC
and washed with 0.1 M of sodium tetraborate pH 8.5, centrifuged
again and stained with anti-BrdU (# 347580, BD Biosciences,
Oxford, UK) for 1 hour, room temperature, in the dark. Cells
were then washed and stained with Dylight 488-goat anti-mouse
IgG (#115-485-062, Stratech, Newmarket, UK) for 1hour at RT.
Stained cells were resuspended in PBS containing 20 mg/ml of
propidium iodide (Sigma-Aldrich, Dorset, UK) and RNase at
100 mg/ml for 30 min at RT. For cell cycle analysis using
propidium iodide, cells were washed twice in ice-cold PBS, fixed in
70% ethanol at 4uC for at least 30 min, washed twice in ice-cold
PBS and then resuspended in PBS containing 4 mg/ml of
propidium iodide and RNase at 100 mg/ml for 30 min at RT,
in the dark. Cells were then analysed on a FACScan (BD
Biosciences, Oxford, UK) using CELLQUEST software.
Results
Willin is Expressed in Fibroblasts within the Sciatic Nerve
Willin was first identified by a yeast two-hybrid screen of a rat
sciatic nerve cDNA library using neurofascin as bait and northern
blot analysis had confirmed Willin’s expression in this structure
[27]. To establish where Willin is located within the sciatic nerve,
we compared the mRNA expression pattern of Willin with the
Schwann cell expressing isoform of the transmembrane receptor
neurofascin [33] by in situ hybridization. The Willin transcript
appeared to be predominately located at the perineurium (the
periphery) of the sciatic nerve (Figure 1A), but also within discrete
cells within the endoneurium. However, from their morphology
these cells appeared to be different from those in which the glial
neurofascin isoform transcript was expressed (Figure 1A). The
sciatic nerve is composed of cell bodies of Schwann cells and
fibroblasts; therefore, to determine the expression of Willin in
either of these cells, both Schwann cells and fibroblasts were
cultured from rat sciatic nerve (Figure 1B). From these cultures,
quantitative RT-PCR demonstrated that the Willin transcript was
expressed 10-fold more in the fibroblasts than in the Schwann cells
(Figure 1C). Since Willin is an upstream component of the Hippo
pathway [9,11] components of this newly emerging signaling
cascade were also analyzed to determine whether they were
expressed within the sciatic nerve. Interestingly, MST2 and
LATS1 were more strongly expressed within the fibroblasts than
Schwann cells, whilst YAP was less expressed and MST1 was
present in both cell types at the same level as assessed by
quantitative RT-PCR (Figure 1C).
Willin Expression Influences the Activation of the Hippo
Pathway in Fibroblasts
Previously, it has been shown that Willin expression in epithelial
MCF10A cells induces YAP phosphorylation at Ser127, by
a MST1/2 and MOBKL1A/B-dependent mechanism [9,11].
Phosphorylation of YAP at Ser127 by LATS1/2 results in YAP
translocation to the cytoplasm and then its subsequent ubiquitina-
tion and concomitant degradation [4,8]. Since YAP regulation
could be context-dependent, Willin was investigated to determine
whether it could activate the Hippo pathway in primary fibroblasts
derived from the rat sciatic nerve. Primary fibroblasts were
infected with retroviruses expressing either Willin or an empty
vector, and stable pools of cells were selected. Upon ectopic Willin
expression (Fibro-Willin cells), as predicted there was a significant
increase in MST1/2, LATS1 and YAP phosphorylation when
compared to the empty-vector control (Fibro-Vector) cells
(Figure 2A). These findings were further supported by knocking
down endogenous Willin using RNA interference. Down-regula-
tion of Willin using siRNA (Fibro-siWillin cells) caused a significant
reduction in MST1/2, LATS1 and YAP phosphorylation
(Figure 2B), when compared with control cells (Fibro-siCtr).
Knockdown of Willin was confirmed by immunoblotting analysis
(Figure 2B). Furthermore, lysates from Fibro-Willin or Fibro-
Vector cells were separated into cytoplasmic and nuclear fractions.
Efficient phosphorylation of YAP at Ser127 induces cytoplasmic
retention through binding to 14-3-3 proteins [8]. As expected,
Willin expression promoted YAP sequestration in the cytoplasm.
Surprisingly, the localization of TAZ, the paralogue of YAP, was
unaffected by Willin expression (Figure 2C). Moreover, investiga-
tions were also carried out to determine whether YAP de-
phosphorylation was accompanied by YAP sequestration in the
with either non-targeting siRNA (siCtr) or siRNA targeting Willin (siWillin) for two consecutive days. Images were taken at low and high density. At low
density, siWillin fibroblasts present a large and flat spindle-shape with multiple oval nucleoli with extended and interconnected cell processes
protruding from the body of each cell. At high density, the cells are confluent and arranged in parallel arrays with the interconnected processes
organized in a dense and close network. This effect is not observed in Fibro-siCtr cells. (F) Proliferation curve of control fibroblasts (siCtr) or
knockdown Willin (siWillin) cells. Cells were transiently transfected with the respective siRNAs and the growth curve monitored over 4 days. 48 h after
the second transfection Fibro-siWillin cells show a 3.46 fold increase in cell proliferation when compared with the Fibro-siCtr cells. Red arrow –
experimental time point indicating when cells were harvested for downstream analyses. Each data point is the mean of three independent
experiments. Error bars represent 6s.d. (n= 3). Fibro-siCtr vs Fibro-siWillin: *p,0.05; ***p,0.001; Student’s t-test.
doi:10.1371/journal.pone.0060028.g003
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nucleus upon Willin knockdown. Indeed, YAP nuclear retention
was observed upon Willin knockdown (Fibro-siWillin cells) when
compared with control cells (Fibro-siCtr). However, TAZ consis-
tently did not translocate from the cytoplasm to the nucleus in this
scenario (Figure 2D). Taken together, the data suggest that within
sciatic nerve fibroblasts, Willin is an upstream regulator of YAP
but not TAZ.
Willin Suppresses Cellular Proliferation in a Cell-cycle
Independent Manner
To explore the effect of Willin and YAP expression on cell
proliferation, primary fibroblasts were infected with retroviruses
expressing Willin, YAP1 (Fibro-YAP) or an empty vector. Stable
pools of cells were selected and equal numbers of cells were
cultured and counted every day for 6 days (Figure 3A). Fibro-
Willin cells showed a significant delay in proliferation when
compared to Fibro-YAP or Fibro-Vector cells. Interestingly,
ectopic YAP expression resulted in increased cellular proliferation,
when compared with Fibro-Vector cells (Figure 3A). Ectopic
expression of Willin and YAP was confirmed by immunoblotting
analysis (Figure 3B).
To determine if the slower proliferation rate of Fibro-Willin cells
was associated with cell cycle changes, these cells were analyzed by
flow cytometry. Fibro-Willin, Fibro-YAP or Fibro-Vector cells
were seeded at 16106 cells (corresponding to day 2 of Figure 3A)
and 24 h later they were pulse-labeled with BrdU for 1 hour and
probed by flow cytometry. There was no statistically significant
difference in the number of cells residing in G0/G1, S or G2/M
phases (Figure 3C) in any of the cell-types tested, suggesting that
there was no cell cycle arrest in Fibro-Willin cells.
Complementing the results observed in the overexpression
scenario (Figure 3C), cells with decreased Willin expression (Fibro-
siWillin), displayed no statistically significant difference in the
number of cells observed in G0/G1, S or G2/M phases compared
to Fibro-siCtr cells (Figure 3D). However, the morphology of
Fibro-siWillin cells was notably different: at low density, the Fibro-
siWillin cells had elongated cell processes and a more pronounced
flat spindle shape compared to Fibro-siCtr cells; after three days,
Fibro-siWillin cells organized into a dense and close network of
multiple interconnected processes protruding from the body of
each cell (Figure 3E). This effect was accompanied by a statistically
significant 3.5 fold increase in cellular proliferation compared to
Fibro-siCtr cells (Figure 3F). These observations suggest that in
fibroblasts Willin expression negatively regulates cellular pro-
liferation but in a cell cycle independent manner.
Willin Expression Promotes Fibroblast Migration
Fibroblasts have an important role in wound healing, since these
cells are the first to bridge the physical gap between the proximal
and distal stumps following sciatic nerve transection [34,35]. To
assess the effect of Willin and YAP expression in promoting
fibroblast wound closure, scratch assays were performed on
confluent fibroblast monolayers and the rate of scratch closure
was observed over 16 h. Strikingly, Fibro-Willin cells demonstrat-
ed a faster scratch closure rate compared to Fibro-Vector cells
(Figure 4A). Cell numbers were counted to determine whether the
faster scratch closure by Fibro-Willin cells was due to increased
cellular proliferation or directional cell migration towards the
wound. There was no change in the number of Fibro-Willin cells
over the time course of the experiment in contrast to Fibro-YAP
cells which showed increased cellular proliferation after 16 h
compared to Fibro-Vector cells (Figure 4B). The impact of Willin
on fibroblasts migration was further confirmed using Fibro-
siWillin cells. As predicted, Fibro-siWillin cells displayed an
inhibition of migration when compared to Fibro-siCtr cells
(Figure 4C). Taken together, the results suggest that Willin
expression promotes the migration of sciatic nerve derived
fibroblasts.
Willin is an Upstream Regulator of EphrinB2 and EGFR
Expression
Previously, Parrinello and coworkers described ephrin/Eph
signaling from fibroblasts is responsible for a directional axonal
outgrowth of Schwann cells [26]. In order to establish whether the
Hippo pathway plays a role in ephrin/Eph signaling, the
expression of ephrinB2 was analyzed in Fibro-Willin, Fibro-YAP
and Fibro-Vector cells. Quantitative RT-PCR (Figure 5A) and
immunoblotting analysis (Figure 5B) showed that ectopic Willin
expression resulted in ephrinB2 down-regulation whereas YAP
induced ephrinB2 up-regulation as compared to Fibro-Vector
cells. This finding was complemented by determining whether
endogenous Willin regulates ephrinB2 expression. As predicted,
knockdown of Willin in Fibro-siWillin cells resulted in an increase
in ephrinB2 levels, both at mRNA (Figure 5C) and protein levels
(Figure 5D), as compared to Fibro-siCtr cells.
These results were also closely mirrored when levels of the
epidermal growth factor receptor (EGFR) were also monitored as
previous studies have shown that activated EGFR leads to
increased cell migration in wound repair mediated by fibroblasts
[36–38]. Notably, there was a down-regulation of EGFR in Fibro-
Willin cells compared to Fibro-Vector cells, both at the mRNA
(Figure 5A) and protein levels (Figure 6B). Conversely, comparing
the Fibro-YAP cells to the control Fibro-Vector cells resulted in
a significant increase in EGFRmRNA levels (Figure 5A) but a non-
significant increase at the protein level (Figure 5B). Confirming the
role of Willin on EGFR expression, Fibro-siWillin cells displayed
a predicted up-regulation of EGFR as compared to Fibro-siCtr
cells, both at the mRNA (Figure 5C) and protein level (Figure 5D).
Figure 4. Willin expression promotes fibroblasts migration. Primary fibroblasts were retroviral infected with Willin, YAP or an empty vector.
Stable pools were selected and maintained in normal fibroblasts medium. (A) Willin overexpression promotes faster cellular migration than YAP.
Wound closure ability of fibroblasts stable cells was assessed by a wound-healing assay. Representative phase contrast images show the wounded
area (0 h) and cell migration towards the wound after 14 h and 16 h. The percentage of scratch covered was measured by quantifying the total
distance the cells moved from the edge of the scratch towards the center of the scratch (shown by red lines), using Image J software, followed by
conversion to a percentage of scratch covered. Data is presented as the mean percentage of scratch covered in three independent experiments. Error
bars represent 6s.d. (n=3). (B) Willin promotion of wound closure is caused by directional cell migration and not by increased cell proliferation. The
number of total cells in each one of the indicated time points was determined by cell count and the percentage of fibroblasts expressing vector,
Willin or YAP relative to 0 h assessed. Means were calculated from three independent experiments. Error bars represent 6s.d. (n=3). (C) Willin
knockdown inhibits fibroblasts migration. Representative phase-contrast images of wound healing assay performed in fibro-siCtr or fibro-siWillin
fibroblasts show the wounded area (0 h) and cell migration towards the wound after 16 h, 20 h and 40 h (shown by red lines). Motility was quantified
as described. Data is presented as the mean percentage of scratch covered in three independent experiments. Error bars represent 6s.d. (n= 3).
doi:10.1371/journal.pone.0060028.g004
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Willin Influences Expression of some but not all Genes
Regulated by YAP in Sciatic Nerve Fibroblasts
Previously, the Willin FERM domain was shown to be sufficient
to influence the activity of genes regulated by YAP [9]. Since the
Hippo kinase cascade has cell-specific regulatory functions in
different tissues [4,13] some of these genes were analyzed to
determine whether they are influenced by Willin and YAP in
sciatic nerve fibroblasts. To test this, quantitative RT-PCR
analysis of CTGF, BMP2, FGF1, RASSF8, IGFBP3 and PRL
mRNA levels was conducted on Fibro-Willin, Fibro-YAP and
Fibro-Vector cells (Figure 6). PRL (prolactin), among all the
analyzed genes was the most strongly up-regulated by 5-fold in
Fibro-Willin cells when compared to Fibro-Vector cells, but down-
regulated in Fibro-YAP cells. Intriguingly, CTGF, a direct YAP
target gene in NIH-3T3 and MCF10A cells [39] was down-
regulated in Fibro-YAP cells as compared to Fibro-Vector cells.
Loss of CTGF expression was also observed in Fibro-Willin cells as
compared to Fibro-Vector cells. Notably, FGF1 and IGFBP3
mRNA levels were significantly up-regulated in Fibro-Willin cells
and down-regulated in Fibro-YAP cells, when compared to Fibro-
Vector cells. Furthermore, BMP2 and RASSF8 were up-regulated
in Fibro-Willin cells when compared to Fibro-Vector cells. These
data demonstrate that, in fibroblasts isolated form the sciatic
nerve, Willin and YAP have antagonistic regulatory functions
upon FGF1, RASSF8, IGBP3 and PRL genes, but other genes
show context-dependent regulation such that BMP2 expression is
influenced by Willin and not YAP, while CTGF expression is
inhibited by both Willin and YAP.
Discussion
Although several advances have been made in the understand-
ing of the emerging mammalian Hippo signaling pathway in its
regulation of organ size control, tissue regeneration and stem-cell
renewal [4,13] little is known about the involvement of this
pathway in the peripheral nervous system where Willin/FRMD6
was first identified [27]. This study establishes a role for Willin in
mammalian peripheral nerve fibroblasts based on four findings.
Firstly, we find that Willin as well as other components of the
Hippo signaling pathway are expressed in these fibroblasts.
Secondly, Willin has previously been shown to activate the Hippo
pathway in epithelial cells [9,11] and we extend this to fibroblasts,
where Willin expression increases MST1/2, LATS1 and YAP
phosphorylation, and consequently a shift of YAP from the
nucleus to the cytoplasm. These findings were further confirmed
by knockdown of Willin. Thirdly, we show that Willin expression
promotes fibroblast wound closure by directional migration in the
absence of proliferation. Fourthly, we show Willin expression
down-regulates ephrinB2 and EGFR (Figure 7).
Fibroblasts are the main mediators of the dynamic and well-
organized process of wound healing. They accumulate at the
injury site [26], synthesize ECM components forming granulation
tissue, and promote mechanical forces within the wound to initiate
tissue contraction, a mechanism that leads to scar formation [40].
Fibroblasts are also involved in angiogenesis, promoting wound
vascularization and inflammation by secreting proinflammatory
cytokines [41]. If extensive invasion and proliferation of scar-
forming fibroblasts occurs, pathophysiological conditions may
arise such as neuromas or hypertrophic scars [42]. During the
process of tissue repair, extracellular matrix goes through physical
changes in terms of elasticity and cell shape. Recently YAP has
been described as a crucial mediator of physical and mechanical
cues in the cellular microenvironment, such that a ‘‘stiff’’
microenvironment activates YAP [43,44]. Therefore, these mod-
ifications may exert mechanical signals that activate YAP, which
would be antagonized by signals from the Hippo pathway.
Willin expression induces wound closure in the absence of
proliferation and this might be associated with an initial injury
event. When the microenvironment becomes more ‘‘stiff’’ upon
the accumulation of fibroblasts, then YAP activation would
predominate, increasing fibroblast proliferation, inhibiting fibro-
blast migration and causing increased Ephrin B2 and EGFR
expression in the fibroblasts. Parrinello and coworkers (2010) [26]
recently described that ephrinB2 ligand expression on fibroblasts
induces activation of the EphB2 receptors located on Schwann
cells. The ephrinB2/EphB2 signal results in an organized
directional cell migration by the Schwann cells as it mediates
their sorting in the form of multicellular cords to guide axons
regrowth across the wound. Activation of EphB2 receptor on
Schwann cells was found to be Sox2 dependent [26]. Sox2 is
pivotal for the maintenance of pluripotency and regulation of stem
cell self-renewal and differentiation [45,46]. Interestingly, YAP has
been shown to regulate Sox2 in mES cells [23] and we observed
higher YAP expression in Schwann cells as compared to
fibroblasts. Without an antagonizing signal this process would
continue resulting in an excess of fibroblasts. In fact, ephrinB2 has
been found overexpressed in different fibroproliferative diseases
[47,48]. Our data suggest a role for the Hippo pathway in the
negative regulation of ephrinB2/EphB2 receptor signaling in
fibroblasts, limiting excessive fibroblast proliferation and inappro-
priate Schwann cell activation by fibroblasts.
Several studies have shown that EGF, by activating EGFR,
leads to increased cell migration, a feature of tumour progression,
metastasis and wound healing [49,50] but in other cell-types leads
Figure 5. Willin is an upstream regulator of EphrinB2 and EGFR. (A) Willin expression is antagonistic to YAP EphrinB2 and EGFR
transcriptional regulation. mRNA levels of Ephrin B2 and EGFR were probed by quantitative real-time PCR. mRNA levels were compared with the
empty vector control fibroblast cells (set to 1). At the transcriptional level, Willin overexpression decreases EGFR and to a less extend EphrinB2
whereas YAP results in an increase in both EphrinB2 and EGFR mRNA levels. Means were calculated from Ct values in six independent experiments. b-
actin was used to normalize for variances in input cDNA. Error bars represent 6s.e. (n= 6). Fibro-vector vs fibro-Willin or fibro-YAP for the analysed
genes: *p,0.05; **p,0.01; ***p,0.001; Student’s t-test. Fibroblasts-vector vs fibroblasts-Willin: EphrinB2 (p = 0.055); Student’s t-test. (B) Immunoblots
analysis of EphrinB2 and EGFR show loss of expression upon ectopic Willin expression and gain of EphrinB2 expression upon YAP overexpression
when compared to empty vector control (set to 1). b-actin was used as a loading control. Means were calculated from six independent experiments.
Error bars represent 6s.e. (n= 6). Fibro-vector vs fibro-Willin or fibro-YAP: *p,0.05; **p,0.01; Student’s t-test. Fibroblasts-vector vs fibroblasts-YAP:
EGFR (p = 0.40); Student’s t-test. (C) EGFR mRNA levels are upregulated upon Willin knockdown but EphrinB2 does not show statistical significant
change at the transcriptional level. mRNA levels of Ephrin B2 and EGFR were probed by quantitative real-time PCR and mRNA levels compared with
the fibro-siCtr cells (set to 1). Means were calculated from Ct values in six independent experiments. b-actin was used to normalize for variances in
input cDNA. Error bars represent 6s.e. (n= 6). Fibro-siCtr vs fibro-siWillin cells: *p,0.05; Student’s t-test. Fibro-siCtr vs Fibro-siWillin cells: EphrinB2
(p = 0.555); Student’s t-test. (D) Immunoblots analysis of EphrinB2 and EGFR show upregulated expression when Willin is knockdown. Relative
expression was determined compared to background expression (Fibro-siCtr cells set to 1). b-actin was used as a loading control. Means were
calculated from three independent experiments. Error bars represent6s.e. (n= 3). Fibro-siCtr vs Fibro-siWillin cells: **p,0.01; ***p,0.001; Student’s t-
test.
doi:10.1371/journal.pone.0060028.g005
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to increased cell proliferation [51,52]. High EGFR expression has
been shown in wound repair of both epithelial and human skin
fibroblasts by promoting cell migration and wound epithelializa-
tion [37,38,53]. In our experiments, an increase in ectopic Willin
expression induced down-regulation of EGFR, with an increase in
cell migration but inhibition/delay of cellular proliferation, whilst
a decrease in Willin expression resulted in an increase in EGFR
expression with a inhibition/delay of cell migration but an
increase in cell proliferation. This suggests that Willin expression
can influence the level of EGFR in sciatic nerve fibroblasts, and
Figure 6. Willin antagonizes some of the genes regulated by YAP in sciatic nerve fibroblasts. mRNA expression of the YAP target genes
CTGF, BMP2, FGF1, RASSF8, IGFBP3 and PRL was probed in fibroblasts expressing Willin or YAP by quantitative real-time PCR. mRNA levels were
compared with the empty vector control (set to 1). Willin overexpression increased BMP2, FGF1, RASSF8, IGFBP3 and PRL mRNA levels and, together
with YAP, decreased CTGF mRNA expression in these cells. Means were calculated from Ct values in three independent experiments. b-actin was used
to normalize for variances in input cDNA. Error bars represent 6s.e. (n= 3). Fibroblasts-vector vs fibroblasts-Willin or fibroblasts-YAP for all the
analysed genes: *p,0.05; **p,0.01; ***p,0.001; Student’s t-test. Fibroblasts-vector vs fibroblasts-YAP: BMP2 (p = 0.217); Student’s t-test.
doi:10.1371/journal.pone.0060028.g006
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that this in turn regulates the potential of over-proliferation,
highlighting the fact that fibroblasts have different functions in
a tissue-context dependent manner. In agreement with our
observations, Merlin in mammalian cells also inhibits EGFR in
mouse embryonic fibroblasts (MEFs) and cells undergo contact-
dependent inhibition of proliferation [54]. Furthermore, in
Drosophila, Merlin and Expanded mutant cells show an up-
regulation of the EGFR signaling pathway [55]. It is also possible
to hypothesise that there may also be an element of feedback
control, as EGF itself has been shown to influence the cellular
distribution of Willin [27]; and also, recently the EGFR ligand,
amphiregulin, has been identified as a transcriptional YAP target
[14].
Willin induced transcriptional activation of BMP2, FGF1,
IGFBP3, PRL and RASSF8. Importantly, we observed that Willin
and YAP displayed opposite effects on FGF1, IGFBP3, RASSF8
and PRL expression. Willin increased expression, while YAP
decreased expression of these genes. While, BMP2 and RASSF8
displayed a similar trend in Willin-induced upregulation with the
data presented by Moleirinho et al. (2013) and Angus et al. (2012)
[9,11], in epithelial MCF10A cells, FGF1, IGFBP3 and PRL were
regulated by Willin expression but displayed the opposite trend.
BMP2 has been shown to induce cell migration in different cell
types, including MEF [56] and its involvement in the liver and
peripheral nerve healing response has been previously described
[57,58]. The pronounced Willin-induced upregulation of BMP2
could also explain the migratory pattern observed in the wound-
healing assay. Expression of CTGF, a YAP direct target [39,59],
in tissue wound repair has been proposed to be a major player in
the pathogenesis of fibrotic processes [60]. We found it down
regulated upon Willin expression.
Our data suggests that the hippo signaling pathway might have
a significant role in both the development and maintenance of the
mammalian peripheral nervous system. Specifically it would be of
great interest to explore this further in both fibroblasts and
Schwann cells to verify how the signaling cascade regulates the
ephrin/Eph signaling, and its ability to control wound repair and,
ultimately, regeneration of the PNS.
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